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SUMMARY
Pro-carcinogens e.g. B[a]P and PhIP require metabolic activation to exert genotoxicity. Both 
B[a]P and PhIP are known to cause different types of cancers, however, very little is known 
about the dose response of these two chemicals at low concentrations. This study was conducted 
to determine the effect of low doses of B[a]P and PhIP and their exposure time on cell lines with 
varying levels of metabolic activity.
Micronucleus and HPRT assays were conducted to determine the effect of low doses of B[a]P on 
micronuclei induction and mutation frequency following 4 or 24 h exposure. MCL-5 and HepG2 
cell lines showed higher induction of micronuclei irrespective of B[a]P dose and exposure time. 
Micronuclei induction was least in AHH-1 while TK-6 cells showed no micronuclei induction. 
HPRT assay also showed higher mutation frequency in MCL-5 as compared to AHH-1 at both 
time exposures. Analysis of mutation spectra of MCL-5 and AHH-1 HPRT mutants revealed that 
the type of mutations observed in B[a]P treated cells were different to those observed in untreated 
control B[a]P-induced mutations were predominantly G->T transversions. Real time PCR assays 
revealed higher induction of CYP1A1 and CY1A2 enzymes in response to B[a]P in MCL-5 and 
HepG2 cell lines.
Studies on PhIP showed significantly higher cytotoxicity, genotoxicity and mutation frequency in 
the MCL-5 and HepG2 cell lines than AHH-1 cells. Micronucleus assays (24h) revealed 1.56 and 
1.9-.fold increase in micronuclei induction in MCL-5 and HepG2, respectively as compared to 
control. A similar trend was observed in 4h PhIP exposure study, where MCL-5 and HepG2 had 
1.83 and 1.92-.fold increase respectively. These findings are in line with the metabolic potential 
of the cell lines. Real-time PCR assays showed that over all, expression of CYP1A1 and CY1A2 
was higher in HepG2 than MCL-5 following PhIP exposure for 24h. PhIP was observed to induce 
a significantly higher mutation frequency in MCL-5 cell lines than untreated control. Mutation 
type also varied among PhIP treated and untreated control of MCL-5. PhIP treated MCL-5 cells 
showed predominantly G->T transversions.
These studies showed that cells with higher metabolic activity are relatively more capable of 
activating B[a]P and PhIP and therefore show higher genotoxicity in response to dose and 
exposure of these pro-carcinogens. Considering the results of this study, potential risk of B[a]P 
and PhIP induced cancers has been discussed.
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Chapter 1 
General Introduction
The genotoxicity of an agent represents its ability to cause genetic alterations in the target 
cell/tissue/organ. These genotoxic agents include chemical compounds, air pollutants, 
nanoparticles and radiation from different sources. Studies to date have shown that several 
factors including type of agent, dose, frequency of exposure and interaction with the host, etc. 
influence the ability of an agent to initiate genetic alterations (Millar and Ramos, 2001). The 
majority of genetic alterations starts with DNA damage in the form of DNA adduct formation 
leading to alterations in nucleotide sequence such as point mutations, and/or changes in the 
chromosome number or structure. These alterations if not repaired by the cell could become 
permanent and trigger carcinogenic processes in the target organ. The DNA sequence within 
the genes and their arrangement in the chromosomes are highly conserved and any change in 
sequence or structure may have harmful consequences on the organism. If such mutations 
occur in germ cells, they tend to cause heritable effects in the offspring which sometime result 
in the evaluation of a species, but if mutations occur in tumour suppressor genes or proto­
oncogenes of somatic cells then they may lead to unregulated cell division and cancer (Loeb 
and Loeb, 2000). Therefore, genotoxicology deals with the assessment of a chemical’s (or 
agent’s) ability to induce such DNA damage in the absence of cell death, because DNA 
damage is the underlying cause of mutations that promote carcinogenesis as well as other 
diseases (Loeb and Loeb, 2000)
Genotoxins induce mutations through DNA damage by various mechanisms. Firstly, a 
genotoxin may form a direct interaction with DNA to produce a lesion and cause mutation 
e.g. mitomycin C and 4-nitroquinoline-l-oxide interact directly with the DNA helix. Such 
chemicals are sufficiently electrophilic in nature and have been reported to cause genotoxicity 
by direct damage to DNA by forming DNA adducts (Lu, 1991). These adduct are capable of 
covalently binding with the nucleophilic centres of DNA and also with cellular proteins. In 
some instances these DNA adducts are efficiently repaired, however DNA repair processes 
are not error-free and some adducts may be missed (or mis-repaired) by the repair machinery. 
The replication of the unrepaired adducts results in the formation of fixed mutations which 
appear as mutated cells (Miller and Miller, 1971). DNA damage can also arise via indirect 
mechanisms, such as when the agents interact with cellular components (other than DNA) and
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this leads to indirect DNA damage e.g chemicals promoting reactive oxygen species (ROS) 
induction which can damage DNA (Wiseman and Halliwell, 1996). Another indirect source of 
genotoxins is where DNA damage is induced through metabolic activation of the compound 
into a more toxic form. For example, metabolic activation of polycyclic aromatic 
hydrocarbons (PAH’s) and heterocyclic aromatic amines (HAA’s) produce metabolic 
products which can covalently interact with DNA and form DNA adducts (Dipple, 1984; 
Hecht, 1999). Such agents are also known as pro-carcinogens; once exposed to eukaryotic 
cells, cellular mechanisms break down these agents into by-products that are sometimes able 
to bind with DNA to initiate carcinogenic processes (Guengerich, 2000; IARC, 2010).
1.1 Mutations results from DNA damage
Mutations can be caused by exogenous (environmental) and endogenous (errors in the cellular 
systems of the cell) factors. The physical or chemical substances that induce mutations in 
DNA are defined as mutagens and the mechanism is called mutagenesis. Exogenous sources 
of DNA damage include exposure to UV radiation from sun which causes cross-linking 
between adjacent pyrimidinse (Cytosine and Thymine) bases in the DNA strand (Ravanat et 
al, 2001). Another environmental source of mutation is ionizing radiation (X-rays) that 
produces free radicals within the cells that lead to the formation of ROS and results in DNA 
strand breaks or apurinic/apyrimidinic sites. Certain chemicals like alkylating agents and 
aromatic amines are also exogenous sources and cause small alterations in DNA. Alkylating 
agents like ethylmethanesulfonate (EMS) alter the base’s structure which results in specific 
DNA mispairing. Some chemicals act as a base analogue and are incorporated into the DNA 
in place of normal bases, and cause mispairing of DNA, for example, 5-bromouracil is an 
analogue of thymine and 2-amino-purine is an analogue of adenine (Griffiths et al, 2000). 
Mispaired DNA bases form fixed mutations when the DNA strand is replicated and an 
incorrect base is incorporated opposite the DNA lesion. In addition to these environmental 
factors, chemicals in foods also cause DNA damage and produce alterations (Ames et al, 
1995; Mamett and Plastaras, 2001).
DNA damage can also result from endogenous sources including DNA replication errors, 
spontaneous lesions and transposable genetic elements. The major endogenous processes that 
lead to significant DNA damage are:
• Oxidation of bases, like 8-oxo-7,8-dihydroguanine (8-oxoG) induced by reactive 
oxygen species that lead to DNA strand breaks (Shibutani et al, 1991). These ROS are
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induced in cells during normal physiological processes such as respiration and 
enzymatic reactions.
• Methylation, such as formation of 7-methylguanine or 0 6-Methylguanine (Ames et al, 
1991). This methyl group comes endogenously as a result of enzymatic reaction of O6- 
methylguanine-DNA methyltransferases
• Hydrolysis of bases such as depurinations, depyrimidations and deamination (cytosine 
to uracil). It has been estimated that each cell undergoes 10,000 depurination per day 
(Lindahl and Nyberg, 1972).
•  Bulky adduct formation e.g. benzo[a]pyrene diol epoxide -dG  adduct. These DNA 
adducts are formed due to the cellular CYP450 enzymatic reactions
It appears that irrespective to the source of DNA damage, the mechanism by which these 
agents can cause mutation generally involves the incorporation of a base change into the 
DNA, where they have the propensity to mispair (Griffiths et al, 2000) and cause DNA 
mutation. If these lesions occurred at high frequency then there is a possibility of 
missing/escaping DNA repair mechanisms and the production of fixed mutations during 
replication by DNA polymerases (Loeb and Cheng, 1990).
1.2 Type of mutations
Mutations can appear at different genetic levels and they can range from small changes 
arising from a single nucleotide change to large chromosomal changes. Gene mutations are 
well documented because such mutations may initiate the cancer events (Knudson, 1971; 
Loeb and Loeb, 2000).
1.2.1 Gene mutations
Gene mutations appear as a result of changes in the small stretches of nucleotides in DNA. 
These mutations manifest themselves in the malfunctioning of genes and appear as following:
Point mutations
Point mutations usually occur when only one base substitution alters. Point mutations include 
transitions and transversions. A purine base is replaced by another purine (adenine or 
guanine) in transitions, and in transversions, a purine is replaced by a pyrimidine (thymine 
and cytosine) or vice versa (Pecorino, 2006). Such mutations may be silent (no change in 
amino acid sequence or cell phenotype), missense (abnormal protein function due to change 
in amino acid) and nonsense (change in triplet codon to a stop codon leading to a non-
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functional protein). The reading frame of DNA is read in a triplicate code; therefore if a base 
sequence is altered due to either an insertion or deletion, the code will be changed completely. 
This is termed a frameshift mutation. Sometimes at the third position of codon is referred to 
as the wobble position. At this position Uracil (U) and Cytosine (C) may be read by a 
Guanine (G) in the anticodon. Similarly Adenine (A) and Guanine may be read by Uracil. In 
tRNA there is one modified nucleotide is Inosine (I). If tRNA contains I in the anticodon at 
the wobble position, this tRNA may read codons having A, U and C in the third position. This 
could be a potential source of translation error, if the mismatch were to cause the wrong 
amino acid to be incorporated into the protein.
Deletions
Deletions can be single base deletion or more. But the deletion of DNA can manifest when 
exons are skipped during mRNA maturation which results in the loss of information for 
protein translation.
Insertions
An insertion mutation is caused by an insertion of one or more nucleotide into the DNA 
sequence. This type of mutation occurs due to polymerase slippage in repeated sequences 
during DNA replication.
1.2.2 Chromosomal Mutations
Mutations can also affect large segments of DNA (>lkb) and can encompass sizeable 
segments of chromosomes and even whole chromosomes.
Change in chromosome number
In this type of mutation, also called aneuploidy, gain or loss of a chromosome(s) takes place. 
The mechanism of aneuploidy in the cell is often due to the failure of the chromosomes to 
separate equally into the daughter cells. It appears as a result of abnormal disjunction during 
meiosis in gametocytes and during mitosis in somatic cells. Indirect genotoxins (aneugens) 
such as carbendazim, colchicine, nocodazole and mebendazole modify the spindle of the 
dividing cells leading to improper chromosopie segregation in the daughter cells. Such 
imbalance of the genetic information is the reason for many reproduction failures (Boue and 
Lazer, 1975), cancer (Boveri, 1914) and other hereditary genetic defects (Korenberg, 1994).
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Change in chromosome structure
This mutation appears due to addition or deletion or re-arrangement of a fragment(s) of a 
chromosome, also known as clastogenicity. The following are the most noticeable 
chromosomal structural mutations (Figure 1.1).
1. Deletion or insertion
The loss of a chromosomal segment is called deletion. Chromosome deletions often occur 
due to double strand breaks separating a fragment from the end of a chromosome, which 
is not incorporated into the daughter nuclei. These are often seen as micronuclei in the 
cytoplasm.
2. Duplication
The presence of two copies of a chromosomal region is called duplication. They occur by 
misreplication, amplifying the DNA sequence contained within.
3. Inversion
A segment of chromosome is reversed in orientation and rejoins the chromosome.
4. Translocation
A segment of chromosome is exchanged for another part of a different chromosome. This 
occurs in two stages; firstly double strand breaks lead to deletion events and the fragments 
are then wrongly joined to another chromosome.
The location of the mutation within a gene will determine the resulting consequence. If the 
mutation arises within the promoter region, this may result in the change of expression of that 
gene, causing either an over expression or under expression of that particular gene product. 
On the other hand, a mutation within the coding region of the gene may result in the protein 
product of the gene having altered structure and function (Pecorino, 2006).
1.2.3 Mutations and cancer
In normal cells mutations are occurring at a rate of 10‘10 mutations per nucleotide per cell per 
generation (Jackson and Loeb, 2001) and it has been estimated that between four and seven 
mutations in key genes are necessary to produce most human cancers (Sarasin 2003). There is 
a correlation between mutation rate and cancer, as mutations are essential for cancer 
evolution. Cancer is a genetic disease with cells containing multiple mutations, indicating that 
tumour progression is driven by mutagenesis (Sarasin, 2003; Loeb and Loeb, 2000). As an 
early event of carcinogenesis, mutations occur in genes which maintain genetic stability in 
normal cell leading to a generation of pre-cancerous cells with genetic instability resulting in 
a cascade of mutations some of which enable cancer cells to bypass the host regulatory
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Figure 1.1 Modification of chromosome structure by insertion, deletion, duplication, inversion 
and translocation. Modified figure from www.tutorhelpdesk.co.uk.
processes that control cell progression, gene adaptation and apoptosis (Loeb and Loeb, 2000). 
Normal mutation rates followed by selective advantage o f  mutated clones are enough to 
produce the numerous mutations found in human cancers (Sarasin, 2003; Loeb et oK 2003). A 
number of exogenous sources introduce mutations into DNA at a much higher level than 
spontaneous and therefore, it is important to detect substances which pose a risk to the human 
population. Genetic toxicology is the field that aims to test chemicals for their genotoxic, 
mutagenic and carcinogenic potential (Loeb and Loeb, 2000).
1.3 Genetic toxicology and hazard identification
Human populations are surrounded by a vast array of genotoxic agents and therefore it is 
important to determine genotoxic potential of the compounds with which we come across as
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part of our daily life, in order to ensure safe exposure. Knowledge and awareness of genotoxic 
potential is not only useful to categorize and regulate these agents but also helps to devise 
strategies on safe use and/or protection against these agents (Doak et al, 2007).
Genotoxicity of a chemical is determined by in vitro (mammalian) and in vivo (animal 
models) tests. Initially, genotoxicity was only associated with external agents, however, later 
studies showed that endogenous processes and viruses could also lead to carcinogenicity 
(Peyton, 1911). The first step in determining risk to humans is to identify the hazardous 
compound; therefore, The International Agency for Research on Cancer (IARC, 2010) has 
developed several groups to categorize carcinogens:
Group 1: Carcinogenic to humans
Group 2A: Probably carcinogenic to humans
Group 2B: Possibly carcinogenic to humans
Group 3: Not classifiable as to its carcinogenicity to humans
Group 4: Probably not carcinogenic to humans
Genotoxicology assays provide vital information on the effect of a genotoxin on the target, the 
dose dependant responses, possible mode of action and potential damage to DNA. Mode of 
action appears to play an important role in determining risk of any genotoxin, therefore, it is 
important to undertake specific genotoxic assays to gain a better understanding of the effects 
of genotoxins.
1.4 Regulatory genotoxicity testing
In vivo and in vitro genotoxicity tests are designed to detect compounds which induce genetic 
damage directly or indirectly by various mechanisms. Many countries have developed 
guidelines for testing the genotoxicity of new chemicals to ensure the standardisation of assay 
methodology. No single test alone can predict the entire spectrum of inducible mutations, 
because of the variety of genetic events that can occur (Cimino, 2006). There is a general 
consensus that genotoxicity testing should consist of two stages i.e. stage 1 involving basic in 
vitro tests and stage 2 involving in vivo genotoxicity testing on compounds observed to be 
positive in stage 1 testing (COM, 2000). In 2011, the Committee on Mutagenicity (COM) also 
recommended to consider stage 0 that involves preliminary considerations on the physio- 
chemical properties of the test agent.
Stage 1 assays are based on in vitro testing such as:
• a bacterial gene mutation assay (Ames test) which uses strains of Salmonella 
typhimurium and Escherichia coli that require specific amino acid supplements to
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detect point mutations. Initially these tests were conducted on agar plates, however, 
further developments of the procedures led to development of a more robust system 
known as the fluctuation method. The fluctuation method uses liquid culture medium 
in a 96 well plate format and mutation frequency is counted by scoring the number of 
wells that turn yellow from purple. Several commercial kits are available which use 
this test and thus offer a high throughput screening procedure. These kits are also 
available with rat liver S9 fraction supplements to mimic mammalian metabolic 
conditions. There are different genotoxic end points that are required to be assessed, 
therefore, it is recommended to use more than one test to detect genotoxic potential of 
any agent. Bacterial gene mutation assays are therefore combined with:
•  In vitro micronucleus assay to assess chromosome damage. This method is the most 
popular for genotoxicity testing because it has an ability to measure both chromosome 
number changes and chromosome breakage, is simple to score, accurate, and widely 
used in different cell types.
These assays help to determine the hazard of a test agent with respect to DNA damage, gene 
mutations, chromosome damage and aneuploidy (COM, 2011). In the case of a negative result 
at stage 1, stage 2 testing is normally not required, however, if the test agent is believed to 
have a prolonged human exposure then stage 2 testing may be considered.
A positive result in stage 1 would lead to further investigation using in vivo testing. Stage 2 
test involves a variety of assays and a testing strategy is decided on a case to case basis. The 
rodent chromosome aberration assays to investigate aneuploidy and clastogenicity and the 
rodent transgenic gene mutation assay and/or comet assay for DNA damage induction are 
most commonly used in stage 2 (COM., 2011).
1.5 Dose-response relationships
Genotoxic potential of any chemical is assessed by dose dependant responses whereby the 
effect of different doses is used to assess its ability to cause genotoxicity. Results of dose 
dependant studies are then used to plot dose-dependent curves. The shape of the curve reflects 
the dose related potency of the chemical. Regulatory bodies use the shape of the dose 
dependant curve in determining recommendations for the chemical. The different shapes of 
dose-response curves are shown in Figure 1.2.
Linear, supralinear and sublinear responses are shown for DNA adducts that may lead to 
mutations involved in initiation of cancer (Swenberg et al, 1995).
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Figure 1.2 Theoretical dose-response curves. A- Sublinear when detoxification or DNA 
repair is saturated, Linear when there is no safe exposure and Supralinear when metabolic 
activation is saturated. B- J-shapes curved then there is hormesis and C- Threshold dose 
response. Modified from Lutz, 1998 and Swenberg et al, 1995.
1.5.1 Supralinear and sublinear
Generally supralinear and sublinear mutations are distinguished at higher doses whereas 
linearity appears at low doses of chemical. Supralinear dose-response can appear when 
saturation of metabolic enzymes are reached. Pro-carcinogens that require metabolic 
activation to convert into DNA reactive electrophiles, are capable of covalently binding with 
DNA and form adducts. Supralinear dose-response was observed in rat lungs where higher
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concentrations were less effective and causing 0 6-methylguanine ( 0 6MeG) adducts 
(Swenberg et al, 1995). These effects could be attributed to cell death due to toxicity at higher 
doses thus removing damaged cells from population (Supralinearity). Sublinearity could 
involve an increased adduct fixation through increased cell division in response to cytotoxic 
doses of genotoxin (Lutz, 1990).
1.5.2 Linear dose-response
The linear dose-response was described after the discovery of x-ray induced mutations in 
Drosophila by Hermann J. Muller in 1927 (Calabrese, 2009). The hypothesis of a linear dose- 
response relationship without a threshold at low doses was proposed on the basis of single-hit 
model of action (Crebelli, 2000) based on historical work with ionising radiation (UNSCEAR, 
United Nations Scientific Committee on the Effects of Atomic Radiation, 1958). Recently this 
model was extended to chemical mutagens, based on the theory that the interaction of a single 
molecule of a mutagen with DNA is sufficient to cause a mutation that can potentially trigger 
a carcinogenic process (Knudson, 1971). It is now known that not all DNA damage cause 
mutations (Swenberg et al, 2008), but there are some cases where mutagenicity is 
proportional to DNA damage due to poor adduct repair or increased mispairing potential 
during DNA replication, such as for aflatoxin B 1 or benzo[a]pyrene (Crebelli, 2000). 
According to the regulatory bodies, the linear model is a default prediction of low dose 
adverse effects in response to genotoxic carcinogens meaning that there is no safe level of 
DNA damage, there is no safe level of exposure. It was also assumed that the direct acting 
genotoxins (including clastogens) have a linear relationship between exposure to genotoxin, 
DNA damage and induction of mutation (Henderson et al, 2000). Linear models could be 
applied to all the chemicals but not for aneugens and non-genotoxic carcinogens, due to their 
mode of action that affects cell division and/or loss or gain of whole chromosomes 
(Calabrese, 2009).
1.5.3 J-shaped dose response
Many toxicological studies have observed a biphasic dose-response where there are decreases 
in the response (measured as genetic damage) to levels below the negative control at low 
doses followed by a substantial increase in measured damage at high doses. This biphasic 
response is called a J-shape or U-shape dose-response and the concept is called hormesis. In 
some cases hormesis (also referred to as an inverted U shaped dose-response) arises as a 
consequence of low doses of a chemical causing stimulation (e.g. of repair) and high doses
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causing inhibition of cellular processes such as growth and reproduction or cell proliferation 
(Calabrese and Baldwin, 2001). In toxicology, hormesis is illustrated by a J-shaped curve, 
reflecting that low doses give a lower response compared to the negative control and high 
doses reflect the occurrence of endpoints in the form of cancer incidence. It was observed that 
when fore-stomach and kidneys of the male F344 rat were exposed to caffeic acid it produced 
a J-shaped dose-response due to the cell proliferation that induced tumour formation (Lutz et 
al, 1997).
It has been postulated that all synthetic and naturally occurring chemicals are toxic at high 
doses and at low doses all chemicals have a hormetic effect (Rozman, 2005), making linear 
risk assessment models obsolete. So far 1600 toxicological dose-response relationships are in 
agreement with the hormesis hypothesis (Calabrese and Baldwin, 2001). Hormesis was 
interpreted as an adaptive response characterized by biphasic dose responses. Induction of 
DNA repair is an adaptive response to DNA damage. The hormetic dose-response represents 
the effects of a repair process that slightly overshoots the original homeostatic set point to 
result in a low-dose stimulatory response (Calaberase, 2009). For example, Escherichia coli 
bacteria treated with low level of alkylating agent N-methyl-N-nitro-N-nitrosoguanidine 
(MNNG), induced mutations for 20min and then become resistant due to the induction of the 
repair of 0 6-methylguanine (Cairns, 1980). Similar DNA repair capability was observed when 
the liver of rats was exposed to nitrosamines (Lutz, 1982).
1.5.4 Threshold dose-response
In genetic toxicology, dose and frequency of exposure to a genotoxic agent plays an important 
role in determining the level of DNA damage. Therefore, even at lower doses for many 
chemicals there is a risk of genetic damage and response can be linear or non-thresholded 
(Kirsch-Volders et al, 2000). However, many studies have reported a non-linear dose 
dependant response for most genotoxic agents, which have non-DNA targets, e.g. nocodazole, 
colchicine, carbendazim (Elhajouji et al, 2011). These studies showed no or little effect below 
a certain dose and thus supporting the theory of a threshold existence. These studies 
concluded that depending upon the chemical involved no observable effect is seen below a 
certain dose and this dose or concentration was termed as a No Observable Effect Level 
(NOEL). As the concentration of chemical increases from a NOEL, a statistically significant 
genotoxic effect is observed and thus these doses were referred to as Low Observable Effect 
Level (LOEL) e.g. a study examining low dose genotoxicity of MMS and EMS in the human 
cell line AHH-1 reported NOEL concentrations of 0.85 and 1.40|Jg/ml for MMS and EMS,
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respectively (p<0.05) above which, increases in chromosomal damage were observed in the 
form of micronuclei formation (Doak et al, 2007).
Considering the variability in cell types and protective mechanisms within cells, it is 
understandable to expect some degree of variation in NOEL and LOEL values; therefore, for 
in vivo data in order to obtain safe exposure levels, regulators use a variation factor of 100 to 
establish NOEL and LOEL for each compound. The critical dose (often the NOEL) is divided 
by 100 to obtain a safe exposure level. This 100 value takes into account and represents 10 
times variability within species and another 10 times factors is applied to counter any 
variation among humans (WHO, 1987).
The threshold model was used in 1920/1930s in establishing radiation health standards. In 
1928 the International Committee on Radiation Protection (ICRP) recommended a tolerance 
dose 1/100 of a 600r of erythema dose in 30 days for occupational radiation exposure. 
Similarly the second radiation standard report was published in 1934 by The National Council 
on Radiation Protection and Measurement (NCRPM), stating that a safe whole body exposure 
is O.lr/day for hard x-rays (Calabrese, 2009).
The concept of thresholds in genotoxicity has been discussed extensively and it has been 
accepted for aneugens, topoisomerase, and polymerase inhibitors on the basis of experimental 
data and mechanistic reasons (Elhajouji et al, 2011). Recent studies with alkylating agents 
such as MMS and EMS support the existence of threshold dose-response for clastogens (Doak 
et al, 2007). There are many biological mechanisms which are induced at low doses such as 
redundant targets, detoxification and error-free DNA repair which are involved in establishing 
the threshold dose response (Jenkins et al, 2005). However, the acceptance of threshold is 
based on a case-by-case basis together with strong experimental evidence, along with 
understanding of the mechanisms involved in the mutagen-target interactions (Elhajouji et al, 
2011).
1.5.4.1 Definitions of Threshold
A threshold dose is a dose of chemical below which it does not induce any effect after 
exposure although it has a potential to induce it (Kirsch-Volders et al, 2000). In toxicology, 
biological or practical threshold is an actual dose below which there was no dose- response. 
This type of threshold is characterised by the inflection point which is the point where the 
change in the gradient is at its maximum (Johnson et al, 2009). For the better understanding 
of threshold dose response it is important to calculate the NOEL and LOEL. According to the 
European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) definition, an
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absolute threshold is “a concentration below which a cell would not ‘notice’ the presence of 
the chemical. In other words, the chemical is present but does not interact with the cellular 
target” . This is almost impossible to measure. The 'pragmatic’ threshold is a concentration 
below which any effect is considered biologically unimportant (Lovell, 2000) (Figure 1.3) and 
often leads to no increase in adverse event (DNA damage) above the background level.
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Figure 1.3 The dose-response curve showing the absolute threshold. Modified from Johnson 
et al, (2009) and Lovell, (2000).
The threshold values can be estimated by using statistical approaches, based upon the 
identification of no observed (adverse) effect levels (NOAEL) or lowest observed (adverse) 
effect levels (LOAELS) (Lovell, 2000). A NOAEL is the highest dose that does not cause an 
adverse effect, whereas the LOAEL is the lowest dose that causes the adverse effects (COT- 
IGHRC, 2007)
According to Lutz (1998) a true threshold dose is a point in the dose response curve where a 
slope 0 changes into a slope >0. It is difficult to find a true threshold for a substance which 
has variable background rate. However a practical threshold dose can be set from the linear 
part o f  the dose-response curve hidden within the background variability (Lutz, 1998) (Figure 
1.3-Shaded area represent the background variability). The background value is always 
variable for every biological mechanism (Kirsch-Volders et a l, 2009). The NOELs and 
LOELs are heavily dependent upon dose spacing, more doses, and more accurate responses.
13
Chapter 1
Nowadays, a threshold level is commonly used to determine or establish a safe limit of a 
chemical for human use. In toxicology in general, thresholds are accepted but the linear 
argument has dominated. This threshold limit is derived from dose dependant responses, 
mathematical and statistical models so as to cover any variability. Typically a threshold level 
is a value between NOEL and LOEL (Kirsch-Volders et al, 2009) and can be confirmed by 
mathematical modelling and statistics (Jenkins et al, 2005). In another assumption, a 
threshold corresponds to the inflection point between the first statistically significant and the 
last non-statistically significant concentrations, and can be estimated by using mathematical 
modelling (Lynch et al, 2003). Toxicity testing recommendations such as recent COM 
guidelines (2011) state however that the justification of the threshold utilising statistical 
modelling is not enough and the biological mechanisms involved in establishing the threshold 
also need to be assessed (Lynch et al, 2003).
1.5.4.2 Mechanisms of threshold
There are significant differences in the mechanisms involved in thresholds for non-DNA 
damaging agents and DNA-damaging agents (Jenkins et al, 2005). The interpretation of the 
threshold results for all types of end points are dependent on (1) the number and identity of 
the targets (2) the mode of interaction between the target and agent and (3) the quantification 
of the end point and its sensitivity (Kirsch-Volders et al, 2000).
Kirsch-Volders et al (2000) further described the relationship between the mutagen, the target 
and the endpoint and proposed the following models depending upon the mode of action of 
mutagen and interaction with the target. These models included;
• Single hit, single target: whereby a single change in one base can lead to mutation. 
This model represents no threshold levels as any concentration of mutagen is able to 
bring about mutations in the absence of repair mechanisms. In this model, mutations 
are defined as a DNA lesions leading to alterations in a gene or chromosome.
• Single hit, multiple targets and multiple hit, single target: represents a variety of 
scenarios where a single hit on multiple targets or multiple hits on a single target 
produces a dose dependant response exhibiting theoretical threshold levels (Kirsch- 
Volders et al, 2000). This model involves multiple events to bring alterations in a and 
p tubulins, topoisomerase, K+ and Ca+ channels and spindle nuclear membrane.
Since these models require multiple interactions and events, several protective mechanisms 
such as detoxification of the genotoxic agents, exclusion from the cell or nucleus, 
conjugation, DNA repair of the induced damage, apoptosis or necrosis can influence threshold
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levels (Jenkins et al, 2005). Another mechanism involved in producing the threshold is DNA 
redundancy in which some DNA mutations are in redundant parts of the genome (inter-genic 
regions or introns) and do not alter protein function. Also noted with redundant non-DNA 
targets, e.g. the effect in spindle fibres, where many need to be damaged to disrupt 
chromosome segregation (Jenkins et al, 2005).
1.5.4.3 Endpoints and their sensitivity
The threshold dose can be used for various genetic endpoints such as DNA adducts and DNA 
and chromosome damage (Kirsch-Volders et al, 2003). If the endpoint involves a different 
target, three different levels can be considered at the cellular level namely:
Proximal: the point is close but still different from the target, for example gene mutations, 
chromosomal structural mutations;
Intermediate: the endpoint is separated by some steps from the target, for example analysis of 
repair and metabolic pathways; and
Distal: the end point is the result of the complex alterations of cellular activities, after the 
initial interaction of compound with the target, such as apoptosis, necrosis and cell survival 
(Kirsch-Volders et al, 2003). The main endpoints for the analysis of threshold dose response 
are DNA adducts formation, gene mutation and chromosomal aberration.
A genotoxic threshold indicates that chemical will not produce any mutation below a critical 
exposure level and therefore, reduces the risk for the induction of cancer.
1.6 Genotoxic threshold for carcinogens
Carcinogenic compounds that lack the ability to induce DNA damage directly or indirectly 
(Cohen, 2004) and have multiple cellular targets in humans and animals are known as non- 
genotoxic. It is now generally accepted by the scientific community and regulators that 
NOELs exist for chemicals that are non-genotoxic carcinogens, such as hormones and tumour 
promoters (Madle et al, 2000). Non-genotoxic carcinogens are considered to have a “real 
threshold” (reviewed by Kirsch-Volders et al, 2000).
1.6.1 Genotoxic threshold for non-DNA reactive genotoxins
The carcinogenic effect of non-DNA reactive chemicals may include an increase in cell 
proliferation or modification of multiple cellular targets, lipid peroxidation, protein adduct, 
inhibition of repair enzymes, proteins controlling cell cycle, apoptosis related genes, defense 
proteins against oxidative damage, metabolizing enzymes and tubulins of the mitotic or
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meiotic spindle. Capen (1998) identified that thyroid-stimulating hormone (TSH) increased 
the mitogenic effect in rat follicular cells that appeared in the form of increased cell numbers 
(IARC WG, 1999) or because of toxicity and regeneration in rodents i.e. sodium saccharin 
(Cohen et al, 2004), melamine, chloroform, d-limonene (Cohen and Arnold, 2011). Other 
non-DNA reactive genotoxins include spindle poisons such as nocodazole (Elhajoujii et al, 
1995) which induces tumour in humans. All of these agents have dose response relationships 
between exposure and tumour formation in animals (Cohen and Arnold, 2010). According to 
previous regulations of non-DNA reactive genotoxins, these compounds do not have a 
threshold mode of action. It was proved with more research that there are exceptions to this 
and that needs justification (Madle et al, 2000). Currently there are few examples of non- 
DNA reactive compounds having a threshold mode of action e.g. spindle poisons such as 
carbendazim, colchicine, nocodazole and mebendazole (Elhajoujii et al, 1995; Kirsch-Volders 
et al, 2003). Mechanistically relevant thresholds for non-DNA reactive chemicals have only 
been shown in vitro (reviewed by Kirsch-Volders et al, 2003) and these include aneugens, 
(Elhajouji et al, 1995), spindle inhibitors (Elhajouji et al, 1997) and topoisomerase II 
inhibitors (Lynch et al, 2003). A “statistical” or “apparent” threshold has been attributed to 
these types of chemicals (reviewed by Bolt et al, 2004) because they are connected with rapid 
degradation and other mechanisms that reduce the target exposure (reviewed by Kirsch- 
Volders et al, 2000).
1.6.2 Genotoxic threshold for DNA reactive genotoxins
DNA acting genotoxins are believed to cause DNA damage by ’’one hit" theory therefore the 
concept of a threshold for direct acting agents (e.g ionizing radiation and alkylating agents) 
has generally not been accepted by regulatory authorities (Kirsch-Volders et al, 2000), 
however, new evidence is changing that attitude. For such agents, a linear non-threshold 
(LNT) model is usually applied whereby DNA damage at any level is considered unsafe 
(Henderson et al, 2000). On the other hand, most researchers believe that a threshold may 
exist as cells may also tolerate low levels of damage. This exposure to low levels could arise 
exogenously (from diet e.g. heterocyclic amine) or endogenously (oxidative stress).
The ability of organisms to tolerate low levels of chemicals has highlighted the need to assess 
each chemical for the existence of a threshold on an agent-by-agent basis (Jenkins et al, 
2005). Due to uncertainty of certain chemical carcinogens, a LNT extrapolation is assumed as 
a precaution. Based on discussions by Streffer et al, (2004), Bolt and Degen (2004) proposed
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a flow scheme to aid in the risk assessment of the four basic types/groups of chemical 
carcinogens (Figure 1.4). The four groups include:-
A: Genotoxic carcinogens, that are non-thresholded and therefore a LNT model is 
applied for low-dose assessment. The ALARA principle (“as low as reasonably 
achievable”), technical feasibility and socio-political considerations all contribute to 
the regulation of these chemicals. An example of a chemical that fits this group is 
Aflatoxin B] (European Commission, 2006; Streffer et al, 2004).
B: Genotoxic carcinogens, where we can not adequately support the existence of a 
threshold. A LNT extrapolation is applied based on the precautionary principle which 
aims to protect humans in the absence of full scientific knowledge. Acrylamide is an 
example of a borderline case (Committee on toxicity, 2002; Streffer et al, 2004).
C: Genotoxic carcinogens which have been shown to have an apparent threshold with 
the supporting mechanistic data. The NOEL is used to decide health-based exposure 
limits. Formaldehyde shows an apparent threshold (Streffer et al, 2004).
D: Non-genotoxic carcinogens and non-DNA reactive carcinogens show a real 
threshold. A NOEL can be used to decide health-based exposure limits. An example of 
a non-DNA reactive genotoxin is nocodazole (Elhajouji et al, 1997).
Determination of threshold mechanism varies among non-DNA reactive and DNA reactive 
chemicals. Multiple targets are involved in non-DNA reactive chemicals, for example 
Elhajouji et al, (1997) reported that colchicine can only induce non-disjunction when 
concentrations are high enough to damage sufficient molecules to disrupt spindle formation. 
In case of direct acting agents, DNA repair mechanisms and single hit theory are considered 
to be significant in determining threshold. Hengstler et al (2003) reported that even a single 
hit of aflatoxin may be able to form a bulky adduct. Direct acting alkylating agents are 
believed to have a non-linear dose response and thus one hit theory does not apply and there is 
a safe exposure level and in vitro studies by Doak et al (2007) and Seager et al (2012) support 
this concept.
1.7 Existence of threshold in Indirect-acting genotoxins (pro-carcinogens)
The indirect-acting genotoxins require metabolic activation and therefore, they are called pro­
carcinogens. The pro-carcinogens themselves are not usually carcinogenic, but their 
metabolism results in by-products that are active carcinogens which interact directly with 
DNA to exert their carcinogenicity. For example, aflatoxin B1 is hepatically metabolized to
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an epoxide intermediate that interacts with DNA causing liver cancer (Smela et al, 2001). 
Similarly in cigarette smoke there are many pro-carcinogens such as PAH’s that turn into 
active carcinogens in lung cells. Since a pro-carcinogen’s ability to cause carcinogenetic 
effects is dependent on cellular mechanisms, therefore, dose dependant responses are believed 
to be much more complex than those observed in direct acting carcinogenic agents.
As compared to direct acting agents, little is known about the threshold of pro-carcinogenic 
agents and further studies are required to understand the dose dependant response of 
chemicals that require metabolic activation to cause carcinogenic effects.
Distinction o f  Carcinogens in View o f  Low -Dose Extrapolation
(according to Streffer et al. 2004)
Chemical carcinogen,
causing tumors in humans and/or experimental animals
Genotoxic Non-genotoxic
DNA reactive,
causing mutations
Genotoxicity only on chromosome
Clearly 
DNA-reactive 
Sc initiating 
 1—
Weak genotoxin,
Borderline secondary mecha­
cases nisms important
A: No threshold.
LNT model to apply
6 :  Situation not clear
LNT as default
Cl Practical/apparent 
threshold likely
D l True/perfect 
threshold likely
Numerical risk assessment, 
technical feasibilities ?
—» ALA R A  principle
NOAEL
-» health-based exposure limit(s)
Figure 1.4 Adaption of a flow scheme proposed by Bolt and Degen (2004) according to 
discussions by Streffer et al (2004) for risk assessment and standard setting for chemical 
carcinogens.
1.7.1 Metabolic activation of pro- carcinogens
The concept of metabolic activation originated in 1960s when Miller and Miller (1966)
suggested that ‘carcinogens could either be electrophiles as such or are metabolically
activated to electrophiles which covalently bind to cellular macromolecules.’ Later on
DeBaun and team discovered that the aromatic amide, 2-acetylaminofluorene (2-AAF), was
metabolically activated to a reactive electrophile, A^-hydroxy-2-acetylaminofluorene which
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reacts with DNA, forming DNA adducts and ultimately leads to mutations in rodents, due to 
the presence of cofactor 3'-phosphoadenosine-5-phosphosulphate (PAPS), required by 
sulfutransferases (SULTs) (DeBaun et al, 1968).
A variety of metabolic processes have been identified in the activation of many classes of 
carcinogens, primarily involving cytochrome P450 enzymes (Guengerich, 2000). Other 
enzyme systems were also identified that participate in the metabolism of various 
carcinogens. All of the enzymatic pathways involved in the metabolisms have different 
kinetics and saturation levels (Guengerich, 2000).
Some metabolic processes lead to the activation to reactive electrophiles but some may lead to 
inactivation of the chemicals by increasing aqueous solubility that is excreted through urine or 
faeces. Therefore exposure to any chemical initiates competing metabolic pathways for 
activation versus inactivation due to the differences in levels of each of the enzyme processes 
in human individuals, variability in induction and environmental influences on induction or 
inhibition of enzymes (Boddy and Ratain, 1997).
1.7.2 Cytochrome P 450 enzymes and carcinogenesis
Cytochrome P450 enzymes are primarily found in liver cells but are also located in cells 
throughout the body. Within cells, cytochrome P450 enzymes are located in a structure 
involved in protein processing and transport (endoplasmic reticulum) and the energy- 
producing centres of cells (mitochondria). The enzymes found in mitochondria are generally 
involved in the synthesis and metabolism of internal substances, such as steroid, hormones, 
cholesterol and other fatty acids. The enzymes in the endoplasmic reticulum usually 
metabolize external substances, primarily medications and environmental pollutants (Nebert 
and Russell, 2002). These enzymes produced from the cytochrome P450 genes are involved in 
the formation (synthesis) and breakdown (metabolism) of various molecules and chemicals 
within cells. (Nebert and Russell, 2002; Guengerich, 2008)). There are approximately 60 CYP 
genes in humans.
Each cytochrome P450 gene is named with CYP, indicating that it is part of the cytochrome 
P450 gene family. The gene is also given a number associated with a specific group within the 
gene family, a letter representing the gene's subfamily, and a number assigned to the specific 
gene within the subfamily. For example, the cytochrome P450 gene that is in group 1, 
subfamily A, gene 1 is written as CYP1A1(Nq\soyi et al, 2004). All cytochrome P450 are part 
of a superfamily and divided into families, sub-families and individual P450s according to the 
identity of their amino acid sequences. The major CYP’s; 1 A l and 1A2 enzymes are involved
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in the metabolism of polycyclic aromatic hydrocarbons and heterocyclic amines, 
nitrosamines, azo-dyes and alkylating agents (Gonzalez and Gelboin, 1994).
When carcinogens enter into a body, they undergo several metabolic pathways. It is 
metabolized by the Phase 1 enzymes that include microsomal CYP families and epoxide 
hydrolases. The metabolites are further modified by the Phase 11 enzymes includeing UDP- 
glucuronosyltransferase (UGTs), sulfutransferases, glutathione S-transferases and N- 
acetyltransferases. These metabolic pathways result in inactivation or detoxification. In this 
pathway, after carcinogenic exposure, the cell metabolize the carcinogen and converts it into 
an activated form or discharges it through a specific transport system or converts the 
metabolites into more active or toxic intermediates that may form DNA-adducts and result in 
mutations which may lead to cell death or cancer when DNA repair mechanisms fail to fix the 
damage (Gonzalez and Gelboin, 1994) (Figure 1.5).
ExcretionCarcinogen
m§ Phase I 
ActivationCytoplasm
Phase I 
Activation
Phase II 
Detoxification Normal cell
DNA repair
DNA'adduct 
Silent mutations 
N u c l e u s  'O ncogene mutations
Tum our suppressor gene mutations 
P53, ras, e t c . . .
Cell death
C ancer cell
Apoptosis , Necrosis, etc..
Figure 1.5 Activation and detoxification pathway o f  carcinogens. Figure modified from 
Oyama et al, (2004).
1.7.3 CYP450 and genetic polymorphism
The frequency o f  variants at a gene locus when occurring greater than 1% of the same 
population is termed a genetic polymorphism (Vineis and Porta, 1996). Various
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epidemiological studies have proved the correlation between genetic polymorphisms in 
xenobiotic-metabolizing enzymes and cancer susceptibility in humans. Individuals have 
different and unique combinations of polymorphic forms of xenobiotic-metabolizing enzymes 
such as some people have defective enzymes that activate polycyclic aromatic hydrocarbons 
(PAHs) but normal enzymes for detoxification. In contrast, other people have normal 
enzymes to activate PAHs and defective enzymes to detoxify them. The genetic 
polymorphism in the CYP enzymes may be due to a single nucleotide polymorphism (SNP) 
and one SNP locus occurs per 1,000 nucleotides approximately in an individual to give those 
different appearances and characters (Buetow et al, 1999; William, 2001; Ingelman-Sunberg, 
2001). High-throughput technology like DNA microarrays has identified SNPs in CYP genes 
which give differences in the transcriptional and translational efficiencies, the enzyme 
properties and their activities For example polymorphisms of CYP 1A1 and GST are 
associated with the risk of lung cancer in smokers who have high CYP1A1 and low GST 
activity (Bartsch et al, 2000). SNPs in the genes encoding Phase I and Phase II enzymes differ 
among racial groups and individuals because of the difference in induction of enzyme 
expression by the increased exposure to carcinogens (Nagata and Yamazoe, 2002).
The activity of P450 depends upon the components constituting the electron transport system 
in microsomal membranes e.g. NADPH-cytochrome R450 reductase, cytochrome bs and 
NADPH-cytochrome bs reductase. The NADPH-cytochrome P450 reductase mediates an 
electron transfer from NADPH to P450, essential for catalytic function of P450. The level of 
these factors controls the activity of the expressed P450 whereas, the level of the reductase 
activity varies among cell lines, it is generally low compared to the levels in the liver (Glatt et 
al, 1990).
Microsomal epoxide hydrolase (mEH) plays an important role in the activation and 
detoxification of many xenobiotic compounds. It catalyzes the conversion of epoxide into 
glycols. For example some polycyclic aromatic hydrocarbons (PAH) like BaP are activated by 
P450-dependent epoxidation and then epoxide is hydrated by mEH. It was found by Glatt et 
al, (1990) that the mEH activity varied among cell lines.
Some other enzymes like N-acetyltransferases, detoxify the reactive intermediates produced 
by the metabolic activation of chemicals. These enzymes catalyzed the conjugation reactions, 
such as acetylation, sulfunation, glucuronidation and glutathione conjugation.
The aryl hydrocarbon receptor (AHR) binds a wide variety of xenobiotic compounds and acts 
as a mediator of the induction of certain xenobiotic drug metabolizing enzymes, is responsible 
for the toxicity of halogenated aromatic hydrocarbons such as 2,3,7,8-tetrachloro-dibenzo-p-
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dioxin (TCDD) or PAHs (Hankinson, 1995; Gasiewicz and Collins, 2008) and is also an 
important component of normal development (Nguyen and Bradfield, 2008). The AHR is a 
basic helix-loop-helix cytosolic protein which forms a complex with two heat shock protein 
90 (HSP90) molecules and XAP2 (X associated protein 2). The regulation of CYP1A1, 1A2 
and 1B1 via the AHR signalling pathway has been reported extensively activation (Nguyen 
and Bradford, 2008).
1.7.4 Metabolism of carcinogens in normal human cells
To understand the role of metabolic activation of chemicals in inducing cancers, primary 
cultures of normal human epithelial tissues and liver cells have been extensively used for the 
chemical to induce mutations as it is not possible to induce cancer in a primary culture. The 
advantages of human tissue and cells used to study the carcinogen metabolism are:
1. They provide the activating system in cell mediated mutagenesis assays;
2. It is easy to measure the unscheduled DNA synthesis in cells and tissues treated 
with the carcinogen; and
3. Can measure the metabolites and their ultimate carcinogenic form by measuring 
their binding to cellular macromolecules, especially DNA.
At the biological active dose the binding of the carcinogenic metabolite to DNA represents an 
important measure for the amount of active metabolites available within the tissues.
A considerable number of chemicals including those originating from industrial processes and 
occupational exposure require metabolic activation to cause carcinogenicity. There are three 
major classes of chemicals requiring metabolic activation:
• Polycyclic aromatic hydrocarbons (PAH): such as Benzo[a]pyrene (B[a]P). These 
hydrocarbons are found everywhere such as automobile exhaust, cigarette smoke and 
cause lung cancer;
• Heterocyclic amines, A-nitrosamines: ingestion or inhalation of certain compounds 
such as 4-(methylnotrosoamine)-l-(3-pyridyl)-l-butanone (NNK), from the 
environment or from nitrosation of exogenous amino precursors in the body are 
associated with an increased risk of oesophageal cancer due to the in situ formed 
nitrosamines (Bartsch et al, 1983); and
• Aromatic amines, through occupational exposure or cigarette smoke are considered to 
be the major factor of human bladder cancer.
Other than tissues and cells, extracellular systems (from human tissues) were also used to 
determine the activity of enzymes involved in the metabolism of carcinogens and as activation
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systems in mammalian and bacterial mutation assays. In standard in vitro genotoxicity testing, 
the induced rat liver S9 fraction has been adopted as an external activating system, to generate 
electrophilic metabolites that react with macromolecules like DNA and proteins (Ames et al, 
1973; Paolini, 1997). The induced rat liver S9 fraction is known as a ‘metabolite factory’ in 
the Ames test and other in vitro genotoxicity tests, especially Aroclor 1254-induced rat S9 
fraction to identify different types o f  compounds as mutagens.
This enzyme system provides a reliable, robust and readily available bio-activation system in 
rodents at a time when human-derived systems were rare and unavailable. It was believed that 
rodent systems can standardized more easily than an exogenous human derived system 
originating from human tissue samples which are known to have significant biological 
variation.
In later studies, the rat liver S9 fraction was not used as a metabolic activation system in in 
vitro genotoxicity testing due to the fact that the rat and human CYP1A enzyme and other 
CYP enzymes are different in structure and function from each other and have their own 
substrate specificity and pathways involved in drug metabolism (Guengerch, 1997) (Figure 
1.6). For example in rat liver S9 mix, the expression levels o f  CYP1A and 2B enzymes are 
elevated after 5,6-benzoflavone induction, but other enzymes show less or decreased 
expression (Guengerich et al, 1982). This system favours the CYP-mediated metabolism 
(Phase I) whereas Phase II enzymes, are not active in the reduced form of  the nicotinamide 
adenine dinucleotide phosphate (NADPH)-supplemented S9 system (S9 mix) because other 
cofactors and additives e.g., uridine diphosphate glucuronic acid, glutathione, acetyl- 
coenzyme A, etc. would be needed (Ku et al, 2007; Obach and Dobo, 2008).
Phase I drug  m etabolizing  enzym es
O x i d a t i o n  R e d u c t i o n  H y d r o l y s i s
Chem ical
Rat liver S9 mix Human hepatocyte
Figure 1.6 Comparison of  rat liver S9 mix and human hepatocytes. Image modified from 
Hashizome and Oda, 2012.
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In some cases the detection of genotoxic potential is dependent on metabolites that are formed 
in target cells by endogenous enzymes; therefore a standard in vitro system does not represent 
the optimum testing system. Application of active metabolite extracellularly showed negative 
results due to low penetration into the cell and access to DNA or interaction of these 
metabolites with components of S9 or cell membrane. For example electrophilic metabolites 
of a chemical bind to serum or S9 proteins, forming protein adduct, and reduces the rate of 
binding to DNA to form DNA adducts.
Therefore, the rat in vitro system was replaced with a human system to identify the 
metabolites hazardous for humans.
1.8 Establishment of genetically engineered cell lines
Many cell lines have been established for metabolic studies in toxicological testing. Most of 
them possess no or very little levels of P450 activities. To overcome this problem two 
metabolic activation systems have been used. One is an externally added cell-mediated 
system, in which target cells are co-cultivated with primary cultured hepatocytes. The other is 
a S9 mix prepared from the rat liver homogenates and added to the culture medium to activate 
the test compound by the enzymes present in the S9 mix. The S9 mix method has been used 
most widely but has its own limitations such as it decreases the viability of cultured cells due 
to its toxicity and secondly the test compounds are metabolized in the culture medium but not 
inside the cells therefore short lived metabolites with high chemical reactivity bind to the 
surface of the cells and only few metabolites are able to penetrate through the cell membranes 
and react with target macromolecules to exert toxicity.
Variation within human populations for enzyme induction after drug intake and the genetic 
polymorphism of certain enzymes, make it impossible to use human liver S9 mix to predict 
the risks for test compounds. Therefore genetically engineered mammalian cell lines, stably 
expressing P450 enzymes were established by Doehmer et al, (1998). The advantages of such 
cell lines were
1 The presence of metabolic activation system of the test compound which is 
responsible for the consequences of cytotoxicity or mutagenicity occur within 
the cell.
2 These cells were highly sensitive to short-lived active metabolites which 
directly react with targeted macromolecules in the same cells.
3 The cells carrying human P450 which are useful to ascertain the roles of 
human P450s in the activation of mutagens.
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1.8.1. Cells with stably expressed P450
The transfection method is used to establish the cells which stably express P450. The 
expression vectors containing cDNA or P450 genes are introduced to recipient cells 
simultaneously with vectors containing a drug resistance gene.
Many cell lines have been established that stably express P450 including AHH-1, MCL-5, 
Chinese hamster cell lines (V79, CHO and CHL), SV40-transformed skin fibroblasts, XPA 
(xeroderma pigmentosum group A), HeLa, HepG2, MCF-7 (mammary tumur), BEAS-2B 
(bronchial epithelial cells) and KH293 (kidney) (Sawada and Kamataki, 1989).
Detailed information will be given in study design for AHH-1, MCL-5, TK6 and HepG2 cell 
lines used in this thesis.
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Study design
Carcinogenic chemicals belonging to polycyclic aromatic hydrocarbon (e.g, B[a]P) and 
heterocyclic aromatic amines (e.g, 2-amino-l-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP))
, are strongly correlated with the aetiology of human cancer. The current study examines the 
genotoxic and mutagenic responses of these chemicals at lower concentrations (pM) There is 
no information regarding B[a]P and PhIP at concentrations that are relevant to human 
exposure, which is important for the risk-assessment of such carcinogens. Human cells 
selected on the basis of their different metabolic competencies and were exposed to chemicals 
individually. The genotoxicity and mutagenicity were assessed using cytokinesis-blocked 
micronucleus assay (CBMN) and hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
assay respectively. The detailed information about chemicals, cell lines and techniques are as 
followed.
1.9 Polycyclic aromatic hydrocarbons
Polycyclic aromatic hydrocarbons (PAHs) are major contaminants of the environment and 
some have mutagenic and carcinogenic properties. PAHs are present in coal tar, motor vehicle 
engine exhausts, wood fires, volcanic activity, refuse burning, oil contamination by disposal 
or spills, cooking food and they can be formed in the incomplete combustions of organic 
matter, and thus are present everywhere in the environment (ATSDR, 1995; Phillips, 1999, 
Lah, 2011). Therefore, human exposure is often unavoidable. In industrial processes, such as 
fossil-fuel processing, aluminium production, steel and iron factories, wood impregnation and 
road paving, exposure to PAHs is increased (Baird et al, 2005). A long term exposure to PAH 
and inhalation through smoking has been linked to increased risk of lung cancer (Belpomme 
et al, 2007). Cigarette smoke condensate is highly enriched in PAH and its uptake is greater in 
smokers as compared to non-smokers (Hecht, 2006). These compounds have been described 
as a ‘smoking gun’ and are considered major carcinogenic agents in cigarette smoke (Smith et 
al, 2000; Tretyakova et al, 2002). According to Roemer et a\ (2004) each cigarette contains 
approximately 3-50ng of PAH carcinogens.
PAHs are a large group of highly lipophilic organic compounds containing two or more 
benzene rings fused to each other or to other hydrocarbon rings and are soluble in organic 
solvents (Figure 1.7). PAHs occur in complex mixtures which consist of hundreds of 
compounds. They have high melting and boiling points, and very low aqueous solubility. 
They are light sensitive, heat resistant, corrosion resistant and having characteristic UV 
absorbance spectra. PAHs usually exist as colourless, white or pale yellow solids.
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Approximately 500 PAHs have been identified in the atmosphere (WHO, 1987) and 50 have 
been identified at hazardous waste sites in the USA (ATSDR, 1995). They are mostly used as 
intermediates in pharmaceuticals, agricultural products, photographic products, thermosetting 
plastics, lubricating materials, dyes and pigments, diluents for wood preservatives, pesticides 
etc.
Benzo[a]pyrene Benz[a]anthracene
Chrysene Pyrene
Figure 1.7 Some common polycyclic aromatic hydrocarbons and their structures present in 
the environment and food. Chemical structures drawn using freeware at www.emolecule.com.
PAHs can be divided into ‘’Bay Region” and ‘’K-region” compounds on the basis of their 
structure and activity. Pullmans (1955) described that the interaction between a K-region and 
some cellular constituents was responsible for initiating the carcinogenic process. Later on, 
Jerina and Daly (1976) suggested that the ‘bay region’ (Figure 1.8) was another structural 
feature that was required for carcinogenic activity and that the strength of the carcinogenic 
PAH is correlated with the formation of carbonium ion within the bay region of molecule. For 
example, the biological activity of B[a]P is dependent on the metabolic formation of the 
reactive diol epoxide (Boyland, 1950) which initiates the carcinogenic process by binding 
covalently to specific targets in DNA (Dipple, 1985).
As previously mentioned, epidemiological studies have shown a correlation between cigarette 
smoking, level of PAH exposure and the formation of DNA adducts in human tissues (Poirier 
et al, 2000). Carcinogenic effects of a PAH rely on the balance between host cell ability to 
activate PAH into a carcinogenic intermediate or being able to remove it from the cell. These 
processes vary among different chemicals and are dependent on chemical structure, solubility
27
Chapter 1
and distribution within host tissue or cells as well as availability and/or activity of cellular 
mechanisms to transform a PAH to a carcinogenic agent (Millar and Ramos, 2001).
Bay Region
OH
OH
B
Figure 1.8 Bay region reactive site on benzo[a]pyrene (A) and carcinogenic metabolite 
Benzo[a]pyrene-dihydrodiol -9,10-epoxide (B). Modified chemical structures from Dipple 
(1985) and drawn using freeware at www.emolecule.com.
If a genotoxic metabolite is produced and forms DNA adducts, and if DNA repair 
mechanisms fail to repair the DNA, it could lead to permanent mutations (Boysen and Hecht,
2003). Moreover if these mutations occur in tumour suppressing regions such as the TP53 
gene, then it could lead to tumour formation (Hainaut and Pfeifer, 2001, Vahakangas, 2003).
Metabolic activation of PAH
Humans are exposed to PAHs through inhalation, ingestion and dermal contact. Their 
lipophilic nature enables them to penetrate through lipid rich cellular membranes (Yu, 2005). 
They are metabolized mainly in the liver, kidneys and lungs and are converted either into 
water-soluble compounds and excreted in the form of bile, urine and breast milk or are 
converted into carcinogenic forms and exert local carcinogenicity.
Metabolic activation of carcinogens like PAH, involve different enzymatic pathways that 
either end in the detoxification and then formation of non-reactive metabolites or results in the 
production of intermediate compounds that bind to DNA to initiate a carcinogenic process 
(Figure 1.9).
There are three main pathways for PAHs activation; formation of PAH radical cation
involving cytochrome P450 peroxidase, formation of PAH-o-quinones by dihydrodiol
dehydrogenase-catalyzed oxidation and creation of dihydrodiol epoxide by cytochrome P450
enzymes (Guengerich, 2000). PAH exposure induces expression of Phase I enzymes such as
cytochrome P450s (CYPs), epoxide hydrolase (EH), peroxidase, catechol-O-
methyltransferase, peroxidases and aldo-keto reductase that oxidizes PAH-transdihydrodiols
to redox-active o-quinones which increase reactive oxygen species (ROS) and oxidative
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damage to DNA by producing 8-oxo-dGuo mutagenic lesions (Quinn et al, 2008). Phase 11 
metabolism is basically a detoxification phase and the enzymes involved are glutathione 
transferases (GST), uridine diphosphate-glucuronosyl transferases (UGT), epoxide hydrolases 
(EH) and sulfotransferases (SULTs) (Baird et al, 2005; Shimada, 2006). Metabolites from 
SULTs and UGTs are polar conjugates and excreted from the body (Bansal et al, 1981). GSTs 
are also involved in conjugation o f  PAH and important for quenching and detoxifying ROS 
and their derivatives (Bonner et al. 2005).
Tissue Damage
Carcinogen
Activation
Necrosis
Reactive Metabolites CANCER
M utation
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N on -R eactive  m etab olite
DNA Damage
Elimination
Figure 1.9 The general overall fate o f  a polycyclic aromatic hydrocarbon (PAH) within the 
cell. Modified from web.sls.hw.ac.uk
Cytochrome P450, particularly CYP1A1, 1A2, 1B1 and 3A4 play an important role to attach 
an epoxide group to a PAH that could lead to its conversion into a dihydrodiol by epoxide 
hydrolase. This metabolite may be further metabolized by CYPs to form a diol epoxide (DE), 
which is essential to initiate pathways for DNA adduct formation and cancer initiation 
(Guengerich, 2000; Shimada and Fuiji-Kuriyama, 2004).
Similarly, a metabolic process was reported by Zhong et al, (2011), whereby a change in a 
PAH’s surface properties can alter the ability o f  the PAH to cause mutation, i.e. highly 
lipophilic PAH such as B[a]P diffuse slowly into tissues (IARC, 2010). Such lipophilic 
molecules can bio-accumulate and are thought to be involved in the production of reactive
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electrophilic products that are capable of binding to DNA and producing DNA adducts 
(Irigaray and Belpomme, 2010). If cellular mechanisms failed to repair DNA damage, it could 
then lead to permanent mutations and cancer (Boysen and Hecht, 2003).
In vivo AhR develops immunological and reproductive functions and adaptive responses to 
light and xenobiotics (Munoz and Albores, 2011). Nebert et al (2000) described the role of the 
AhR in PAH metabolism. They reported that PAHs act as ligands for AhR to induce CYPs 
which in turn increase metabolism of PAHs. This pathway involves binding of a PAH to 
AhR-interacting protein to form a complex with other proteins (Figure 1.10). Translocation to 
the nucleus and subsequent heterodimerisation of this complex with the AhR nuclear 
translocator (ARNT) leads to binding with DNA via xenobiotic-responsive elements (XRE; 
5'-TNGCGTG-3') situated in the promoter region of CYP1A and CYP IB and other genes 
involved in the PAH metabolism (Shimada et al, 2002). Hence, PAH’s can increase the CYP 
expression and activity through the AhR receptor binding ability. The role of AhR in the 
carcinogenic process may be positive or negative, depending on the level and length of 
exposure, cellular context and other conditions within the tissue (Gasiewicz, 2008).
Different factors including human heterogeneity in AhR inducing genes are believed to 
influence PAH- related carcinogenesis (ATSDR, 1990). Polymorphisms of Phase I and II 
enzymes affect the metabolizing rate and adduct formation. Similarly, DNA repair variability 
can be associated with the DNA damage within populations and species (Binkova et al, 
2007).
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Figure 1.10 Aryl hydrocarbon receptor (AhR) activation pathway involves, binding o f  
Polycyclic Aromatic Hydrocarbon (PAH) like Benzo[a]pyrene to AhR, which changes to 
AhR- PAH complex in the presence o f  other proteins such as heat shock protein (hsp90). 
Upon its translocation to nucleus, AhR-PAH binds with AhR nuclear translocator (ARNT) 
which then activates transcription of genes involved in CYP1A1, CYP1A2, and CYP1B1 
expression. Modified from Munoz and Albores (2011).
1.9.1 Benzo[a|pyrene
Among PAHs, B[a]P is one o f  the most extensively studied pro-carcinogens. It is a large flat 
molecule, having five aromatic benzene-like rings fused together in a honey comb-like 
structure (Figure 1.11). Its crystals are yellowish and needle-like with a faint odour (ATSDR, 
1995). It has a melting point at 178°C, with a very low vapour pressure (7.3x1 O'7 Pa at 25°C) 
and low water solubility (3.8|igL_1 at 25°C) (WHO, 1998). It can pass easily through the cell 
membranes and travel quickly into cells.
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Figure 1.11 Molecular structure of benzo[a]pyrene. Chemical structure drawn using freeware
at w \v u  .e m o le c u lc .c o m
B[a]P is an environmental pollutant generated through the burning o f  fossils fuels or wood, 
vehicle exhaust emission, heat and power generation, industrial processes or oil contamination 
and is commonly found as a mixture with other PAHs like in, cigarette smoke, charcoal- 
cooked food and industrial waste by-products (ATSDR, 1995; TEACH, 2007). Human 
environmental exposure to B[a]P mainly occurs through cigarette smoking, the ingestion of 
contaminated food and water (ATSDR, 1995), with significant concentrations found in 
Western diet such as fried and grilled meats (Table 3.1). Both environmental and dietary 
factors are associated with an increased risk o f  different organ cancers (Botteri et a l, 2008), 
autoimmune (Neal et al, 2008) and inflammatory diseases (Klareskog et a l, 2007).
Table 1.1 Concentrations of benzo[a]pyrene in food and environment. Modified from Uno 
and Makishima (2009).
Items B[a]P concentrations
Tobacco smoke 20-40ng/cigarette
Diesel exhaust <5ng/m3
Sesame oils_______ 0.36ng/g
Peanuts 0 . 4 4 n g / g ~ _ ™ _ J
I_______Fried chicken 5.3-5.6ng/g
Potato chips | <4 .1 ng/g
Grilled beef 58.8-66.3ng/g
Grilled lamb 42.0-45.6ng/g
Smoked diet beef 5.5ng/g
Smoked cheeses 0.2-2.4ng/g
The daily intake of B[a]P in the average human diet has been estimated to range from 120- 
2800ng/day (Hattemer-Frey and Travis, 1991). B[a]P has been detected in concentrations 
ranging from 20 to 40ng per cigarette in mainstream cigarette smoke, 40 to 79ng per cigarette
in side-stream smoke, and 96 to 292ng per cigar in mainstream cigar smoke. Concentration of
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B[a]P in full flavoured cigarettes has also been reported to be about 9 -lOng per cigarette 
(Hoffmann and Hoffmann, 1997), which is equivalent to an intake of about 200ng/day for a 
pack-a-day cigarette smoker (Scherer et al, 2000).
Metabolism of B[a]P
B[a]P is transported across the membrane by lipoproteins (Hanson-Painton et al, 1981). The 
protein carriers present in the cytoplasm are actively involved in transferring the B[a]P to the 
microsomes but are also capable of accepting the oxidized B[a]P from the microsomes. 
Therefore, it is possible that such active transport processes can be saturated at high doses. 
B[a]P presence activates the AhR, which binds with AhR nuclear translocator (ARNT) and 
induces the expression of genes involved in B[a]P metabolism (Figure 1.10).
Toxic metabolites of B[a]P
Metabolic activation of B[a]P produces multiple products which can lead to cytotoxicity, 
cause DNA and protein damage and overall defects in cell function and integrity. B[a]P is 
first oxidized at the bay region by Phase I CYP1A1 into B[a]P-7,8 epoxide, which through 
hydration by epoxide hydrolase is metabolized to B[a]P-7,8-dihydrodiol (BPD). This BPD 
either serves as a substrate for a second CYP dependent oxidation reaction and generates the 
metabolite B[a]P-7,8-dihydroxy-9.10-epoxide (BPDE) (Kim and Guengerich, 2005) or it is 
converted into B[a]P-7,8-dione (B[a]P ort/zo-quinone, BPQ) in the presence of aldo- 
ketoreductaselCl (Burczynski and Penning, 2000). Both BPDE and BPQ are genotoxic due 
to their ability to interact with DNA and form stable and depurinating DNA adducts 
(Shimada, 2006; Uno and Makishima, 2009) (Figure 1.12).
Another alternative B[a]P metabolic pathway is production of phenols such as 3-hydroxy- 
B[a]P and 9-hydroxy-B[a]P by other CYP enzymes. These phenols are then converted into 
quinones like B[a]P-l,3-, 1,6-, and 3,6-quinones. These metabolites are converted into B[a]P 
diols and induce the production of ROS thereby causing oxidative stress (Shimada, 2006; An 
et al, 2011) (Figure 1.12).
Among all of the metabolites produced by B[a]P activated metabolism, BPDE forms DNA 
adducts most effectively and is identified as a putative carcinogen (Miller and Ramos, 2001). 
BPDE contains an epoxide ring within the bay region making it highly susceptible to bind 
with DNA. The amount of B[a]P that binds to DNA through BPDE increases with exposure 
time. The conversion of BPDE-DNA starts with the induction of CYP 450 1A1 by B[a]P 
(Kim et al, 1998) which increases the metabolism of B[a]P to its ultimate carcinogen.
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Figure 1.12 B[a]P is metabolized into genotoxic forms B[a]P-7,8-diol-9,10-epoxide (BPDE) 
and B[a]P o-quinone (BPQ) due to their reactivity with DNA, and form bulky DNA adducts 
to exert mutagenesis; BPQ production can also lead to reactive oxygen species (ROS) 
production, resulting inflammation in cells. Modified from Uno and Makishima (2009).
Detoxification of B[a]P
In spite of the formation of intermediates that promote cellular damage and toxicity, 
metabolism of B[a]P is also undergo detoxification and elimination pathway. Phenols and 
diols become conjugated to water-soluble compounds by either UGT or SULT respectively 
(Phase II enzymes).
1.10 Heterocyclic aromatic amines
Heterocyclic aromatic amines (HAAs) are a class of toxic chemicals formed during the
heating process of organic products containing nitrogenous compounds, mainly proteins
(Alaejos et al, 2008). HAAs are formed at temperatures between 100 and 300°C and are
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generated from the reaction o f  free amino acids, creatine and hexoses. So far 30 different 
HAAs have been identified and named (Alaejos et al, 2008). A few are presented in Figure 
1.14.
NH2
c h 3
PhIP
M eAaC
/ fi 1
/ V
N
M elQ
CH3
Trp-P-2
Figure 1.14 Some Heterocyclic aromatic amines (HAAs); PhIP: 2-Amino-l-methyl-6- 
phenylimidazo(4,5-b)-pyridine, MelQ: 2-Amino-3,4-dimethyI-imidazo(4,5-f)-quinoline,
MeAaC: 2-Amino-3-methyl-9H-pyrido(2,3-b) indole and Trp-P-2: 3-Amino-l-methyl-5H 
pyrido(4,3-b) indole. Structures drawn using freeware at www.emolecule.com.
Many HAAs are formed from high temperature cooking, frying and grilling o f  meat, fish and
poultry (Sugimura et a\, 2004; Turesky, 2007; Turesky and Marchand, 2011). HAAs are also
detected in processed food flavourings, high-temperature burning o f  tobacco, wine, beer,
environmental particulates, surface water, diesel exhaust, etc. (Manabe et a l, 1993; National
Toxicology Program, 2011). The HAA levels in cooked meat vary from below 1 to about
500ng/g (from 0.001 to 0.5ppm), (Wakabayashi et al, 1992; Sinha et al, 1995) and according
to the National Toxicology Programme (2011, US) the exposure o f  HAAs through diet was
estimated to range from less than 1 to 17ng/kg o f  body weight per day. Similarly, Muller et al,
(2006) reported safe daily PhIP intake of 1.5pg/day (1500ng) over a life time or up to
120pg/day (12000ng/day) in one month and suggested these doses to be used as Threshold
Toxicological Concern (TTC), thus any intake above these limits could pose genotoxic risks.
The formation of HAAs in cooked meat is dependent upon the method o f  cooking, variety of
meat being cooked, temperature and duration of cooking. The prolonged cooking time and
high temperature cooking surfaces produce the highest quantities o f  HAAs, depending on the
presence o f  particular amino acids, e.g. 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)
formation needs the mixture o f  glycine, serine and proline, while PhIP formation requires
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phenylalanine and leucine (Knize et al, 1994). The meats prepared for domestic use have very 
low concentrations of HAAs (low parts-per-billion (ppb) range) as compared to well-done 
cooked meats or poultry (Skog et al, 1998) or grilled or pan-fried scraping used for gravies (as 
high as 500ppb) (Skog et al, 1998; Gross et al, 1993), and fumes arising from cooking oils 
(Yang et al, 1998).
To date, more than 25 HAAs have been isolated and characterized as potent mutagens in the 
Ames test using Salmonella strains (Sugimura and Sato, 1983; Schut and Snyderwine, 1999; 
Zhang et al, 2013), and more have been identified from cooked foods. Oral administration of 
almost all of these HAA are carcinogenic and induce tumours at multiple sites like the oral 
cavity, liver, stomach, lung, colorectum, prostate and mammary glands, in laboratory animals 
such as rodents (Sugimura et al, 2004). HAAs are mutagenic in bacteria and mammalian cells 
and produce chromosomal aberrations and sister chromatid exchanges in cultured cells 
(Alaejos et al, 2008). Epidemiological studies have reported that in humans they induce colon 
(Sinha et a\, 1999), stomach (Ward et al, 1997), lung (Sinha et al, 1998), breast (Sinha et al, 
2000) and prostate cancer (Tang et al, 2007). The toxicity data reviewed by the International 
Agency for Research on Cancer (1993) listed HAAs as “probable or possible human 
carcinogens” (Group 2A) and the 11 edition (2005) of the Report on Carcinogens have 
concluded that prevalent HAAs are “reasonably anticipated” to be human carcinogens. 
Considering the worldwide meat consumption coupled with globalization of food industry the 
potential exposure and health risks of these HAA has increased.
Metabolism of HAAs
HAAs undergo extensive metabolism in experimental animals and in humans. Enzymes 
involved in the metabolic activation of HAA are polymorphic in nature thus leading to 
variability in an individual’s ability to metabolise HAA (Turesky, 2002). HAAs require 
metabolic activation for DNA adduct formation (Schut and Snyderwine, 1999; Turesky, 
2007) and their metabolism is most actively mediated by CYP1A2 in the liver. The pathway 
starts with the metabolic activation of HAAs with the N-hydroxylation of the exocyclic amino 
group, catalysed by the Phase I enzymes CYP1A1 or CYP1A2 (Turesky, 2007). This 
oxidation reaction is also catalyzed by CYP1A1 and CYP1B1 in extrahepatic tissues (King et 
al, 2000). The N-hydroxyarylamine derivatives either directly react with DNA or require 
second metabolic activation by Phase II enzymes such as N-acetyltransferases (NATs), 
sulphotransferase (SULTs) etc. to form highly unstable esters that react with DNA to form 
adducts as summarized in Figure 1.15.
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Sinha, (2002) reported the presence of basal and inducible CYP1A2 activity in humans, 
whereby inducible activity increased with consumption of well-done meat containing high 
levels of HAAs, increasing the risk of breast cancer. There is a large inter-individual 
variation in CYP1A2 activity. CYP1A2 mRNA expression varied as much as 15-fold 
(Schweikl et al, 1993) and CYP1A2 protein varied by 25-fold in human liver between 
individuals (Turesky et al, 1998) thus indicating variability in the ability to metabolize HAA 
within the human population.
NATs (NAT1 and NAT2) are critical enzymes involved in the genotoxicity of HAAs. NAT2 
is involved in A-acetylation of aromatic amines and Oacetylation of the N-hydroxylated 
derivatives. A-acetylation is a detoxification mechanism whereas the O-acetylation is an 
activation step. Several SULTs also bio-activate HAAs, but SULT1A1 is reported to be the 
most active isoform to catalyse A-hydroxy-PhIP and A-hydroxy-MeAaC (Glatt et al, 2004; 
Wu et a\, 2000). The activated esters lead to the formation of DNA-adducts. The reaction of 
the esterified A-hydroxy-HAAs and the C-8 atom of deoxyguanosine (dG) produces dG-C8- 
HAA adducts, which is believed to involve reactive nitrenium ion as an intermediate (Schut 
and Snyderwine, 1999; Turesky and Vouros, 2004). In relatively fewer cases, DNA adducts 
also form at the A2 group of dG and at the C-5 atom of the heterocyclic ring structures, 
indicating charge delocalization of the nitrenium ion over the heteronuclei of these HAAs 
(Turesky and Vouros, 2004). Some metabolites can be conjugated by sulphation and 
glucuronidation mechanisms and form polar products that are not reactive and are excreted by 
the urine.
Molecular epidemiological studies do not show a consistent pattern between cooked meat 
consumption and cancer development in the general population (Sachse et al., 2003), 
however, these studies concluded that carcinogenicity related to cooked meat consumption 
increases among people who have a higher frequency of cooked meat consumption and have 
the ability to metabolise HAA rapidly (Le Marchand et al, 1994).
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Figure 1.15 Scheme presentation of the metabolism of Heterocyclic Aromatic Amines 
(HAAs). Image adapted from Alaejas et al, (2008).
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1.10.1 2-Amino-l-methyl-6-phenylimidazo (4, 5-b) pyridine (PhIP)
2-Amino-l-methyl-6-phenylimidazo (4, 5-b) pyridine (PhIP) is the most abundant HAA 
formed during the cooking of protein rich food like meat and fish at high temperature (Figure 
1.16) (Felton et al, 2007; Knize et al, 1999). PhIP has been identified in smoke condensates 
from frying of meat (Thiebaud et al, 1995), detected from the air-borne particles, diesel- 
exhaust particulates and incineration ash from garbage-burning plants and also found in 
cigarette smoke (Manabe et al, 1993). PhIP is also a urinary mutagen in smokers of black 
tobacco (Peluso et al, 1991).
According to IARC (1997) PhIP has been found in grilled beef, pork, chicken and fish 
products at concentrations up to 70ng/g. To estimate the PhIP intake, Keating et al, (2007) 
and Sinha et al, (2005) established a HAAs database in which they suggested that the 
estimated mean daily intake of PhIP is between 43 and llOng/day. It is also found in 
mainstream cigarette smoke (level up to 23ng/cigarette), beer and wine (Manabe et al, 1993; 
Hecht, 2002). Its concentration is measured as low as 0.1 ppb in cooked meat and chicken and 
up to 500ppb in well-done flamed-grilled chicken (Ni et al, 2008). The following table (Table 
5.1) shows that the amount of PhIP produced from cooked food is highly dependent on the 
type of meat and its portion, variety of different cooking methods and severity of cooking 
(rare, medium, well-done and very well-done). Several factors such as presence of anti­
carcinogen e.g. fibre or chlorophyllin, which directly bind to PhIP and prevent absorption, 
flavonoids that are known to inhibit metabolic activation, and substances that prevent 
formation of the carcinogen during cooking influence exposure of PhIP to individuals.
The formation of PhIP can be reduced by decreasing the temperature and length of cooking 
time. PhIP formation can be reduced by marination with herbs such as garlic, rosemary, basil, 
mint, sage, savoury, marjoram, oregano, olive oil and cherries; and vitamin E has been shown 
to reduce its formation. Recently, Hansol et al, (2014) reported significant reduction in the 
concentration of proline, valine, methionine, and phenylalanine which are the building block 
of PhIP, in marinated meat. Similarly pre-heating of meat in the microwave have been shown 
to remove creatine which is a building block in the formation of PhIP (Felton et al, 1994; 
Salmon et al, 1997).
PhIP and its metabolites have been reported in colon tissue, blood, lymphocytes and in urine 
of individuals following consumption of cooked meat (Boobis et al, 1994; Dingley et al, 
1999; Magagnotti et al, 2003; Fede et al, 2009). In other studies, PhIP has been linked with 
carcinogenic affects, therefore, it is considered as a dietary risk factor for cancer of the colon,
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breast, stomach and prostrate (Ito et al, 1991; De Stefani et al, 1998; Tang et al, 2007; 
Choudhary et al, 2012).
Table 1.2 PhIP concentrations depend on different meat types and variation in cooking. 
Modified table from Norrish et al, (1999).
Meat Type Cooking variation PhIP ng/g
Beef (1.5cm thick)
Fried- medium rare (51°C) 0.29
Fried- well-done (63°C) 0.73
Fried- very well-done (74°C) 7.33
Lamb chop Fried- medium (75°C) 0Fried- well-done (85°C) 2.4
Pork (2cm thick) Fried-medium (63°C) 0.37Fried- well-done (83°C) 7.82
Minced beef patty 
(2cm thick)
Fried- medium (51°C) 0
Fried-well-done (58°C) 3.96
Chicken (2.5cm, no 
skin)
Fried- lightly browned (63°C) 0.2
Fried- well-done (79°C) 17.54
Sausage Fried- lightly browned (42°C) 0Fried- well browned (70°C) 0.61
Bacon, middle Fried- lightly cooked 0.11Fried- well cooked 1.93
Metabolism of PhIP
Like many other HAAs chemical carcinogens, PhIP requires metabolic activation for DNA 
adduct formation and genotoxicity (Kato and Yamazoe, 1987; Thompson et al, 1987; 
Snyderwine et al, 1992). In humans, PhIP is metabolically activated via Phase I CYP 1A2 
mediated N-hydroxylation to N-hydroxy-PhIP (Crofts et al, 1998; Zhao et al, 1994) followed 
by esterification of the N-hydroxy-PhIP into derivatives that can bind covalently at the C-8 
position of guanine to form the DNA adduct N-(Deoxyguanosin-8-yl)-2-amino-l-methyl-6- 
phenylimidazo[4,5-P]pyridine (dG-C8-PhIP) (Schut and Snyderwine, 1999), both in vivo and 
in vitro (Turesky, 1994; Pfau et al, 1997).
PhIP toxicity- DNA adducts
The PhlP-adducts are reported to be critical in inducing carcinogenesis of the mammary gland 
(Ghoshal et al, 1995) The formation of PhlP-adducts bring structural changes in DNA and 
also induces mutations in genes controlling cell proliferation that leads to tumour formation 
(Nagaoka et al, 1992).
Three activated intermediate metabolites have been reported to form DNA-adducts; N- 
hydroxy PhIP and its O-acetyl and sulphate conjugates (Patterson et al, 2010) (Figure 1.17).
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These esterified intermediates can covalently bind to DNA at the C-8 atom of 2'- 
deoxy guano sine (dG) to form DNA adducts, N-(deoxyguaunosin-8-yl)-2-amino-l-methyl-6- 
phenylimidazo (4,5- b) pyridine (dG-C8-PhIP) (Lin et al, 1992; Felton et al, 1997; Turesky 
2007), causing the generation of predominantly G—»T transversion mutations in mammalian 
cells through mis-pairing of the adducted guanine base with adenine (Wu et al, 1995; 
Shibutani et al, 1999).
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Figure 1.17 Major PhIP metabolic pathways in experimental animals and humans. 
Black arrows showed the toxification pathway and red arrows showed the 
detoxification pathway of PhIP. Modified image from Turesky (2007) and 
Gooderham et a l, (2001).
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PhIP detoxification
PhIP also undergoes a parallel detoxification pathway, producing metabolites by 
glucuronidation (through Phase II enzymes) o f  N-hydroxy-PhIP, 4 ’hydroxylation of  PhIP and 
subsequent sulphate conjugation (Figure 1.18). The UDP-glucuronosyl-transferase 1A1 
(UGT1A1) is the most active enzyme in the glucuronidation process (Malfatti and Felton,
2004). N2-(p-l-glucosiduronyl-2-(hydroxyamino)-l-methyl-6-phenylimidazo (4,5-b) pyridine 
(HON-PhIP-N2-Glu) is the major PhIP metabolite excreted in human urine (Malfatti et al, 
2006). N-hydroxy-PhIP may also undergo detoxification by NADPH reductase and be 
converted back to PhIP (King et al, 2000). The A-Acetoxy-PhIP (ester o f  A-hydroxy-PhIP) is 
detoxified mostly by the active enzyme gltutathione S-transferase (GST1) through unstable 
glutathione (GSH) conjugate (Lin et al, 1994; Coles et al, 2001).
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Figure 1.18 Detoxification pathways o f  PhIP metabolism in humans. PhIP is metabolized by 
CYP1A2 and (UGT) and (GST1) enzymes. Modified image from Walters et al, (2004).
Expression variation in genes involved in PhIP metabolism and exposure to PhIP play an 
important role in DNA adduct formation therefore, DNA adducts can be used as an effective 
biomarker to study genetic variation in PhIP metabolism (Bendaley, 2009).The most frequent 
mutational signatures reported to be induced by PhIP are single base substitutions which are 
predominantly GC^-TA transversions, a high percentage o f  -1G frameshift mutations and a 
preference for 5'-GGA-3 motifs (Gooderham et al, 1997). DNA damage following exposure
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to activated PhIP is the first step (Zhu et al, 2000) which could either lead to the cells demise 
by apoptosis or retention of the damage as a mutated gene.
Wild and Kerder, (1998) reviewed results generated from different studies involving different 
tests such as HPRT assay, Ames and tests for sister chromatid exchange (SCE test) in 
mammalian cells and concluded that PhIP is a highly potent genotoxin. They explained that 
genotoxicity of PhIP is dependent on the host organism's metabolic activity to generate 
reactive DNA-binding PhIP intermediates (nitrenium ions). These studies suggest that the 
ability to transform PhIP to electrophilic nitrenium ions is more likely to induce genotoxicity 
rather than the quantity of PhIP present in the diet. The DNA-binding potency of nitrenium 
ions is related to their electrophilic reactivity and mutagenic potency. PhIP nitrenium ions 
bind preferentially to guanine nucleotides in DNA, such as the mononucleotide, 
deoxyguanosine-3' - phosphate (dGp).
PhIP metabolism varies within and among species e.g. rodent CYP450 enzymes are involved 
in detoxification process through 4'-hydroxylation whereas human processes involve the 
production of N- hydroxy metabolites that leads to esterification and production of active 
electrophilic metabolite (Cheung et al, 2005). This variability makes it difficult to rely on 
laboratory experiments while assessing human risk to PhIP exposure. Turesky (1998a) also 
noted a differences in the amount of CYP1A2 in human and rodent liver, with its expression 
up to 10 -fold greater in human liver as compared to that of rodents (Turesky et al, 1998a). 
Among humans, metabolic processes such as variability in levels of CYP1A2 determine the 
risk of carcinogenicity to HAAs (Hammans et al, 1997). To better understand the human risk 
of PhIP induced mutagenicity, it is important to consider interspecies variability in catalytic 
activity and expression levels of CYP1A2. PhIP metabolism represents a competing process 
between activation of PhIP and detoxification process. Whether PhIP undergoes activation or 
detoxification is dependent on PhIP dose and metabolic activity of the individual.
1.11 Cell lines
The following cell lines having different metabolic competencies were used in this study 
conducted at Swansea University.
AHH-1 TK+/- (Suspension cells)
The human lymphoblastoid cell line AHH-1 cell line was developed by Crespi and Thilly and 
originally derived from RPMI-1788. It is free of mycoplasma and has Aryl Hydrocarbon 
Hydrolase (AHH) activity for xenobiotic metabolism (Crespi and Thilly, 1984, Crespi et al, 
1991; Freedman et al, 1979). AHH-1 is a human lymphoblastoid cell line, transformed by an
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Epstein Barr virus (EBV) that expresses high level of CYP1 Al (Crespi et al, 1993; Crespi and 
Thilly, 1984) responsible for the oxidation of many chemicals present in our environment 
(Gonzalez et al, 1991). AHH-1 cells do not contain any detectable microsomal epoxide 
hydrolase (mEH) activity (Penman et al, 1994). AHH-1 cells have a heterozygous transition 
mutation (C->T) in the p53 locus at the codon 281/282 interface within exon 8 (Guest and 
Parry, 1999), yet despite this express phosphorylated-p53 and p-21 (Doak et al, 2008) and are 
capable of apoptosis (Zair et al, 2011). AHH-1 TK+/- can be used in chromosome aberration 
tests and in studying the induction of gene mutations at both the thymidine kinase (tk) locus 
and the hypoxanthine guanine phosphoribosyl transferase (hprt) locus. The population 
doubling time of AHH-1 cells is 22-24h. These cells were purchased from American Type 
Culture Collection (ATCC, Middlesex, UK).
MCL-5 (Suspension cells)
MCL-5 cells are derived from L3 cells, a subpopulation of AHH-1 cells transfected with two 
plasmids; one containing two copies of CYP3A4 complementary DNA (cDNA) and one copy 
of CYP2E1 cDNA and a second plasmid containing one copy of each CYP1A2, CYP2A6 and 
microsomal epoxide hydrolase (mEH) (Crespi et al, 1991). These cells also carry a 
hygromycin B resistance gene and like AHH-1 cells, carry a heterozygous mutation in the p53 
locus at codon 282 (Guest and Parry, 1999).
MCL-5 cells stably express all five cDNAs and has increased levels of CYP1A1 as compared 
to AHH-1 cells. Therefore, MCL-5 cells have shown to be more sensitive than AHH-1 TK+/- 
to the mutagenic properties of many pro-mutagens and procarcinogens and direct acting 
agents (Crespi et al, 1991, Doherty et al, 1996). The population doubling time of MCL-5 cells 
is 22-24h. MCL-5 cell lines were purchased from American Type Culture Collection (ATCC, 
Middlesex, UK).
TK6 (Suspension cells)
The human lymphoblastoid cell line TK6 is a derivative of the Wil-2 cell line. The cells have 
a stable genome, heterozygosity at the tk locus and contain functional wild-type p53 gene. 
TK6 cells were purchased from the European Collection of Cell Cultures (ECACC, Salisbury, 
UK). The population doubling time of TK6 cells is 18h.
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HepG2 (Adherent cells)
These cell lines were isolated by Aden et al, in 1997 from a primary hepatoblastome of an 11- 
year old Argentine boy. HepG2 have epithelial-like morphology which resembles liver 
parenchymal cells and retain many of the specialized functions in culture such as secretion of 
major plasma proteins (Knowles et al, 1980; Aden et al, 1979). HepG2 cells have 
chromosomal number of 52 and range of 48-54 chromosomes per cell (Natarajan and 
Darroudi, 1991). The population doubling time of HepG2 is longer (20-28h) than that of 
lymphoblastoid cell lines (AHH-1 and MCL-5) (Natarajan and Darroudi, 1991). HepG2 cell 
line expresses a wide range of Phase I and Phase II enzymes which play an important role in 
the activation and detoxification of genotoxic pro-carcinogens.
HepG2 cells are used to detect cytotoxic and genotoxic substances by using the different 
genotoxicity assays. HepG2 cells have also been used for anti-mutagenic studies (Mersch- 
Sundermann et al, 2004). This cell line was purchased from the European Collection of Cell 
Cultures (ECACC, Salisbury, UK).
These cell lines are stable in expressing cytochrome P450 except TK6 and thus serve as a 
good tool to investigate the role of P450 enzymes in assessing the genotoxicity of chemicals 
that require metabolic activation. The stable expression system also helps to understand the 
process from metabolic activation of test compounds to the appearance of toxicological 
consequences entirely in the same intact cells. We used these cell lines to investigate the 
effect of two pro-carcinogens B[a]P and PhIP on these cell lines in order to gain a better 
understanding of the variability in metabolic potential and genotoxic effects caused by these 
agents.
1.12 Cytokinesis-block micronucleus assay (CBMN) and its application in research
The CBMN assay was initially developed to study chromosomal damage in human 
lymphoblastoid cells (Fenech and Morley, 1985) but now it is successfully applied for 
population monitoring of genetic damage, screening of chemicals for genotoxic potential and 
for the prediction of the radiosensitivity of tumurs. The in vitro CBMN method has an ability 
to measure both clastogenic (structural) and aneugenic (numerical) chromosomal changes. It 
is being used successfully for human lymphocytes (Fenech, 2000), fibroblasts (Heddle et al, 
1990), keratinocytes (He and Baker 1989), nucleated bone marrow cells (Odagiri 1994) and 
primary tumour cell cultures (Masunaga et al, 1991).
In the CBMN assay, cells that have passed through one mitosis, are prevented from 
undergoing cytokinesis by using cytochalasin-B (Cyto-B) exposure to the cells in culture.
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Cyto-B is a metabolite of the fungus Helminthosporium dematioideum that blocks cytokinesis 
but not karyokinesis and results in the formation of binucleated cells that have undergone one 
nuclear division (Carter, 1967). Cyto-B binds high molecular complexes in the plasma 
membrane to inhibit formation of daughter cells by preventing induction of actin 
polymerisation and resultant formation of microflilaments and increases the sensitivity and 
consistency of the experiment (Figure 1.20).
Cytological end-point
i- MNi in BN cells
ii- Distribution of chromosome-specific 
centromeric probes in BN cells
;
iii- Nucleo-plasmic bridges in BN
iv- Ratios of mononucleate, binucletate and 
mutinucleated cells
Genotoxicity end-point scored
i- Chromosome breakage /loss
ii- Excision-repaired lesions in ARA-C treated 
cultures
i- Aneuploidy due to chromosome loss in MNI
ii- Aneuploidy due to unequal distribution of 
chromosomes in BN cells
Dicentric bridges?
i- Mitogenic response or cytostatic effect
ii- HPRT variants identified as multinucleated 
cells in cultures with 6-TG
Figure 1.20 A schematic diagram showing the end-points that can be scored with the CBMN 
assay. Figure modified from Fenech, 1997.
Thus studying micronuclei levels in binucleated cells offers the opportunity to assess the level 
of DNA damage in cells that have undergone division after exposure with the test chemical 
(Figure 1.21) (Fenech, 2000), as it enables cells that are not dividing to be distinguished from 
dividing cells within the cell population. It also provides reliable comparison of chromosome 
damage between cell populations that may differ in their cell division kinetics (Fenech, 2000).
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This test system also offers the possibility o f  detecting dicentric bridges as well as 
chromosome loss and non-disjunction events (Fenech, 1997).
OECD 487 guideline (2007) provides well established guidelines to perform the CBMN 
assay. The scoring criteria was established and validated by Human MicroNucleus (HUMN) 
international collaborative project (http://www.humun.org). CBMN assay has an ability to 
detect both clastogenic and aneugenic events (Fenech, 2000) and these events can be achieved 
at low doses of  mutagen exposure (Vral et a l, 1997; Touil et al, 2002).
The efficiency of  cyto-B inhibition of cytokinesis is dependent on the concentration used. It 
might be causing micronuclei induction in binucleated cells but many studies have confirmed 
that there is no dose-response effect for micronucleus induction over the concentration o f  1- 
6pg/ml (Fenech, 1997).
Figure 1.21- Photomicrographs o f  binucleated cells (a,b) and binucleated cells with 
micronuclei (c,d) (Fenech et al, 2003).
CBMN assay has been widely used, for example, to study spontaneous micronucleus 
frequency in gender and individual susceptibility (Fenech et al, 1994) and for assessing the 
effect o f  nutritional deficiency such as homosyteine and Vitamin C (Fenech, 2004). 
Micronucleus levels have also been a good indicator o f  cancer. For example, lymphocytes o f  
cancer patients and patients with certain syndromes have increased micronucleus frequency 
(Duffaud et al, 1997; Rudd et al, 1988), deficiency o f  vitamin folate in blood associated with
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increased risk for some cancers (Blount et a\, 1997; Fenech, 1998) and diagnosis of early 
stages of cervical carcinogenesis in women (Olaharski et al, 2006).
1.13 Hypoxanthine guanine phosphoribosyl transferase H(G)PRT
Monitoring point mutations at the genetic level in humans is a useful biomarker to evaluate 
the cancer risk from exposure to environmental mutagens (Au, 2007). Several assays which 
detect DNA damage have been developed for use in human cells, such as hypoxanthine 
guanine phosphoribosyl transferase H(G)PRT -Forward Mutation Assay (Crespi and Thilly, 
1984). The HPRT assay is a very common and sensitive method to examine the point 
mutations induced by mutagen exposure at low doses. Indeed, the HPRT assay has well 
established regulatory guidelines (OECD guideline 476, 1997) these well validated protocols 
exist for its use in mutation research. Parry et al, (2005) and Albertini (2001) have utilised the 
HPRT assay for human bio-monitoring. In this assay both HPRT + and HPRT " cells can grow 
in the simple selective media. After exposure to the chemical of interest, cells deficient in the 
HPRT gene are selected by resistance to the cellular poison 6 -thioguanine (6 -TG). The 
experimental end point is expressed in the form of Mutation Frequency (MF) which is the 
frequency of HPRT mutant cells among the cell population in the medium. This assay has 
been widely used to screen mutagens or carcinogens and to study mutagenicity expressed in 
the form of DNA base pair substitutions, small base deletions or frameshifts in the HPRT 
gene. Many mammalian cell lines have been used successfully for the HPRT assay such as 
mouse lymphoma cells, Chinese hamster cell lines (CHO and V79) (OECD, 1997; Tindal and 
Srankowski, 1989), and the human lymphoblastoid cells AHH-1, MCL-5 and TK6  (Crespi et 
al, 1991; Crespi and Thilly, 1984; Parry et al, 2005). The HPRT loci is located on the X 
chromosome, therefore, it is also used to study mutagenic effects in primary male cell lines 
(Tates et al, 1994; van Dam et al, 1992). However, this method is not suitable to detect the 
mutagenicity of chemicals that cause X chromosome lethality (Johnson, 2012).
1.13.1 HPRT assay and the study of mutations
The HPRT assay was used by DeMarini et al, (1989) for the detection of gene mutations in 
the mammalian cells. HPRT gene is located on the long arm of X chromosome at position 
Xq26-27 (Pai et al, 1980) in mammalian cells and is hemizygous in male i.e. a single copy of 
the gene in male cells (Stout and Caskey, 1985). It has 47542 base pairs (bp) and a protein- 
coding region of 657bp over 9 exons, which are spliced together forming 1435bp of mRNA 
(Figure 1.22). Human HPRT gene mutations happen due to alterations in splicing of the
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mRNA and most of these mutations have been found in all eight splice sequences (O’Neil et 
al, 1998). HPRT deficiency in humans can cause a biochemical defect called Lesch-Nyhan 
syndrome (Caskey and Kruch, 1979).
The HPRT gene encode the hypoxanthine-guanine phosphoribosyltransferase enzyme (HPRT, 
EC 2.4-2.8), which is in a soluble form and present in the cytoplasm of all cells. Each 
monomer of HPRT protein contains 217 amino acids and has a molecular weight of 24,470 
kDa (Wilson et al, 1983). The HPRT enzyme plays an important role in the purine salvage 
pathway involved in DNA synthesis. There are two pathways involved in the production of 
purines for DNA and RNA biosynthesis. These are:
The de novo pathway:
It is a complex and energy-expensive pathway, involving eleven enzymatic steps to form 
inosine monophosphate (IMP) nucleotide. The pathway starts with the synthesis of 5- 
phosphoribosyl-1-pyrophosphate (PRPP) from ribose-5-phosphate and ATP (Figure 1.23). 
After IMP nucleotide is formed it then converts to either AMP (adenosine monophosphate) or 
GMP (guanosine monophosphate) by using the purine bases adenine hypoxanthine or 
guanine, respectively (Zaharevitz et al, 2004). This is the default pathway which is 
compensated by the salvage pathway. Purine synthesis is important for DNA synthesis, 
therefore it is extensively studied for chemotherapeutic purposes (Jancso et al, 2001) as 
blocking salvage pathway (with nucleoside analogues) can halt cancer cell growth. In the 
absence of the HPRT enzyme, the concentration of PRPP will increase, resulting in an 
increase in the rate of purine biosynthesis by the de novo pathway (Natsumeda et a\, 1984). 
This over-production of purines is responsible for HPRT deficiency syndrome (Lesch-Nyhan 
syndrome) leading to build up of urate in all body fluids causing severe gout and kidney 
problems (Camici et al, 2010).
Salvage Pathway: This is a recycling biochemical pathway that converts degraded DNA 
bases into useful purine nucleotides for re-use in synthesis. It is an energy saving pathway and 
90% of free purines in mammalian cells are recycled (Lehninger, 1978). Erythrocytes are 
deficient in the de novo pathway for the synthesis of purine and therefore use the salvage 
pathway (Fontele and Henderson, 1969). The HPRT enzyme in the presence of Mg+2 uses 
PRPP as a substrate and catalyzes the transfer of 5-phosphoribosyl group to the 9 position of
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purine bases hypoxanthine and guanine to form IMP and GMP respectively for DNA or RNA 
synthesis (Figure 1.23) (Torres and Puiq, 2007).
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Figure 1.23 Recycling o f  purine through salvage pathway. Image modified from Torres and 
Puiq. 2007.
1.14 Selection for (HPRT+) wild type and (HPRT ) deficient cells
1.14.1 (HPRT+) wild type
HPRT mutants are always removed in the beginning o f  the HPRT assay to increase the 
sensitivity o f  the assay to chemical mutagenesis. Wild type (HPRT^) cells are selected using 
HAT media (hypoxanthine, aminopterin and thymidine) as a supplement in tissue culture 
media. HAT blocks de novo purines for DNA synthesis and so forces the cells to use other 
pathways or results in cell death in HPRT- cells (Caskey and Kruh, 1979). Cells can 
sometimes, due to the loss o f  heterozygosity mutations (deletions), become deficient in 
HPRT, and in HAT media are unable to synthesise purines so undergo apoptosis through an 
unknown mechanism possibly involving c-myc proto-oncogene expression (Chung et al, 
2001). The aminopterins in HAT inhibit the enzyme dihydrofolate reductase (DHFR) which is 
important in the de novo nucleotide synthesis (Figure 1.24). DHFR converts folic acid into 
intermediates such as dihydrofolate (DHF) and tetrahydrofolate (THF). THF is then converted 
by formate-tetrahydrofolate ligase (FTL) into 10-formyl tetrahydrofolate (10-formyl THF),
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which donates formyl (CHO) groups to intermediates o f  the de novo purine biosynthesis 
pathway (Figure 1.24) (Huennekens et al, 1963; Zaharevitz et al, 2004). Without 10-formyl 
THF purine biosynthesis only occurs through HPRT and the salvage pathway. As a result of 
inhibition o f  DHFR, depletion o f  intracellular pools of nucleotides occurs, affecting DNA 
strand synthesis during S phase of the cell cycle and limiting the cell’s capacity to divide 
(Tsurusawa et al, 1990). In present study the cells were transferred from HAT media to HT 
media (rescue media) which provide purines and pyrimidine to overcome the effects of 
residual intracellular aminopterin. Cells were grown in HT media until de novo biosynthesis 
pathway were reestablished.
A m in o p te rin
DHFR DHFR FTL
Folic acid ------------ ► DHF ------------ ► THF  “► 10-formylTHF
Figure 1.24 Aminopterin inhibits the conversion o f  folic acid into 10-formylTHF by blocking 
the enzyme DHFR. 10-formylTHF is an essential intermediate o f  the de novo purine 
biosynthesis pathway. DHFR: Dihydrofolate reductase, DHF: dihydrofolate, THF:
tetrahydrofolate, FTL: formate-tetrahydrofolate ligase. Constructed from Lightfoot et al 
(2005).
1.14.2 (HPRT ) deficient cells
The mutant cells deficient in HPRT (HPRT- ) are selected through use o f  the guanine 
analogue, 6-thioguanine (6-TG) which is toxic only to cells having functional HPRT. 
Previously, 8-azaguanine was used as a guanine analogue for selecting HPRT mutants, which 
later proved to be a poor substrate for HPRT (Arlett et a\, 1975; van Diggelen et al, 1979). 
Cellela et al (1983) discovered that wild type HPRT has a higher affinity for 6-TG and thus 6- 
TG provides precise mutant selection. Wild type HPRT cells convert 6-TG to 6-thioguanine 
monophosphate (6TGMP), this analogue blocks purine synthesis through inhibition of 
amidophosphoribosyl and IMP dehydrogenase (Figure 1.27) (Aubrecht et al, 1997). These 
processes increase the probability o f  6TGMP incorporation into nucleic acid and its 
subsequent incorporation into DNA (Nelson et al, 1976). Incorporation o f  6-TG into DNA is 
believed to be involved in the development o f  single strand DNA breaks due to replacement 
of guanine by thioguanine and also results in blockage o f  strand extension because of  the
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inefficiency o f  thioguanine to act as a substrate for DNA polymerase and DNA ligase (Ling et 
al, 1992). Hence, 6-TG kills dividing cells. Balajee and Geard (2004) proposed that an 
accumulation o f  Replication Protein A (RPA p34) and y-H2AX foci (double strand break 
binding factor) at the site of replication blockage which are responsible for double stranded 
breaks (DSBs) are as a result o f  6-TG. Yan et al (2003) observed a significant increase in 
single stranded DNA breaks in mismatch repair (MMR) proficient cells and suggested a role 
of 6-TG in triggering apoptosis through MMR processes. These mechanisms enable counter 
selection of wild type or HPRT mutant strains and provide an effective tool in determining the 
mutagenic effect o f  a test chemical.
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Figure 1.25 Metabolism of  6-thioguanine (6-TG) in HPRT+ cells where 6-TG is converted 
into 6-thioguanine monophosphate (6-TGMP) by HPRT, which inhibits de novo purine 
synthesis and therefore purine incorporation into DNA resulting to cell death. In HPRT 
deficient cells 6-TG will not metabolise and cell will survive. Modified from Aubrecht et al 
(1997).
1.15 HPRT assay methodology
The HPRT assay has been described by Crespi and Thilly (1984) in the AHH-1 cell line. It 
has three important stages; i. HPRT mutant cleansing, ii. Treatment with mutagen, and iii. 
mutant's selection and quantification, 
i HPRT mutant cleansing
To reduce the mutation background i.e. the mutation frequency in untreated cells, media is 
supplemented with HAT which blocks de novo purine synthesis; thus only cells that can use
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the salvage pathway for purine synthesis can grow in this media. Selection allows growth of 
HPRT+ cells and lead to a reduction in HPRT “ mutant cells to background levels of 1-100 
mutant cells in a population of 105 cells. Cells are then maintained under normal conditions 
for 3 days to achieve the required cell count for treatment exposure.
ii Test compound treatment and sub-culturing
Cells are then treated with different concentrations of test compound as per OECD guideline 
476 (1997). The test compound is then removed and cells are cultured in normal media for 13 
days. Initial cell divisions result in permanent mutations, with the possibility of changing the 
structure and function of the resulting HPRT proteins. The mutated proteins accumulate and 
then change the phenotype of the cells with respect to HPRT function (the salvage pathway). 
Subsequent culture growth over 13 days allows mutant HPRT to replace the wild type HPRT 
within the cell to HPRT Cultures are diluted with fresh media on alternating days to 
replenish nutrients. Depending upon cell type, maximum mutation frequency is achieved 4-9 
days post treatment and remains stable up until 17 days (Diamond et al, 1982; Grosovsky and 
Little, 1983).
iii Mutation selection and quantification
At 13 days post treatment, the culture consists of a mixture of HPRT+ and HPRT- cells. To 
isolate HPRT- cells for propagation and colony counting, cells are diluted and pipetted into 96 
well plates in the presence of 6 -TG which becomes toxic when catalysed by HPRT in HPRT+ 
cells. Each well represents an independent count and a higher number of counts are 
recommended for statistical threshold analysis (Doak et al, 2007). Each HPRT~ colony 
derives from a single mutated cell and thus represents one colony.
1.16 Alternative mutation assays
Other biological tests are available as alternatives to the HPRT assays. These alternatives 
include Ames, Pig-a and Thymidine kinase (TK) assays.
• Ames is a bacterial reverse mutation assay which uses amino acid-dependent strains of 
Salmonella typhimurium and Escherichia coli that carry mutations in the genes 
required for histidine synthesis (Ames et al, 1973). The test measures the reverse 
mutations to form histidine biosynthesis capability in the absence of histidine or in 
histidine free culture media. Mutagens cause an increase in the number of revertant 
colonies as compared to that of spontaneous reversions. The Ames test has been used 
in initial screening of the genotoxicity of chemicals and has well defined OECD
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guidelines. It is widely used in a battery of mutation tests for regulatory purposes 
(COM guidelines, 2000). Limitations of the assay include reliance on bacterial cells 
which therefore does not represent a perfect model for humans.
• Pig-a is a flow cytometry based assay that detects mutations in Pig-a, a gene whose 
product is essential for the synthesis of glycosylphosphatidylinositol (GPI) anchors. In 
the absence of these anchors, surface markers (CD58, 59) will not be expressed. The 
assay measures the frequency of cells without these surface markers. It is a rapid 
screening assay that can also be used ex vivo, however, it has not been validated by 
OECD. Another limitation of the assay is that it does not identify the sources of Pig-a 
mutation.
• The TK assay is used to detect mutations at the thymidine kinase locus involved in 
pyrimidine biosynthesis. Mutant cells, lacking in TK are resistant to the cytotoxic 
effect of pyrimidine analogues such as trifluorothymidine (TFT) (Clive and Spector, 
1975). An increase in the number of mutant cells represents mutagenicity of the test 
chemical. This assay can detect recombinations, non-disjunctions and larger deletions 
but it has a higher background than the HPRT assay (Doak et al, 2007).
1.17 Construction of mutation spectrum
Mutation spectra are recognised as sequence maps that represent the types and distributions of 
initial lesions caused by exposure to mutagens. They also reflect the characteristics of DNA 
replication and repair mechanisms present in the cell lines involved (Rogozin et al, 2003). 
Nowadays, there is a growing interest in identifying the correlation between exposure to 
certain carcinogens and the risk of cancer induced by alterations in mutated genes. Mutation 
spectra in cancer genes have already been examined in various studies in in vivo (Burkhart- 
Schultz et al, 1993; Boyiri et al, 2004) and in vitro experimental systems (Chan 2002; 
Gottschalg et al, 2007) shedding some light on the mechanisms involved in carcinogenesis 
(Dogliotti etal, 1998).
It is possible to construct the mutation spectra of HPRT mutants by DNA sequence analysis. 
Mutation spectra provide the information about the location and frequency of mutations in a 
DNA sequence. In the present study, the HPRT gene was used to build the mutation spectra 
induced by B[a]P.
The mutation spectra are useful to understand the mechanisms of mutation in single cell 
organisms, and causes of genetic changes in human organs (Chen and Thilly, 1996). Kohler,
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et al (1991) used the lacl gene to construct the spectra of spontaneous and mutagen-induced 
mutations in transgenic mice exposed to ENU and B[a]P, and concluded that the pattern of 
mutation induction was mutagen specific (Chen and Thilly, 1996). Therefore, mutation 
spectra can provide the information of mutation induction caused by different mutagens, 
define mutation hotspots (Casciano et al, 1999), can compare mutation induction in vivo and 
in vitro in repair deficient and proficient cells ((Tomita-Mitchell et al, 2003; Chen et al, 1992; 
Yang et al, 1994) and aid in understanding the molecular nature of spontaneous mutations 
(Zhang et al, 1992; Lewis et al, 2001).
1.18 DNA sequencing
DNA sequencing is the process to determine the actual order of nucleotides within DNA. 
Sanger in 1977 developed a rapid DNA sequencing method. Recently many methodologies 
have been developed based on Sanger’s method but with automation to achieve better results 
with less cost. The method employed in the current study used four dideoxynucleotides 
(ddATP, ddCTP, ddGTP and ddTTP), each ddNTP with a different fluorescent tag, were 
mixed with sample DNA. The ddNTP’s contain a hydrogen group (H) instead of a hydroxyl 
group (OH), and as such once incorporated into the DNA strand during synthesis, block the 
addition of further nucleotides and terminate the DNA chain into the growing DNA strand. 
The result is a mixture of oligonucleotide fragments of varying sizes. The fragments are then 
separated by size and fluorescence emission. It is important to sequence the genomic DNA to 
define the exact mutation present within the HPRT gene.
1.19 Quantitative Real- time Polymerase Chain Reaction (qRT-PCR)
qRT-PCR was first described in the mid- 1990 and is the variation of the standard PCR 
technique. It is an efficient, sensitive and robust method of detecting and quantifying gene 
expression (Bustin, 2009). This technique allows detection and quantification in real time 
during each cycle and removes the need for post PCR product processing. It uses a similar 
principle to PCR, however, it relies on detection and quantification of a fluorescent reporter 
which is directly proportional to the amount of amplicon being generated (Ginzinger, 2002). 
There are two common methods to quantify the amount of DNA in real time.
1. The first method involves the use of non-specific fluorescent dyes such as SYBR 
Green that binds to any double stranded DNA (Morrison et al, 1998; Schmittgen et al, 
2000). SYBR Green binds to the minor grooves of the DNA double helix and can be
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used to detect any double stranded target including primer dimers. To improve the 
specificity of SYBR Green based qRT-PCR, PCR reactions must be optimized to 
reduce primer dimers and amplification of non-specific products (Bustin, 2000). The 
only disadvantage of using DNA binding dyes is that they will bind to all DNA 
present in a sample.
2. The second method relies on DNA probes that transmit fluorescence upon binding to 
sequence specific DNA (Bustin, 2000). The most commonly used probes include 
hybridisation probes, molecular beacons and hydrolysis probes such as TaqMan 
probes. These probes are sequence specific thus only bind to target DNA and increase 
specificity. These probes can also be used in the presence of non-specific DNA or to 
amplify more than one target in a multiplex reaction. Due to their high sequence 
specificity, these probes can only be used for one target, and thus requires design and 
optimization of a new probe for each target (Bustin, 2000).
Quantification of real time PCR can either be done using an absolute or a relative 
quantification method. The absolute method involves the use of a standard curve generated 
from a known product to quantify the amount of unknown target in samples (Bustin, 2000). A 
standard curve is obtained by a serially diluted standard solution Relative expression is based 
on expression levels of a target gene against a housekeeping gene and thus is considered to be 
the most adequate method of investigating physiological changes in gene expression (Livak, 
2001, Bonetta, 2005)
In ordered to obtain a standard curve a housekeeping gene such as Beta-actin (0- actin) is 
used. With a housekeeping gene as a standard it is therefore possible to measure increase or 
decrease in required gene copy number relative to housekeeper.
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1.20 Aims of Thesis
The aim of this thesis were to
• Understand the in vitro dose response relationship of two pro-carcinogens B[a]P and 
PhIP at low doses using cell lines with different metabolic potential.
• Determine whether these pro-carcinogens follow linear or nonlinear dose-responses as
there is no evidence of genotoxic thresholds for these chemicals..
• Understand the underlying mechanisms in the metabolic activation dependant 
mutagenesis of B[a]P and PhIP,
• Determine genetic mutations caused by B[a]P and PhIP to analyze mutation spectra to
understand the types of mutations caused by these chemicals.
• Determine the effect of B[a]P and PhIP on CYP450 expression in cell lines with
varying level of metabolic activity.
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Chapter 2 
General Materials and Methods
2.1 Tissue culture
All tissue culture was carried out in sterile Biological Safety Cabinets (Scanlaf Mars Pro 
class2, VWR International Ltd, Leicestershire, UK) pre-cleaned with 70% ethanol and UV 
sterilisation. The equipment and media used were sprayed with 70% ethanol before placing in 
the safety cabinets. When handling toxic chemicals appropriate safety precautions including 
lab coat, goggles and over-arm gloves were used.
2.1.1 Cell lines
AHH-1, MCL-5 , TK6  and HepG2 cell lines were used in this study.
2.1.2 Cell culture 
MCL-5, AHH-1 and TK6
All cells were cultured in RPMI 1640 (GIBCO®, Paisley, UK) supplemented with 10% horse 
serum (GIBCO®, Paisley, UK) and 1% L-Glutamine (GIBCO®, Paisley, UK). In addition 
MCL- 5 cells were supplemented with hygromycin B (final concentration 200pg/ml, see 
Appendix I, A) at each passage to ensure plasmid retention (Crespi et al, 1991).
All cells were cultured in growth media in humidified atmosphere at 37°C, 5% CO2. 
Mycoplasma testing was carried out routinely by using MycoAlert® mycoplasma detection kit 
(Lonza, Slough, UK). The cell concentrations were maintained between 1-3 x 105cells/ml and 
sub-cultured every 2  days, when cell populations reached confluency, which was confirmed 
by microscopic examination under xlOO objective on a Ziess Axiovert 25 light microscope. 
For sub-culturing, cells were centrifuged at 113 x g (1200 rpm) for 10 minutes and then re- 
suspended in a volume of 50ml culture medium in 75 cm flasks. The cells were counted with 
a haemocytometer (Hawksley, Sussex, UK) or the Z1 Coulter Particle Counter (Beckman 
Coulter Inc., High Wycomb, UK) and diluted to a final concentration of 1.5 x 105cells/ml in 
,50ml media. MCL-5 and AHH-1 cell lines have a cell cycle time of 22-24h and TK6  cells 
have 18h cell cycle.
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HepG2
HepG2 cell line was cultured in DMEM (GIBCO®, Paisley, UK) supplemented with 10% 
foetal bovine serum (FBS, GIBCO®, Paisley, UK). Sub-culturing or processing of HepG2 
cells was performed by trypsinisation with trypsin/EDTA solution (0.05%) (GIBCO®, 
Paisley, UK). Firstly, the old media was discarded and cells were washed twice with 
phosphate buffered saline (PBS, GIBCO®, Paisley, UK) to remove traces of media. Then cells 
were washed twice with warm trypsin. Finally a sufficient amount of trypsin was added to 
cover the whole surface of cells, and the flask left for 6 -8  minutes, after which the flask was 
gently tapped to dislodge cells from its surface. Once the cells were lifted they were 
transferred to a multipurpose container (Greiner bio-one) using a syringe with a 1G needle 
(BD Microlance 3) and 5ml of PBS was added to dilute the trypsin. Cells were then 
centrifuged at 113 x g (1200rpm) for lOmin, the supernatant discarded, and washed with PBS 
and 5 ml growth media.
Cells were counted with a haemocytometer (Hawksley, Sussex, UK) or the Z1 Coulter 
Particle Counter (Beckman Coulter Inc., High Wycomb, UK) and diluted to a final 
concentration of 1.5 x 105cells/cm2 in 15ml of media in a 75 cm2 flask (Cellstar). These cells 
were cultured in growth media in humidified atmosphere at 37°C, 5% CO2. Mycoplasma 
testing was carried out routinely by using MycoAlert® mycoplasma detection kit (Lonza,
r j
Slough, UK). The cell concentrations were maintained between 1-3 x 10 cells/ml or cm and 
sub-cultured every 5 days, until they reached confluency, with microscopic examination under 
x 40 objective on a Ziess Axiovert 25 light microscope.
2.1.3 Measurement of cell concentration
The amount of cells per ml of culture media was measured by either the haemocytometer or 
the Z1 Coulter Particle Counter.
Haemocytometer
For the haemocytometer lOpl of cell suspension was taken from the culture flask after gentle 
shaking and spread on the haemocytometer slide. The number of the cells were scored from 
each of the four large comer counting chambers (each comprised of 16 small squares), 
averaged and multiplied by lx l 04 to obtain the final cell number per ml of media (Figure2.1)
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Figure 2.1 Diagram of a haemocytometer grid. Cells (red dots) were counted from A, B, C 
and D labelled squares, averaged and multiplied by lxlO4 to get final cell number per ml of 
media. Modified from h o m e . c . c . u m a n i t o b a . c a . u k .
Z1 Coulter particle counter
For the Z1 Coulter Particle Counter lOOpl o f  cell suspension was taken from culture flask 
after gentle shaking and poured into a cuvette containing 10ml o f  dilute conducting liquid 
(Coulter Isoton). The particles passed through an aperture of  defined size and cell number is 
displayed on a screen as cells per ml of media (Figure 2.2).
Figure 2.2 Z1 Coulter Particle Counter. Cell suspension was mixed into Coulter Isoton in the 
cuvette and the particles passed through the aperture their number displayed on screen. Image 
derived from ww vv . b i o n i q u e s t . c o m . u k .
The following equation was used to calculate the appropriate cell concentration for all 
experiments.
C ,xV,=C2xV2
Therefore,
V2={CixVi}
c2
Where
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C]= Concentration needed (cells/ml)
Vi= Volume needed (ml)
C2= Culture concentration (cells/ml)
V2= Volume of stock (ml)
For example; dilute a cell stock of 1,3xl06cells/ml to 50ml at 1.2xl05cells/ml.
V r=q .2 x l0 5x5(ft 
1.3xl06 
V2= 4.6ml
Therefore,
4.6ml (from stock) + 45.4ml growth media will give 50ml at 1.2xl05cells/ml.
2.1.4 Cell freezing for long term storage
Cell stocks were stored at an ultra-low temperature by cryopreservation process. Confluent 
cell suspension was poured into a multipurpose container (Greiner bio-one) and centrifuged at 
113 x g (1200rpm) for lOminutes. The supernatant was discarded and the pellet was re­
suspended in 4ml of horse serum containing 10% v/v dimethyl sulfoxide (DMSO, Fisher 
Scientific). Subsequently, 1.5ml of cell suspension was aliquoted into cryovials®(Elkay 
Laboratories products) and then did gradual freezing by placing overnight into -80°C freezer 
(New Brunswick Freezer) in Biofreezing vessels (Bicell) and then cryovials were transferred 
to liquid nitrogen at -196°C for long term storage.
To use the frozen cells, the cryovial® was removed from the liquid nitrogen and thawed
rapidly at 37°C using water bath (Grant) before transferral to 50ml growth media.
2.2 Preparation of chemical stocks for experiments
All toxic chemicals were handled inside an allocated sterile Biological Safety Cabinet 
(Scanlaf Mars Pro class2, VWR International Ltd, Leicestershire, UK) pre-cleaned with 70% 
ethanol and UV sterilisation. All pieces of equipment were also sterilized prior to use. To 
prevent the leaching of plastics, stocks were prepared and diluted in glass vials (Sigma, 
Gillingham, UK) using appropriate solvents (Table 2.1). All the toxic waste material was 
carefully disposed of in plastic containers intended for incineration.
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Table 2.1 Chemicals and their stock information
Chemical name Solvent Stockconcentration
Final 
concentration 
in media
Storage after 
reconstituted
(°C)
Benzo-a-pyrene
(B[a]P) DMSO 1M
Refer to 
Table 3.1 4 for 2weeks
N-Cyclohexyl-N'-
dodecylurea
(NCND)
Methanol lOmM 170nM -20 up to 3 months
2-Amino-1 -methyl- 
6 -phenylimidazo 4,5- 
b)pyridine (PhIP)
DMSO 1M Refer to Table 5.1
Discarded 
after use
6 -thioguanine
(6 -TG)
1M
sodium
hydroxide
(NaOH)
1.5pg/ml 0 .6 pg/ml -2 0
2.2.1 Benzo[a]pyrene (B[a]P)
Benzo[a]pyrene (B[a]P)(Sigma. UK)
Catalogue Number: B1760 
Molecular Formula: C20H12 
Molecular weight: 252.32g/ml 
CAS Number: 50-32-8
2.2.2 Soluble Epoxide Hydrolase Inhibitor, N-Cyclohexyl-N-dodecylurea (NCND)
(Calbiochem, EMD Chemicals Inc. an affiliate of Merk KGaA, Darmstadt, Germany)
Catalogue Number: 324813
Molecular formual: C19H38N2O
Molecular weight: 310.5g/ml
CAS Number: 402939-18-8
2.2.3 2-Amino-l-methyl-6-phenylimidazo 4, 5-b) pyridine (PhIP)
2-Amino-l-methyl-6-phenylimidazo (4,5-b) pyridine(PhlP) (Santa Cruz Biotechnology, Inc)
Catalogue Number: 1530
Molecular Formula: C13H12N4
Molecular weight: 224.26/ml
CAS Number: 105650-23-5
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2.2.4 6-thioguanine (6-TG)
The lx  stock of 6-TG was prepared in 0.1M sodium hydroxide solution (NaOH. Appendix I, 
B) from 30x stock (4.5mg/ml; Sigma), and filter sterilized by 0.2pM filter. To minimize 
freeze and thaw cycles, 5ml working stocks at 0.15mg/ml (lx) aliquots were prepared and 
kept at -20°C. To get a final concentration of 0.6pg/ml, 40pl of lx 6-TG was added to 10ml of 
culture flask. One stock of 6-TG was used for all HPRT assays. The quality of stock was 
checked by determining the absorbance ratio of 320/260nm and reliable stock has >2.5 ratio. 
The stock used here had a 4.8 (0.708/0.149) ratio.
2.3 Assessing cytotoxicity using relative population doubling (RPD)
Relative population doubling (RPD) toxicity measure was used to calculate the cytotoxicity of 
the chemical in the absence of cytochalasin B (Lorge et al, 2004). RPD was determined by 
counting the number of cells before and after treatment. For each cell line 10ml cell 
suspensions per dose were seeded at 1 x 105cells/ml (AHH-1, MCL-5 and TK6) or 1.2 x 105 
cell/cm2 (HepG2) for 24h at 37°C, 5% CO2. Each treatment flask of HepG2 was counted on 
day of seeding. After 24h each flask (AHH-1, MCL-5 and TK6) was gently shaken and 100pl
culture media was pipetted out and mixed with 10ml Isoton diluent (Beckman) and the cell
number was counted using the Beckman coulter counter. Each flask was treated with 
appropriately diluted chemical and incubated for 4h or 24h at 37°C, 5% CO2. After different 
incubation times the flasks were washed twice with growth media (without supplements) and 
re-suspended in 10ml growth media. Again lOOpl was sampled and counted to obtain 24h 
post-treatment counts. Cytotoxicity analysis was performed in triplicate. All three pre- and 
post-counts were averaged and used for calculating relative population doubling by using the 
following formula:
RPD = Number of population doubling (PD) in treated cultures x 100 
Number of population doubling (PD) in control cultures
Where,
PD = riog(24h Post-treatment cell number/initial cell number)!
Log2
2.4 The in vitro Cytochalasin-Blocked Micronucleus (CBMN) Assay
The semi-automated scoring protocol, using the Metafer-System (MetaSystems, Altlussheim, 
Germany) was performed in this study (Decordier et al, 2009).
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2.4.1 Initiation of the assay
To analyse the levels of chromosomal damage induced by a chemical, 10ml cell suspensions 
per dose were seeded at 1 x 105cells/ml (AHH-1, MCL-5 and TK6) or 1.2 x 105 cell/cm2 
(HepG2) for 24h at 37°C, 5% CO2 into 25cm2 flasks. Each was dosed with appropriately 
diluted test chemical (Table 3.1; Table 5.1) for different time points (4h and 24h). After a set 
time point the suspensions (from AHH-1, MCL-5 and TK6) were transferred to labelled 
tubes. The cells (AHH-1, MCL-5 and TK6) were spun down for lOmin at 113 x g (1200rpm) 
and washed twice with growth media (without supplement) to remove any residual chemical. 
The media with chemical was pipetted out. from HepG2 flasks . The cells were washed with 
PBS twise. Cells were again re-suspended in 10ml of growth media and transferred to 25cm 
flasks. Then 40pl (4pg/ml, AHH-1, MCL-5 and HepG2) or 20pl (2pg/ml, TK6) depending on 
the cell line, cytochalasin B (Merk) was added to the flasks for one cell cycle. HepG2 cells 
were trypsanised and then wash with PBS.
2.4.2 Cell harvesting and slide preparation
For semi-automated scoring, cells were prepared as described by Verga et al, (2004). After 
washing the cells with PBS (Lonzo, Blackley, UK), the cells were treated with 0.56% KC1 
solution, centrifuged for lOmin at 800rpm and supernatant was discarded. Cells were then 
fixed with methanol/acetic acid/ 0.09% NaCl (5:1:6) solution for 10 min. Centrifuged at 124 x 
g (800rpm) for lOmin at 4°C (Centrifuge 581 OR, Eppendorf) and the supernatant was 
discarded. Next, a second fixation step was performed by adding methanol/acetic acid (5:1) 
for lOmins, centrifuged for lOmin (124 x g or 800rpm) at 4°C, and the supernatant discarded. 
This second fixation wash was repeated four times. Cells were incubated in fixative 2 for 
16hours at 4°C.
The fixed cells were dropped across the length of labelled slides and mounted in Vectashield 
anti-fading solution containing 4,,6-diamidino-2-phenylindole (DAPI) stain (Vector) and 
covered with a cover-slip (25 x 60mm, VWR International).
2.4.3 Scanning and scoring
The slides were scanned at 1 Ox magnification with the Metafer 4 master station, coupled to an 
Olympus BX50 fluorescent microscope (Carl Zeiss), a Dell computer hub loaded with the 
Metafer 4 Version 3.8.5 software and a high resolution megapixel charge coupled device 
(CCD) camera (Axiocam; Carl Zeiss) for image capture. A number of grid positions evenly 
distributed across the scan area determined the plane of focus and a predetermined scan area
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was used for all slides. Classifiers developed by Metasystem were modified to detect 
binucleated cells. The search definition classifiers were used to define the size and shape of 
nuclei and micronuclei (MN) (Table 2.2).
Table 2.2 Classifier settings on the Metafer-System to define binucleated cells and 
micronuclei (MN)
Binucleated cells
Nuclei MN
Object threshold 30% 8%
Minimum area 20pm2 1.5pm2
Maximum area 400pm2 55 pm2
Maximum relative concavity o f  depth 0.9 0.9
Maximum aspect ratio 1.5 4
Maximum distance between 30pm 25pm
Maximum area asymmetry 70% -
The detection and scoring process for the Metafer-system was done in three steps: firstly the 
slides were scanned and binucleated cells detected. Secondly MN-positive binucleated cells 
were validated microscopically and finally manual confirmation of the MN was performed in 
the image gallery (Figure 2.3). A minimum of 10,000 or 6000 binucleated cells per dose were 
scored for B[a]P and PhIP respectively.
Metafer 4
» •
•  *
•  • •
A B
Figure 2.3 Metafer 4 master station (A) and Metafer image gallery showing a binucleated cell 
with micronuclei (B)
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2.5 The mammalian cell HPRT assay
The hypoxanthine phosphoribosyl transferase (HPRT) is a gene mutation assay which detects 
mutations that destroy the functionality of the HPRT gene or protein by positive selection 
(Johnson et al, 2012).
2.5.1 Mutant cleansing stage
This first step was necessary to establish a HPRT mutant free cell stock, and involved adding 
lml of hypoxanthine-aminopterin-thymidine (50x HAT, Invitrogen, Paisley, UK) to 49ml 
AHH-1 or MCL-5 cultures (4xl05 cells/ml), which were then grown for 3days. After that the 
cells were centrifuged at 113 x g (1200rpm) for lOmin, washed with PBS and re-suspended in 
49ml fresh growth media supplemented with lml HT (HAT media without aminopterin, 
50xHT, Invitrogen, Paisley, UK) for appropriate cell sub-culturing. Cells were grown in the 
presence of HT for 24h, washed with PBS and re-suspended in 100ml normal growth media 
for 2days. Cells were then frozen according to the method outlined in Section 2.1.4.
2.5.2 Treatment protocol
After the mutant cleansing stage the cells were revived as mentioned in section 2.1.4 and 
grown in normal growth media for 2 days. 10ml cell cultures were established into 25cm 
flasks at a concentration of 4x105 cells/mland incubated at 37°C, 5% CO2. The cell cultures 
were then treated with the appropriate test chemical for a set time period (4h or 24h). After 
treatment time the chemical was washed off with growth media (without supplements), the 
cells re-suspended in 50ml growth media in 75cm2 flasks and left to grow for thirteen days at 
37°C, 5% CO2 to enable expression of a mutant HPRT (HPRT-) phenotype. The day treatment 
was removed was counted as day 0 and sub-culturing took place on days 1, 3, 5, 7, 9 and 11. 
On day 7, during the mutant expression period, some cultures were frozen down in liquid 
nitrogen for further analysis. Upon revival, cells were designated day 7 and sub-cultured on 
day 9. After the phenotypic expression period at day 13, cell suspensions were transferred to 
96 well plates (lOOpl per well).
For mutation frequency (MF) analysis, cell cultures with a concentration of 4x105 cells/ml in 
60ml were treated with 240pl of 6-TG (0.6pg/ml) for selection. Ten or five plates per dose 
were loaded with lOOpl of cell suspension in each well (4xl04cells/well). HPRT + cells 
incorporate 6-TG into the DNA and die, where as HPRT- cells cannot incorporate the toxic 
analogue into their DNA and consequently survive (Johnson, 2012).
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For plating efficiency (PE), 200cells/ml (20cells/well) in lOOpl non-selective media were 
added into each well of 5 plates per dose.
All plates were incubated at 37°C, 5% CO2 for 14 days before cell colonies scored. Only 60 
wells per plate were scored; the perimeter wells were excluded because the media partially 
evaporated. Colonies having >20cells in diameter with a smooth and shining outer boundary 
and a light colour were identified as positive mutants. The experiment was carried out in 
triplicate.
2.5.3 Equations for mutation frequency and plating efficiency
Percentage Plating Efficiency (%PE) = -Ln (Xq/N0) x 100
Cell Viability (%) = PE x 100
PE of control
Mutation Frequency (MF) = -Ln (X</N«) x DF
-Ln (X > J0)
DF = Dilution factor = fNo. of initial cells per well) Non-selective conditions
(No. of initial cells per well) selective conditions
Xs = No. of wells without colonies ~'i
Ns = Total no. of wells y  Selective conditions
X0 = No. of wells without colonies 1
N0 = Total no. of wells f  Non-selective conditions
2.5.4 Enumeration of mutant colonies
At the end of the HPRT assay, colonies from the solvent control and selected dose plates were 
aspirated and transferred to 24 well plates (Nunc, ThermoScientific, Loughborough, UK) 
containing 2ml growth media per well. The colonies were grown for sufficient RNA yield. 
The plates were left to grow at 37°C, 5% CO2 for 5 days and then individual cell colonies 
were carefully aspirated using a 300pl pipette, mixed with 5 volumes (1.5ml) RNA protect® 
cell reagent (Qiagen, Sussex, UK) and stored at -20°C for RNA extraction.
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2.6 RNA extraction
2.6.1 RNA extraction from cultured cell lines
(K)Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Sussex, UK) according to the 
manufacturer’s instructions. All surfaces and equipment were wiped with RNAzap® (Applied 
Biosystems, Warrington, UK) to remove RNAses. All the centrifugation was done at 25°C for 
15sec at 9503 x g (10,000rpm) in (BIOFUGE Fresco, Heraeus) a centrifuge with a radius of 
85mm, unless stated otherwise. Cells in the RNA protect® cell reagent were defrosted at room 
temperature and pelleted by centrifuging at 275 x g (1700rpm) for 3mins (Centra CL 3 R) and 
re-suspended in 350pl RLT cell lysis buffer. The cells were homogenized by passing the 
lysate 5 to 6 times through a 20G needle (0.9 x 40mm, BD Microlance 3) fitted to a 2ml 
syringe. Next an equal volume (350pl) of 70% ethanol was added, which binds RNA to the 
spin column, the sample was mixed thoroughly and applied to the spin column. The column 
was centrifuged and the flowthrough discarded. The column was washed with 350pl RW1, 
centrifuged and flowthrough discarded. Genomic DNA was digested using the RNase-free 
DNA set (Qiagen, Sussex, UK). For each column 80pl DNase mix (lOjil DNaseI+70pl RDD 
buffer) was applied and incubated at room temperature for 15mins, followed by another 
washing step with 350pl wash buffer RW1. Then 500pl buffer RPE was added to the column 
and the sample centrifuged. A second 500pl buffer RPE wash was performed but centrifuged 
for a longer time (2min) to dry the column from ethanol present in the buffer RPE. The 
column was then transferred to a new collection tube; 30pl water was added directly to the 
column and incubated at room temperature for lOmins. Finally RNA was eluted by 
centrifugation.
2.6.2 Quantification and storage of RNA
The concentration of RNA and its purity (A26o:A28o) was determined with a NanoDrop (ND- 
1000 Spectrophotometer, Labtech International, Uckfield, UK). Nucleic acids absorb at 
260nm and contaminating proteins and other material absorb at 280nm. RNA was considered 
suitably pure for use if the A260/A280 ratio was greater than 1.6.
To calculate lpl RNA for cDNA synthesis following formula was used.
Volume (pi) of sample to give lpg RNA = lOOOfngl
Amount of RNA (ng/pl)
For example, if the amount of RNA in sample is 350ng/pl then 2.85pl of sample would give 
1 pg for cDNA synthesis
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The samples were divided into two aliquots and stored at -80°C (New Brunswick freezer). 
The first RNA aliquot was used for end-point PCR and mutation detection through 
sequencing and the second aliquot to confirm mutations in the same samples.
2.6.3 Complementary DNA (cDNA) synthesis for end-point PCR
RNA samples were converted into cDNA using RETROscript® kit (Applied Biosystems, 
Warrington, UK). The cDNA synthesis reactions were set-up on ice within a purifier vertical 
clean bench (Labconco, USA) pre-cleaned with RNAzap®. The volumes of reagents used per 
reaction are given in Table 2.4.
Table 2.4 Reagents per sample for cDNA synthesis
Reagents Volume (pi)
RT Buffer 1
Oligo (dT) 1
dNTP 2
RNase inhibitor 0.5
MMLV-reverse transcriptase enzyme 0.5
RNA template i^g
Nuclease-free water = 5 -  volume of RNA
Total volume 10
The icycler (Bio-Rad, Hemel Hemstead, UK) was used to run the reaction at 44°C for 60min 
followed by lOmin at 90°C to inactivate the reverse transcriptase enzyme. cDNA was stored 
at -20°C until further use.
2.6.4 End-point PCR
Oligo (dT) primers targeted all mRNA transcripts from the total RNA extracted from cells 
while p-actin is an abundant target with optimised primers. Therefore, p-actin primers were 
used to amplify the p-actin cDNA which clarifies the success of the cDNA reaction. The 
master mix was prepared for this reaction from reagents listed in Table 2.5. All the reagents 
used to prepare the master mix were purchased from Promega (Southampton, UK) and P-actin 
forward and reverse primers were synthesized by MWG Eurofins (Germany) with instructions 
for reconstitution of lyophilized primers to lOOpM (pmol/pl) with nuclease free water. The 
primer master stock was further diluted to 1:10 (lOpl stock + 90jnl water) to lOpM working 
stock in nuclease-free water and frozen (-20°C) as single use (lOpl) aliquots.
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Table 2.5 Components for master mix to amplify P-actin cDNA
Reagents Final Volume (pi) in p-actinconcentration master mix
5x Go Taq® Flexi Buffer IX 5
lOmM dNTP mix 0.2mM each 0.5
25mM Magnesium Chloride 2mM 1.5
p-actin forward primer 0.2pM 0.5
P-actin reverse primer 0.2pM 0.5
GoTaq® DNA polymerase (5u/pl) 1.5U 0.15
cDNA template - 1
Water - 15.85
Total - 25
The conditions used in the icycler (Biorad. Hemel Hemstead, UK) for the amplification o f  p- 
actin mRNA are shown in Table 2.6.
Table 2.6 Thermo-cycling conditions for P-actin mRNA amplification
Steps Temperature
(°C)
Time Number of cycles
Initial denaturation 93 2min 1
Denaturation 93 lOsec
Annealing 60 20sec 25
Extension 72 lOsec
Preservation 4 Infinity -
Upon reaction completion, samples were stored at -20°C until required for gel electrophoresis 
and DNA sequencing.
HPRT cDNA was amplified by using two pairs o f  overlapping primers (D and K) to obtain 
83% gene coverage. The oligonucleotide sequence for each primer is listed in Table 2.7 and 
their location on the HPRT  gene is shown in Figure 2.4.
Table 2.7 Primers name and sequences used for the amplification o f  p-actin and HPRT cDNA
Primer Name Sequence (5' -  3 f ) Product size (bp)
p-actin Forward GATGGCCACGGCTGCTTC 100
p-actin Reverse TGCCTCAGGGCAGCGGAA
D Forward (HPRT NF2 S-M) G A ACCTCTCGGCTTTCCC 537
D Reverse (HPRT NR2 MS) TGCCAGTGTCAATTATATCTTCC
K Forward (HPRT NF3) GATGATCTCTCAACTTTAACTGG
715K Reverse(l 1PRT Inner
Reverse)
CTTACTTTTCTAACACACGGTGG
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1 GGCGGGGCCT GCTTCTCCTC AGCTTCAGGC GGCTGCGACG AGCCCTCAGG CGAACCTCTC
6 1 GGCTTTCCCG CGCGGCGCCG CCTCTTGCTG CGCCTCCGCC TCCTCCTCTG CTCCGCCACC
1 2 1 GGCTTCCTCC TCCTGAGCAG TCAGCCCGCG CGCCGGCCGG CTCCGTTATG GCGACCCGCA
1 8 1 GCCCTGGCGT CGTGATTAGT GATGATGAAC CAGGTTATGA CCTTGATTTA TTTTGCATAC
2 4 1 CTAATCATTA TGCTGAGGAT TTGGAAAGGG TGTTTATTCC TCATGGACTA ATTATGGACA
3 0 1 GGACTGAACG TCTTGCTCGA GATGTGATGA AGGAGATGGG AGGCCATCAC ATTGTAGCCC
3 6 1 TCTGTGTGCT CAAGGGGGGC TATAAATTCT TTGCTGACCT GCTGGATTAC ATCAAAGCAC
4 2 1 TGAATAGAAA TAGTGATAGA TCCATTCCTA TGACTGTAGA TTTTATCAGA CTGAAGAGCT
4 8 1 ATTGTAATGA CCAGTCAACA GGGGACATAA AAGTAATTGG TGGAGATGAT CTCTCAACTT
5 4 1 TAACTGGAAA GAATGTCTTG ATTGTGGAAG ATATAATTGA CACTGGCAAA ACAATGCAGA
6 0 1 CTTTG CTTTC CTTGGTCAGG CAGTATAATC CAAAGATGGT CAAGGTCGCA AGCTTGCTGG
6 6 1 TGAAAAGGAC CCCACGAAGT GTTGGATATA AGCCAGACTT TGTTGGATTT GAAATTCCAG
7 2 1 ACAAGTTTGT TGTAGGATAT GCCCTTGACT ATAATGAATA CTTCAGGGAT TTGAATCATG
7 8 1 TTTGTGTCAT TAGTGAAACT GGAAAAGCAA AATACAAAGC CTAAGATGAG AGTTCAAGTT
8 4 1 GAGTTTGGAA ACATCTGGAG TCCTATTGAC ATCGCCAGTA AAATTATCAA TGTTCTAGTT
9 0 1 CTGTGGCCAT CTGCTTAGTA GAGCTTTTTG CATGTATCTT CTAAGAATTT TATCTG TTTT
9 6 1 GTACTTTAGA AATGTCAGTT GCTGCATTCC TAAACTGTTT ATTTGCACTA TGAGCCTATA
1 0 2 1 GACTATCAGT TCCCTTTGGG CGGATTGTTG TTTAACTTGT AAATGAAAAA ATTCTCTTAA
1 0 8 1 ACCACAGCAC TATTGAGTGA AACATTGAAC TCATATCTGT AAGAAATAAA GAGAAGATAT
1 1 4 1 ATTAGTTTTT TAATTGGTAT TTTA A TTTTT ATATATGCAG GAAAGAATAG AAGTGATTGA
1 2 0 1 ATATTGTTAA TTATACCACC GTGTGTTAGA AAAGTAAGAA GCAGTCAATT TTCACATCAA
1 2 6 1 AGACAGCATC TAAGAAGTTT TGTTCTGTCC TGGAATTATT TTAGTAGTGT TTCAGTAATG
1 3 2 1 TTGACTGTAT TTTCCAACTT GTTCAAATTA TTACCAGTGA ATCTTTGTCA GCAGTTCCCT
1 3 8 1 TTTAAATGCA AATCAATAAA TTCCCAAAAA TTTAAAAAAA AAAAAAAAAA AAAAA
Figure 2.4 Sequence o f  HPRT  mRNA or gene, with colour coded primer locations; red- D
forward, green- K forward, blue-D reverse and pink-R reverse.
The H PRT  primers were designed using Beacon 2 software (Premier Biosoft) and synthesized 
by MWG Eurofins (Germany) with instructions for reconstitution o f  lyophilized primers to 
lOOpM (pmol/pl) with nuclease free water. The primer master stock for H PRT  amplification 
was further diluted to 1:10 (10pl stock + 90pl water) to 10pM working stock in nuclease-free 
water and stored as single use (lOpl) aliquots at -20°C. All the reagents used to prepare master 
mix were from Promega (Southampton, UK). Two master mixes (D and K) were prepared for 
each primer pair according to the volumes (0.2pM) shown in Table 2.8.
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Table 2.8 Components of each master mix to amplify HPRT mRNA.
Reagents Finalconcentration
D Master 
mix
K Master 
mix
Volume (pi) Volume (pi)
5x Go Taq® Flexi Buffer IX 10 10
1 OmM dNTP mix 0.2mM each 1 1
25mM Magnesium Chloride 2mM 4 4
D forward primer 0.2gM 1 0
D reverse primer 0.2gM 1 0
K forward primer 0.2pM 0 1
K reverse primer 0.2pM 0 1
GoTaq DNA polymerase 
(5u/pl)
1.5U 0.3 0.3
cDNA template - 2 2
Water - 30.7 30.7
Total - 50 50
Both master mixes were run in the icycler (Biorad, Hemel Hempstead, UK) machine 
simultaneously under the conditions given in Table 2.9. After completion of the reaction, 
samples were stored at -20°C until required for gel electrophoresis.
Table 2.9 Thermo-cycling conditions for amplification of HPRT cDNA with D and K 
primers.
Steps Temperature(°C) Time
Number of 
cycles
Initial denaturation 93 2min 1
Denaturation 93 lOsec
30Annealing 52.6 20sec
Extension 72 lOsec
Preservation 4 Infinity -
2.7 Visualising PCR products
2.7.1 6% Polyacrylamide Gel Electrophoresis (PAGE) preparation
Vertical 6% PAGE gel were used to verify the success of PCR amplification. The reagents 
and their volumes used for the preparation of two 6% PAGE gels (7.5cm x 9cm in size) are 
listed in Table 2.10.
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Table 2.10 Reagents for the preparation of two 6% PAGE gels.
Reagent Supplier Volume
Distilled water - 16ml
lOx TBE (Tris/Borate/EDTA) Sigma 2.3ml
10% APS (Ammonium per sulphate) Sigma llOpl
30% Acrylamide/Bis acrylamide Bio-Rad 4ml
N,N,N’,N'- Tetramethylethylenediamine 
(TEMED) Sigma 22.5pl
One litre of lOxTBE and 10% APS were prepared as mentioned in Appendix I, D. Stock 
lOxTBE was autoclaved for 20min. Gels were constructed as follows; 1.5mm glass plates 
were wiped with 70% ethanol and assembled in the casting stand. The reagents in Table 2.10 
were mixed in a glass beaker and added to the casts. A 15 well comb was inserted in each gel 
and the gel left to polymerise for 30min at room temperature. The reservoir between the two 
plates was filled with lx TBE buffer. The lOpl of each sample was mixed with 2pl loading 
dye (RETROscript® cDNA synthesis kit). The 1 jllI of 100 base pair (bp) DNA ladder 
(Promega, Southamptom, UK) was mixed with 2pl loading dye. The combs were removed 
carefully and samples/ ladder were carefully loaded into wells using a pipette. The whole gel 
apparatus was put into a tank filled with lx TBE buffer and the gel was run at 170V for 
30min using a mini protean® 3 cell kit and a power pac 300 (Biorad, Hemel Hempstead, UK). 
The product bands were visualized by silver nitrate staining.
2.7.2 Silver nitrate staining of gels
The silver stain was prepared and developed within a fume hood (Clean Air limited) 
according to methods stated in Appendix I, D. Gels were immersed in silver nitrate for 8min 
at room temperature on agitator at low speed. Then gels were washed twice with distilled 
water and then incubated at room temperature in developing solution with gentle agitation 
until the bands were visible. The photographs were taken using Biorad Universal Hood II 
(Biorad).
2.8 Preparation of HPRT samples for sequencing
The remaining 40pl of PCR product was purified using a PCR purification kit® (Qiagen, 
Sussex, UK) according to the manufacturer’s instructions. Briefly, 200pl (5x volume) of 
buffer PE, with pH indicator was added to the reaction mixture. The solutions were applied to 
the provided Qiaquick spin columns and centrifuged for lmin at 16060 x g (13,000rpm) in a 
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Biofuge Fresco centrifuge and the flowthrough were discarded. The 750pl of wash buffer was 
added with repeat centrifugation and the flowthrough was discarded. The columns were 
centrifuged to remove ethanol, present in the wash buffer. Finally 30pl of nuclease-free water 
was added, incubated for lmin at room temperature and eluted by centrifugation.
The samples were sent to Genome Enterprise Limited (Norwich, UK) for sequencing. 
According to the instructions of Genome Enterprise Limited, 20pl of each sample were put 
into PCR tubes (Fisher Scientific, Loughborough, UK) in supplied sequencing boxes for 
shipping. The 1.5pM D forward, D reverse, K forward and K reverse primers were also added 
into separate tubes in sufficient volume to run 5pl per sequencing reaction. Mutations were 
identified using mutation surveyor software (3.3). Any mutations found were confirmed by 
repeat processing of the second aliquot of RNA.
2.9 Construction of mutation spectrum
Mutation spectra were constructed using iMARS software, kindly provided by Dr Paul Lewis 
at Swansea University (Morgan and Lewis, 2006).
The whole FIPRT assay methodology is represented in the form of flow chart in Figure 2.5
2.10 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
For evaluating the induced expression of CYP1 A l, CYP1B1 and CYP1A2 in human cell lines 
AHH-1, MCL-5, TK-6 and HepG2, RT-PCR was performed. The doses of B[a]P and PhIP 
treatment selected were based upon the LOEL dose obtained as a result of cytokinesis block 
micronucleus assay (Table 3.1 in Section 3.4 for B[a]P and Table 5.1 in Section 5.4 for PhIP). 
All four cell lines were treated with B[a]P and PhIP for 24h.
2.10.1 Genomic DNA (gDNA) elimination reaction
Firstly, the genomic DNA (gDNA) elimination reactions were prepared by using QuantiTect® 
Reverse Transcription kit (Qiagen). The reactions were prepared using the reagents in Table 
2 . 11.
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Figure 2.5 Representation o f  HPRT assay methodology to quantify mutagenic 
potential of Benzo-a-pyrene on the basis o f  hypoxanthine guanine phosphoribosyl 
transferase (HPRT) mutant colony formation in a treated cell population.
Chapter 2
Table 2.11 Components for the elimination of genomic DNA from RNA samples.
Reagent Volume per reaction
gDNA wipeout buffer, 7x 2  pi
Template RNA Ipg
Rnase-free water Make total volume upto
Total 14pl
The reagents were vortexed and centrifuged and then incubated for 2min at 42°C on an 
Thermal Cycler (BIO-RAD T100™, Hampstead, UK). After the completion of the reaction, 
sample tubes were immediately placed on ice.
2.10.2 cDNA synthesis reaction
Following gDNA elimination, the reverse-transcription master mix for multiple reactions was 
prepared using reagents listed in Table 2.12. The 6 pl of this reverse transcription master mix 
was added into each genomic DNA elimination reaction tube.
Table2.12 Components for cDNA synthesis reaction.
Component Reagent Volume per reaction (pi)
Reverse-
transcription master 
mix
Reverse transcriptase 1
RT Buffer, 5x 4
RT Primer Mix 1
Template RNA Entire genomic DNA elimination 
reaction
14
Total 20
The tubes were vortexed, centrifuged and again incubated for 15min at 42°C followed by 
3min at 95°C in a thermal cycler (BIO-RAD T100™, Hampstead, UK) to inactivate the 
Quantiscript reverse transcriptase. On completion the tubes were stored on ice.
2.10.3 End-point PCR
The master mix was prepared for this reaction from reagents listed in Table 2.13. All the 
reagents used to prepare master mix were from the GoTaq® Flexi DNA Polymerase kit 
(Promega, Southampton, UK) and all forward and reverse primers for respective genes listed 
in Table 2.15 were synthesized by Sigma-Aldrich (UK) with instructions for reconstitution of 
lyophilized primers to lOOpM (pmol/pl) with nuclease free water. The primer master stock 
was further diluted to 1:10 (lOpl stock + 90jil water) to lOpM working stock in nuclease-free 
water and stored as single use (lOpl) aliquots at -20°C until further use.
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Table 2.13 Components of master mix to amplify cDNA of CYP1A1, CYP1A2 and p-actin.
CYP1A1
master
mix
CYP1A2
master
mix
p-actin
master
mix
Reagents Final Volume Volume Volumeconcentration m (Pi) (Pi)
5x Go Taq® Flexi Buffer IX 5 5 5
1 OmM dNTP mix 0.2mM each 0.5 0.5 0.5
25mM Magnesium Chloride 2mM 1.5 1.5 1.5
Forward primer 0.2pM 0.5 0.5 0.5
Reverse primer 0.2pM 0.5 0.5 0.5
GoTaq DNA polymerase (5u / j l l 1) 1.5U 0.15 0.15 0.15
cDNA template - 1 1 1
Nuclease-free water - 15.85 15.85 15.85
Total - 25 25 25
The oligonucleotide sequence for each primer is shown in Table 2.14. After completion of the 
reaction, samples were stored at -20°C until required for gel electrophoresis.
Table 2.14 Primer names and their sequence to amplify the cDNA.
Prim er name Sequence ( 5 ' - 3 ' ) Product size (bp)
CYP1A1 Forward primer ATCCTTGTGATCCCAGGCTCC 76CYP1A1 Reverse primer TAGGGATCTTGGAGGTGGCTGA
CYP1A2 Forward primer CCAACGTCATTGGTGCCATG 262CYP1A2 Reverse primer GTGATGTCCCGGACACTGTTC
p-actin Forward primer GATGGCCACGGCTGCTTC
100p-actin Reverse primer TGCCTCAGGGCAGCGGAA
All the master mixes were run simultaneously under the conditions given in Table 2.15 using 
an Thermal cycler (BIO-RAD T100™, Hampstead, UK).
After the reaction completion, samples were stored at -20°C awaiting 6 % PAGE gel 
electrophoresis.
Table 2.15 Thermo-cycling conditions for amplification of cDNA.
Steps Temperature(°C) Time
Number of 
cycles
Initial denaturation 94 2 min 1
Denaturation 94 30sec
34Annealing 60 30sec
Extension 72 30sec
Final extension 72 2 0 sec
Preservation 12 Infinity -
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2.10.4 Visualizing PCR product
The PCR product was vusualized using 6 % polyacrylamide gel followed by silver staining 
A photographic record was kept using a Biorad Universal Hood II (Biorad).
2.11 Quantitative Real-time Polymerase Chain Reaction (Real-time PCR)
cDNA was prepared as mentioned in Section 2.11.2 and 2.11.3. Real-time PCR was 
performed immediately after cDNA synthesis. The expression analysis was performed using 
QuantiFast™ SYBR® Green PCR Kit (Qiagen, Sussex, UK).
The reactions were set up in the PCR hood under sterile conditions. The components of each 
reaction are listed in Table 2.16
Table 2.16 Components of each well of a 96-well plate for Real-time PCR.
Components Volume per reaction (96 well plate) (pi)
2xQuantifast SYBR Green PCR Master Mix 12.5
Primer A 0.25
Primer B 0.25
cDNA template 1.5
RNase-free water 10.5
Total 25
Firstly, master mix for each sample was prepared by mixing QuantiFast SYBR® Green Master 
mix, primers and water to ensure that the same reagents were present in each reaction well. 
Then 4.5pi sample cDNA (1.5pi per reaction) was added into each master mix. From each 
master mix 25 pi was aliquoted into wells of a sterile 96-well PCR plates (Multiplate™ PCR 
plate, white, BIORAD, UK). In all experiments the housekeeping gene |3-actin was used as a 
standard to compare gene expression change. Standard samples and negative controls were 
also included for each primer pair. In negative controls the cDNA was replaced with water. 
The plates were sealed after loading all the reactions into the wells with Microseal B 
Adhesive sealer (MSB-1001, BIORAD, UK). The plates were briefly centrifuged to bring all 
the contents to the bottom of the wells and placed in the CFX Connect™ Real-Time System 
(Biorad, Hertfordshire, UK) and run under the following thermocycling conditions:
1. 95°C for 5min
2. 95°C for lOsec "1
U  x 40
3. 60°C for 30sec p
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5. 55°C for lmin
6 . lOsec at each 0.5°C increase in temperature from 55°C
to 95°C to generate a melt curve
The first step activates the HotStarTaq Plus DNA polymerase. Step 2 and 3 represent the PCR 
reaction, while steps 4 to 6  enable melt curve analysis.
From the amplification reaction the fluorescent data was collected at step 3 as well as 
analysed in real-time. The melt curve analysis was done by collecting the data from step 6  and 
analysed in real time.
2.11.1 Data analysis
The CXF Manager Software (Biorad, Herdfordshire, UK) was used to analyse the data. Each 
sample was analysed individually.
The melt curve of all the samples were analysed for the specificity of the PCR reaction
product. If the melt temperature was incorrect for any sample, this sample was removed from
the analysis.
For the relative quantification of gene expression the standard curve method was used. 
Standard samples with known template amounts were defined in the “sample setup” view. 
Therefore stock cDNA samples were diluted (10-fold dilutions with the dilution values: 1, 10, 
100, and 1000). The results from wells defined as Standards were used to generate a standard 
curve. The crossing points (Cjs) were plotted against the log of the template amount, resulting 
in a straight line. Threshold cycle (Cj) values for these samples and the standard curve were 
then used to calculate the amount of starting template in the experimental samples.
The samples were normalized by their respective endogenous control results to calculate a 
normalized target value:
Normalized target = Target
Endogenous control
The normalized target values were then divided by one another to calculate the fold difference 
in target quantity:
Fold difference in Target = Normalized target (treated sample)
Normalized target (untreated control)
N-fold differences observed were considered as change in gene expression if <0.5 or >1.5 as 
defined by Doak et al, (2004) and statistical analysis was conducted.
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2.12 DNA extraction from cultured cell lines for TP53 gene
All TK6 , AHH-1, MCL-5 and HepG2 cell lines (5xl06) were centrifuged at 9503 x g 
(10,000rpm) for lOmin at 4°C. The supernatant was discarded and the cells were resuspended 
in ice cold PBS and recentrifuged. The cell pellet was again resuspended in ice cold PBS and 
centrifuged at 300 x g (1800rpm) for lOmin at 4°C. The supernatant was then removed and 
DNA was extracted using the DNeasy Blood and Tissue Kit® (Qiagen, Sussex, UK) according 
to the manufacturer’s instructions. All the centrifugation was done at 25°C in (BIOFUGE, 
Fresco, Heraeus). The cell pellet was resuspended in 200pl PBS and 20pl proteinase K. Then 
4pl RNase A was added (to get RNA-free genomic DNA) mixed by vortexing and left for 
2min incubation at room temperature. Then 200pl Buffer AL was added and mixed 
thoroughly by vortexing and incubated again at 56°C for lOmin. Afterwards 200pl ethanol 
(96-100%, Fisher Scientific) was added and mixed by vortexing. The mixture was pipetted 
into the DNeasy Mini spin column placed in a 2ml collection tube, centrifuged at 6000 x g 
(8000rpm) for lmin. The flow-through and collection tube was discarded. The spin column 
was placed in a new 2ml collection tube and 500 j l l 1 Buffer AW1 added centrifuged for lmin at 
6000 x g (8000rpm) and again discarded the flow-through. The spin column was again placed 
into new 2ml collection tube and 500pl Buffer AW2 was added, centrifuged for 3min at
20,000 x g (14,000rpm) to dry the membrane. The flow-through and tube was discarded. 
Finally the spin column was placed in clean 1.5ml centrifuge tube and 200pl Buffer AE was 
added onto the DNeasy membrane and incubated at room temperature for lOmin and DNA 
was eluted by centrifugation for lmin at 6000 x g (8000rpm).
The concentration of DNA and its purity was determined as mentioned in Chapter 2 Section 
2.7.2. The samples were divided into two aliquots and stored at -20°C.
2.12.1 Polymerase chain reaction
The GoTaq® Flexi DNA Polymerase Kit (Promega) was used for PCR reaction. The volumes 
of the reagents used per reaction are given in Table 2.17. The TP53 forward and backward 
primers used were synthesized by Sigma (UK). Their name and sequence are listed in Table 
2.18.
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Table 2.17 Components for master mix to amplify TP 5 3 cDNA.
Reagents Final concentration Volume (pi) in master mix
5x Go Taq® Flexi Buffer IX 5
1 OmM dNTP mix 0.2mM each 0.5
25mM Magnesium Chloride 2mM 1.5
Forward primer 0.2pM 0.5
Reverse primer 0.2pM 0.5
GoTaq DNA polymerase (5u/pl) 1.5U 0.15
DNA template - 0.7jig
Nuclease-free water - To makeup total volume
Total - 25
Table 2.18 The TP53 primers and sequences used for the amplification of p53 DNA.
Primer name Sequence (5'-3') Product length (bp)
Forward primer TTGGGAGTAGATGGAGCCT 445Reverse primer AGT GTT AG ACTGG A A ACTTT
The conditions used for the icycler (Biorad, Hemel Hemstead, UK) for the amplification of 
p53 DNA were shown in Table 2.19.
Table 2.19 Thermo-cycling conditions for p53 DNA amplification.
Steps Temperature°C Time
Number of 
cycles
Initial denaturation 92 2 min 1
Denaturation 94 30sec
34Annealing 60 30sec
Extension 72 5 sec
Final extension 72 2 0 sec
Preservation 12 Infinity
The PCR product was then loaded on 6% ployacrylamide gel, stained with silver staining to 
visualize.
2.12.2 Sample preparation for sequencing and construction of mutation spectra
Samples were purified using PCR purification kit ® (Qiagen, Sussex, UK). For detailed 
methodology see Chapter 2 Section 2.9. Samples were sent to Source Bioscience, Sanger 
sequencing (Rochdale, UK) for sequencing. Mutation spectra was constructed using iMARS 
software, kindly provide by Dr Paul Lewis at Swansea University (Morgan and Lewis, 2006).
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Chapter 3
Investigation of the Genotoxic Potential of 
Benzo[a]pyrene in Human Cells 
With Differing Metabolic Activation Capacity
3.1 Introduction
B[a]P is considered to be a “probably carcinogenic to humans”, categorized as Group 2A by 
IARC 1987 (IARC, 1987). USEPA in 2001 concluded B[a]P was a “probable human 
carcinogen” (B2), on the basis of sufficient evidence of its carcinogenicity in laboratory 
animals in 1992 and other data generated from genotoxicity assays. B[a]P has been used as a 
model compound to study carcinogenic effects (Phillips, 1983). Due to the unavoidable 
human exposure it is a serious threat to carcinogenicity. B[a]P is known to cause lung, head- 
and-neck cancers as well as other diseases such as atherosclerosis (Miller and Ramos, 2008; 
Shimada and Fujii-Kuriyama, 2004).
Upon exposure to cells, different pathways attempt to detoxify and eliminate B[a]P from the 
cell but this process also results in the formation of intermediate products that are able to bind 
with DNA to form DNA adducts. In the absence of DNA repair mechanisms, it could lead to 
permanent mutations and carcinogenic process (Hoeijmakers, 2001). Earlier research on 
B[a]P focussed on evaluating carcinogenetic activities of different B[a]P products, for 
example, Levin et al (1976) showed a higher tumour formation in response to B[a]P- 7,8-diol 
than B[a]P- 7,8-oxide whereas in another study Kapitulnik et al (1977) injected newborn mice 
with B[a]P, B[a]P- 7,8-diol, and BPDE and reported a higher incidence of cancerous growth 
in different organs. This study also showed that B[a]P- 7,8-diol was more carcinogenic than 
B[a]P; and BPDE was highly mutagenic to bacterial and mammalian cells and considered as 
the ultimate carcinogen.
Studies performed in vitro have demonstrated that CYP1A1 and mEH are involved in the
metabolic activation of B[a]P into reactive intermediates, and is responsible for B[a]P-
mediated mutation and cancer (Millar and Ramos, 2001). Among the various forms of P450
determined so far, CYP1A1 and CYP1B1 have been shown to be the most important human
P450 enzymes in the metabolic activation of PAHs and PAH dihydrodiols (Shimada et a 1,
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2002). Deutsch-Wenzel et al, (1983) studied rats and indicated higher carcinogenic effects of 
B[a]P than the benzofluoranthenes or indeno(l,2,3-cd)pyrene. Although other PAH such as 
dibenz(a,h)anthracene, 5- methylchrysene, and dibenzo(a,i)pyrene are substantially stronger 
lung tumourigens than B[a]P in mice or hamsters, but their concentration in cigarettes are 
relatively lower, therefore, they have not been studied as extensively as B[a]P (Nesnow et al, 
1995; Sellakumar and Shubik, 1974). B[a]P is thought to be responsible for a reproductive 
toxic effect as well. For example Neal et al, (2008) found high levels of B[a]P from the 
follicular fluid of women exposed to mainstream smoke.
As discussed in chapter 1, several factors such as the nature of the chemical and its interaction 
with the target, variability in cells, tissues and cell protective mechanisms etc. influence dose 
dependant responses (Jenkins et al, 2005). Therefore, it is important to consider these factors 
while determining threshold of any genotoxins.
These considerations become even more complex if the genotoxin involved is a pro­
carcinogen that requires metabolic activation to initiate genotoxicity. As compared to direct 
acting agents, little is known about the threshold of pro-carcinogenic agents and further 
studies are required to understand the dose dependant response of chemicals that require 
metabolic activation to cause carcinogenetic effects. This chapter deals with the genotoxic 
thresholds at low doses caused by B[a]P and the potential mechanisms behind the threshold 
dose response to such pro-carcinogens.
Over recent years OECD developed several guidelines for the testing of chemicals (OECD, 
2005). Those guidelines are internationally accepted and used by government, industry and 
independent laboratories. The data produced from studies following the guidelines are 
accepted by all OECD member countries (Cimino, 2006). Therefore, the present study is 
focuses on testing of chemicals using the in vitro cytokinesis-block micronucleus (CBMN) 
assay guided by OECD (2005) for the hazard characterization that can be used in risk 
assessment. This test is used in genotoxicity testing as an initial screening for mutagenicity 
and carcinogenesis.
3.1.1 Aims of the study
As already mentioned above, much work has been done to find out the genotoxic threshold of 
chemicals that interact with DNA directly, with the potential to form DNA adducts and exert 
carcinogenicity. Currently there is no evidence of genotoxic thresholds for chemicals 
requiring metabolism to form products that are capable of binding to DNA, forming DNA 
adducts and leading to mutation. Considering this, the aim of this study was to identify the
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existence of a potential threshold for B[a]P, which is one of the extensively studied 
clastogenic PAHs. The results obtained from this study will tell whether there is
1. A differential genotoxicity of B[a]P in different human cell lines based on their 
metabolic capacity and
2. An exhibited threshold for genotoxicity for B[a]P after metabolic activation at low 
doses.
The study utilised the in vitro CBMN assay, in the human lymphoblastoid cell lines AHH-1, 
MCL-5, TK6 and human hepatoma line HepG2, which are known to have differential 
expression of CYP450 enzymes, to evaluate the dose related responses by the induction of 
micronuclei.
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3.2 Materials and Methods
3.2.1 Cell lines
AHH-1, MCL-5 and HepG2 cells were used for both 4h and 24h B[a]P exposure studies. TK- 
6  cells were used in 24h B[a]P exposure studies only.
3.2.2 Cell culture
Cell culture was performed as described in Chapter 2 Section 2.1.2.
3.2.3 Test chemical B[a]P and dosing regime
All the flasks were seeded at lx l0 5cells/ml (lOml/flask, MCL-5) and 1.2xl05 cells/cm2 (10ml 
flask, HepG2) before treatment with the chemical for 24h or 4h at 37°C, 5% CO2. Satellite 
flasks were also prepared for each dose for cytotoxicity analysis.
The 1M stock solution of B[a]P was prepared by dissolving 0.050g of B[a]P powder (Sigma, 
UK) into 200pl DMSO. This stock was kept at 4°C for 2weeks for further use. For each 
replicate a new working stock was prepared. Working stocks of B[a]P were prepared by 
dissolving the 1M stock further in DMSO+RPMI1640 (1:2) to obtain the required working 
stocks. These working stocks were added into 10ml cell culture to get the desired 
concentrations mentioned in Table 3.1 and incubated for different time points e.g. 4h or 24h. 
After treatment time the chemical was washed off using growth media (without 
supplements).
Table 3.1 Range of B[a]P doses and amount of two working stocks used
Doses (pM) ImM working stock lOmM working stockVolume (pi) Volume (pi)
1 10 -
2 2 0 -
3 30 -
4 40 -
5 50 -
10 100 -
25 - 25
30 - 30
50 - 50
70 - 70
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3.2.4 Cytotoxicity Assay
The Relative Population Doubling (RPD) toxicity measure was used to calculate the 
cytotoxicity of the chemical in the absence of cytochalasin B as described by Lorge et al, 
(2008). Briefly, the satellite flasks for suspended cells (TK6 , AHH-1 and MCL-5) were 
counted one hour before dosing using a Coulter counter (Z1-Coulter Particle Counter, 
Beckman Coulter, Inc). HepG2 cells were counted on the day of seeding. After each treatment 
time, 4h or 24h, cells were incubated for another 24h in fresh media and counted again as 
described in Chapter 2 Section 2.3. The experiment was repeated three times.
3.2.5 Micronucleus Assay
Cytochalasin B was added as described in Chapter 2 Section 2.4.1. The cells were washed 
with 0.56% KC1, fixed with fixative 1 and 2 and harvested onto slides as described in Chapter 
2 Section 2.4.2. Cells were stained with DAPI+Vectorshield solution and then scanned for 
binucleated cells on the Metafer system (Chapter 2 Section 2.4.3). Binucleated cells with 
positive micronuclei were validated microscopically using a lOOx objective and then manual 
confirmation of the micronuclei was done by visualizing the gallery images.
3.2.6 Scoring
The CBMN assay slides were scored using the criteria described in Chapter 2 Section 2.4.3. 
To increase the confidence on the Metafer system and the statistical power of the test, the 
experiment was run in triplicate and 1 0 ,0 0 0  binucleated cells were checked for the presence of 
micronuclei per dose.
3.2.7 Pre-treatment of MCL-5 with NCND before B[a]P 24h exposure for 
micronucleus induction
Soluble epoxide hydrolase inhibitor NCND (Calbiochem, EMD Chemicals Inc., Germany) 
was used to inhibit the activity of microsomal epoxide hydrolase (mEH) in the MCL-5 cell 
line. The data sheet stated an IC50 (Inhibition concentration 50) at 85.2nM for recombinant 
human mEH, and therefore, a two-fold concentration of NCND (170nM) was used to incubate 
MCL-5 cells with for 2h before B[a]P treatment for 24h.
The lOmM stock solution of NCND was prepared by dissolving 0.03 lg of NCND powder 
into 10ml methanol (Sigma). Aliquots (100pl) were prepared and the stock was kept at -20°C 
for 3 months for further use. For each replicate a new working stock was prepared by diluting 
the lOmM stock in methanol+RPMI1640 (1:2).
Chapter 3
All the flasks were seeded at lx l0 5cells/ml (lOml/flask) for 24h The IC50 value is 85.2nM for 
recombinant human sEM (soluble Epoxide Hydrolase) therefore we used 170nM to gain 
IC100. This concentration was used to treat MCL-5 cells for 2h prior to 70pM B[a]P exposure 
for 24h and then proceed as mentioned in Chapter 2 Section 2.4.
3.2.8 Statistical analysis
A one-way ANOVA followed by Dunnett’s post-hoc test (2-tailed) was used to compare all 
treatment data from control data using IBM SPSS software (version 19). A confidence limits 
of 95% (p<0.05), 99.9% (p<0.01) and 99.99% (p<0.001) were applied. The hockey stick 
modelling software, provided by Lutz and Lutz (2009) and implemented in the R package 
(version 2.9.1), was used to estimate a threshold dose.
3.2.9 RNA extraction
Total RNA was extracted from the human cell lines TK6 , AHH-1, MCL-5 and HepG2 from 
control and 24h post B[a]P treatment. The doses of B[a]P treatment selected were based upon 
the LOEL dose obtained as a result of CBMN assay (Table 3.2 in Section 3.4.1). Details of 
method are described in Chapter 2 Section 2.6.1.
3.2.10 Reverse Transcription with elimination of genomic DNA and cDNA synthesis
The reverse transcription reactions and cDNA synthesis are described in detail in Chapter 2 
Section 2.10.1 and Section 2.10.2. This experiment was repeated three times.
3.2.11 -End-point PCR
This procedure was performed to study the expression of CYP1A1 and CYP1A2 in cDNA 
from different treated and untreated cell lines, d method described in detail in Chapter 2 
Section 2.10.3 and Section 2.10.4.
3.2.12 Real-time PCR
The detailed method was described in Chapter 2 Section 2.11 and 2.11.1.
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3.3 Results
To determine the cytotoxic and genotoxic effects of B[a]P on cell lines with different levels of 
metabolic activity, MCL-5, AHH-1, TK6 and HepG2 were exposed to different doses of 
B[a]P and dose-responses were assessed utilising the CBMN assay. Micronucleus frequency 
was used to assess the levels of chromosomal aberration. Soluble epoxide hydrolase (sEH) 
inhibitor, NCND was also used to determine the importance of microsomal epoxide hydrolase 
(mEH) in the metabolism of B[a]P and determined its effect on the induction of micronuclei 
in the MCL-5 cell line. The RT-PCR was used to evaluate the difference in basal and induced 
expression of CYP1A1 and 1A2 in all four cell lines (treated with LOEL dose of B[a]P for 
24h obtained as a result of CBMN assay).It is important to note LOEL doses varied for each 
cell line, therefore, in this study each cell line was treated with different B[a]P doses i.e. its 
respective LOEL dose. These different doses were selected to compare the effect of B[a]P on 
CYP1A1 and CYP1A2 expression at doses where micronucleus induction become significant 
in the respective cell line. The difference in CYP1A1 and CYP1A2 expressions were 
quantified by real-time PCR.
3.3.1 Cytotoxicity and genotoxicity of B[a]P after 24h exposure
All four cell lines TK6, AHH-1, MCL-5 and HepG2 were treated with B[a]P for 24h using a 
dose range of l-70pM B[a]P. These doses were chosen to represent a range of doses as 
described in previous studies. Relative Population Doubling (%RPD) and average percentage 
of binucleated cells that contained micronuclei (%Mn/Bn) was used to assess cytotoxicity and 
genotoxicity, respectively (Table 3.2). For all cell lines, average cytotoxicity and genotoxicity 
(from three replicates) in response to different doses of B[a]P is shown in Table 3.2 and 
individual results are discussed below for each cell line.
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Table 3.2 A summary table showing the average results o f  cytotoxicity (%RPD) and average 
percentage o f  binucleated cells that containing micronuclei (%Mn/Bn) with 24h 
benzo[a]pyrene treatment in all four cell lines.
Dose
(pM)
TK6 AHH-1 MCL-5 HepG2
%RPD %Mn/Bn %RPD %Mn/Bn %RPD %Mn/Bn %RPD %Mn/Bn
0 100.00 0.91 100.00 1.35 100.0 1.51 100.00 0.65
1 101.55 0.82 104.95 1.33 72.8 1.67 84.42 0.77
2 104.63 0.87 104.36 1.36 71.0 1.81 77.99 0.89
3 102.73 0.84 102.42 1.42 65.8 2.05* 77.73 1.03*
4 106.68 0.8 96.13 1.5** 63.98 2.18** 61.45 1.13 :
5 109.02 0.82 95.46 1.57** 60.41 2 2* * * 53.60 1.38
10 101.62 0.75 91.57 1 72*** 55.78 2 32* * * 38.04 1.50**
25 107.63 0.71 83.20 | o j :|c * * 52.72 2.42** 17.47
30 112.82 0.78 81.78 2.05** 41.04 2.76*** -17.86
50 101.76 0.79 81.06 2 ] *** 38.25 -32.38
70 85.70 0.74 61.48 2 23 * * * 16.03 3.38** -43.52
*, **, *** Indicates a statistically significant did 
and p<0.001 respectively)
erence compared to control (p<0.05, p<0.01
3.3.1.1 TK6 cells
B[a]P did not show any significant effect in TK6 cell line at any o f  the doses tested. Relative 
population doubling and micronuclei induction values varied non-significantly between the 
untreated control and any of the B[a]P dose which ranged from 0-70pM (Table 3.2, Fig. 3.1, 
Raw data in Appendix II, Table A.l). Since the TK6 cell line has minimal CYP 450, there is 
little cellular mechanism to metabolize B[a]P in these cells. These results are in line with 
earlier reports that metabolic activation of B[a]P is required to cause genotoxicity (Gelboin, 
1980).
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Figure 3.1 Relative population doubling (% RPD) and average percentage o f  binucleated 
cells that contained micronuclei (%Mn/Bn) with 24h benzo[a]pyrene treatment in TK6 cells. 
Points', mean o f  3 replicates, Bars: standard error.
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3.3.1.2 AHH-1 cells
In contrast to TK6 cells, AHH-1 cells showed a reduction in %RPD values with increasing 
doses o f  B[a]P but overall these responses did not vary significantly with that o f  the untreated 
control (Table 3.2, Figure 3.2, Raw data in Appendix II, Table A. 2). There was a slight 
increase in cytotoxicity observed over the whole dose range ( lp M  to 70pM) but 50% 
cytotoxicity was not achieved even at the highest dose (70pM). AHH-1 cells showed 
increasing gentoxocity with increasing dose o f  B[a]P. A linear dose-response was observed in 
AHH-1 cells and the frequency o f  Mn/Bn cells was significantly increased from 1.5% to 
2.23% at 4|iM (p<0.01) to the top dose o f  70|lxM (p<0.001), respectively.
The result o f  the Hockey stick model for estimation o f  the dose-response relationship revealed 
that B[a]P exhibited a linear dose response in AHH-1 after 24h exposure and a threshold 
model was rejected (Figure 3.3).
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Figure 3.2 Relative population doubling (% RPD) and average percentage o f  binucleated 
cells that contained micronuclei (%Mn/Bn) with 24h benzo[a]pyrene treatment in AHH-1 
cells. Points', mean o f  3 replicates, Bars: standard error, **, *** Indicates a statistically 
significant difference in %Mn/Bn compared to control ( p<0.01 and pO.OOl respectively)
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Figure 3.3 Graph generated by the Hockey stick threshold model using the Lutz approach for 
the analysis o f  dose-response relationship in AHH-1 cells to benzo[a]pyrene.
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3.3.1.3 MCL-5 cells
MCL-5 cells showed a linear increase in cytotoxicity with B[a]P dose and 50% cytotoxicity 
was achieved between the dose ranges o f  25-70pM B[a]P (Figure 3.4, Raw data in Appendix 
II, Table A.3). At 25pM, RPD was 52.72% and decreased to 16.03% at 70pM. A linear 
genotoxic dose-response was observed in MCL-5 cells treated over the lpM  to 70pM dose
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range o f  B[a]P. The frequency o f  Mn/Bn cells was significantly increased from 2.05% to 
3.38% at 3pM (p<0.05) to the top dose of 70pM (p<0.001).
The result o f  the Hockey stick model for the estimation o f  dose-response relationship revealed 
that B[a]P exhibited a linear dose response in MCL-5 cells after 24h exposure (Figure 3.5) 
and no threshold dose was found.
Figure 3.4 Relative population doubling (% RPD) and average percentage o f  binucleated 
cells that contained micronuclei (%Mn/Bn) with 24h benzo[a]pyrene treatment in MCL-5 
cells. Points: mean o f  3 replicates, Bars: standard error, **, *** Indicates a statistically 
significant difference in %Mn/Bn compared to control (p<0.01 and p<0.001 respectively)
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Figure 3.5 Graph generated by the Hockey stick threshold model using the Lutz approach for 
the analysis of  dose-response relationship in MCL-5 cells to benzo[a]pyrene.
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3.3.1.4 HepG2 cells
B[a]P treated HepG2 cells showed a linear increase in cytotoxicity with increasing dose and 
50% cytotoxicity was achieved at 5pM (Figure 3.6, Raw data in Appendix II, Table A. 4). 
Cell viability (RPD) dropped to 17.48% at 25pM and at 70pM reached -43.52% indicating a 
strong cytotoxic effect. It is important to note, the HepG2 cells showed increased sensitivity 
to B[a]P over the other cell lines. For example, at concentrations o f  25pM of B[a]P and 
above, cytotoxicity caused HepG2 cells numbers to decrease below the original seeded 
concentration, a phenomenon not observed in the other cell lines. Due to the high cytotoxicity 
o f  B[a]P, HepG2 cell were not tested for doses above lOpM for micronuclei frequency. A 
linear genotoxic dose-response was observed in HepG2 cells treated with a lpM  to 10pM 
dose range o f  B[a]P. A significant increase in the frequency o f  Mn/Bn cells was observed at 
3pM which is 1.04% (p<0.05) and this reached to 1.50% at lOpM (p<0.001).
The result o f  the Flockey stick model for estimation o f  the dose-response relationship revealed 
that B[a]P exhibited a linear dose response in HepG2 cells after 24h exposure to B[a]P 
(Figure 3.7) and again no threshold dose was found.
Figure 3.6 Relative population doubling (% RPD) and average percentage o f  binucleated 
cells that contained micronuclei (%Mn/Bn) with 24h benzo[a]pyrene treatment in HepG2 
cells. Points’, mean o f  3 replicates, Bars: standard error, *, *** Indicates a statistically 
significant difference in %Mn/Bn compared to control (p<0.05, and p<0.001 respectively)
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Figure 3.7 Graph generated by the Hockey stick threshold model using the Lutz approach for 
the analysis of  dose-response relationship in HepG2 cells to benzo[a]pyrene.
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3.3.2 Cytotoxicity and genotoxicity of B[a]P after 4h treatment
As 24h exposures to B[a]P caused significant cytotoxic and genotoxic effects (apart from in 
TK6 cells), a shorter exposure to B[a]P was performed. TK6 cells have minimal ability to 
metabolically activate B[a]P and thus did not show any cytotoxicity and genotoxicity after 
24h exposure to B[a]P as such, a 4h exposure to B[a]P in TK-6 cells was not included in the 
study. AHH-l, MCL-5 and HepG2 cell were treated with B[a]P for 4h using a dose range of 
l0-70|iM. The average results o f  cytotoxicity and genotoxicity are shown in Table 3.3. The 
table shows the dose of B[a]P (pM), the average percentage o f  %RPD and the average 
percentage of binucleated cells that contained micronuclei (%Mn/Bn) for all three cell lines. 
Individual results were discussed below for each cell line.
Table 3.3 A summary table showing the average results o f  cytotoxicity (%RPD) and average 
percentage of binucleated cells containing micronuclei (%Mn/Bn) with 4h benzo[a]pyrene 
treatment in all three cell lines.
Dose AHH-1 MCL-5 HepG2
(pM) %RPD %Mn/Bn %RPD %Mn/Bn %RPD %Mn/Bn
0 1 0 0 . 0 0 1.32 1 0 0 . 0 0 1.44 1 0 0 . 0 0 1 . 1 0
10 122.31 1.37 8 6 . 0 1 1.46 52.25 1.15
2 0 107.43 1.36 80.66 1.53 41.00 1.47*
30 108.23 1.32 67.57 1.56 32.75 1.38*
40 98.04 1.30 67.34 1.75- 35.05 1.57***
50 96.55 1.41 60.42 1.84** 29.59 1.85***
60 107.16 1.43 56.90 2 .0 1 *** 9.46 2 | ] * * *
70 92.02 1.54 45.18 2.26*** 7.20 9 4 9 ***
*, **, *** Indicates a statistically significant difference compared to control (p<0.05, p<0.01 
and p<0.001 respectively)
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3.3.2.1 AHH-1 cells
AHH-1 cells showed little change in the cytotoxicity level with increasing B[a]P dose. 
Cytotoxicity decreased from 122.31% at 10pM B[a]P to 92.02% at 70pM B[a]P. Similarly, a 
small non-significant elevation in genotoxicity was observed from 1.37% to 1.54% as the 
tested dose range increased (Table 3.3, Figure 3.8, Raw data in Appendix II, Table A. 5).
The Hockey stick model for estimation o f  the dose-response relationship was not applied as 
there was no significant increase in the genotoxicity observed.
Figure 3.8 Relative population doubling (% RPD) and average percentage o f  binucleated 
cells that contained micronuclei (%Mn/Bn) with 4h benzo[a]pyrene treatment in AHH-1 cells. 
Points', mean of 3 replicates, Bars: standard error.
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3.3.2.2 MCL-5 cells
MCL-5 cells showed no significant change in cytotoxicity until the top dose o f  70pM was 
reached and RPD values dropped from 86.01% to 45.15%. A non-linear increase in genotoxic 
dose-response was observed in MCL-5 cells across the dose range o f  B[a]P. The frequency of 
%Mn/Bn cells significantly increased from 1.44% in untreated controls to 1.75% at 40pM 
(p<0.05) and reached up to 2.26% at 70pM (p<0.001) (Table 3.3, Figure 3.9, Raw data in 
Appendix II, Table A).
The result o f  the Hockey stick model for estimation o f  the dose-response relationship revealed 
that B[a]P exhibited a non-linear dose response in MCL-5 cells after 4h exposure and thus a 
threshold dose exists for B[a]P induced chromosome breakage in these cells (Figure 3.10). 
The estimated threshold dose (IP) was 25.46pM. The low^r limit o f  90% confidence interval 
(Cl) is 14.60pM (indicated by broken line) at p<0.002.
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Figure 3.9 Relative population doubling (% RPD) and average percentage o f  binucleated 
cells that contained micronuclei (%Mn/Bn) with 4h benzo[a]pyrene treatment in MCL-5cells. 
Points', mean of 3 replicates, Bars: standard error, *, **, *** Indicates a statistically 
significant difference in %Mn/Bn compared to control (p<0.05, p<0.01 and p<0.001 
respectively).
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Figure 3.10 Graph generated by the Hockey stick threshold model using the Lutz approach 
for the analysis o f  dose-response relationship in MCL-5 cells treated with benzo[a]pyrene for 
4h.
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3.3.2.3 HepG2 cells
HepG2 cells showed a linear increase in cytotoxicity and 50% cytotoxicity was recorded at 
lOpM B[a]P. Cytotoxicity was 47.75% at lOpM and at 70 |liM it decreased by 92.8% (7.20% 
RPD). An increasing genotoxic response was observed in HepG2 cells across the lOpM to
98
Chapter 3
70pM dose range of B[a]P. A significant increase in frequency o f  %Mn/Bn cells was first 
observed at 20pM where 1.47% (p<0.05) genotoxicity was observed, and reached to 2.49% at 
70pM (p<0.001) (Table 3.3, Figure 3.11, Raw data in Appendix II, Table A).
The result o f  the Hockey stick model for estimation o f  the dose-response relationship after 
4hrs exposure to B[a]P, favoured a linear model and rejected a threshold model despite 
showing a non-linear dose curve in HepG2 cells (Figure 3.12).
Figure 3.11 Relative population doubling (% RPD) and average percentage o f  binucleated 
cells that contained micronuclei (%Mn/Bn) with 4h benzo[a]pyrene treatment in HepG2 cells. 
Points: mean o f  3 replicates, Bars: standard error, *, *** Indicates a statistically significant 
difference in %Mn/Bn compared to control (p<0.05 and p<0.001 respectively).
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Figure 3.12 Graph generated by the Hockey stick threshold model using the Lutz approach 
for the analysis o f  dose-response relationship in HepG2 cells treated with benzo[a]pyrene for 
4h.
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3.3.3 Effect of NCND on micronuclei induction in MCL-5 cells
In order to investigate the role of the metabolising enzyme microsomal epoxide hydrolase 
(mEH) in the metabolism of  B[a]P and its resultant genotoxicity, an inhibitor of  this enzyme 
was used. The average results o f  cytotoxicity and micronucleus induction in MCL-5 cells pre­
treated with NCND for 2h prior to B[a]P (70pM) exposure for 24h are represented graphically 
in Figure 3.13. There was non-significant difference in cytotoxicity between control and 
NCND treated MCL-5 cells (t-test). However, cytotoxicity was significantly higher in B[a]P 
treated cell as compared to control (p<0.001) and NCND+B[a]P (p<0.001) (Figure 3.13, Raw 
data in Appendix II, Table A. 8). There was no significant difference in %MnBn between 
control and NCND only treated cells. B[a]P treatment o f  cells pre-treated with NCND 
induced statistically significant higher %Mn/Bn cells (p<0.01) when compared to the negative 
control, however, it was significantly lower than the cells treated with B[a]P alone. MCL-5 
cells without pre-treatment exposed to B[a]P also showed significantly higher levels of 
%Mn/Bn cells (p<0.001) when compared to the control. Percentage Mn/Bn frequency in 
B[a]P only treated cells was 3.15% as compared to NCND-treated plus B[a]P treated cell 
which was 1.93%, thus represent 1.63 fold increase in % Mn/Bn frequency in B[a]P only 
treated cells (Figure 3.13).
Figure 3.13 Effect on micronucleus frequency in MCL-5 cells pre-treated with soluble 
epoxide inhibitor, NCND before benzo[a]pyrene exposure for 24h. Points: mean o f  3 
replicates, Bars', standard error, *, *** Indicates a statistically significant difference compared 
to control (p<0.05 and pO.OOl respectively)
NCND+B|a|PControl NCND
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3.3.4 Basal and induced expression of CYP1A1 and CYP1A2 enzymes
Expressions o f  CYP1A1 and 1A2 enzymes in MCL-5, AHH-1, TK6 and HepG2 cells were 
determined by RT-PCR. There was a difference in basal and induced expressions of CYP1A1 
for all cell lines at different doses of  B[a]P evaluated. It was confirmed by measuring the 
intensity o f  each band by intensitometry method using Chemidot software (For figures see 
Appendix III, Figure A. 1) and further confirmed by Real-time PCR . Induction o f  CYP1A1 
expression was 2.9-fold in MCL-5 and 1.28 fold in AHH-1 cell line observed when compared 
to LOEL dose. In TK6 and HepG2 cell lines, induced CYP1A1 increased by 1.2-folds and 
2.3-fold respectively (Figure 3.14 A) For CYP1A2, expression was 3.2-fold and 2-folds 
increase in MCL-5 and HepG2 cell lines respectively. While in TK6 and AHH-1 cell lines no 
fold increase in CYP1A2 expression was observed (Figure 3.14 B)
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Figure 3.14 Fold change in (A) CYP1A1 and (B) CYP1A2 expressions vs. P-actin after 24h 
B[a]P exposure in MCL-5- (0) Untreated control, (1) 3pM, (2) 4pM, AHH-1 - (1) 4pM, (2) 
5pM, TK6-(1) 5pM, (2) 10pM, HepG2- (1) 3pM, (2) 4pM
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3.4 Discussion
This chapter describes the genotoxic effect of B[a]P on cultured human cell lines expressing 
different levels of the metabolising enzymes CYP450s. B[a]P itself is not DNA reactive, but 
when absorbed in the human body, it is metabolised by cytochrome P450 enzymes, especially 
CYP1A1, into its genotoxic and carcinogenic intermediates that bind to DNA and lead to the 
formation of BPDE (Kim and Guengerich, 2005). Studies were aimed at determining the 
effect of B[a]P dose and exposure time on the cytotoxicity and formation of micronuclei in 
response to varying metabolic potential of selected cell lines. Cytotoxicity data is represented 
as a measure of reduction in relative population doubling following exposure to B[a]P for 
either 4h or 24 h. Genotoxicity data is represented as dose-related responses of chromosomal 
damage in the form of micronucleus induction. Since B[a]P requires metabolic activation to 
cause genotoxic effects therefore metabolically competent cell lines, MCL-5, AHH-1 and 
HepG2, and with minimal CYP450 activity the cell line TK6 were used as in vitro models for 
studying the cytotoxicity and genotoxicity of B[a]P at different exposure times and doses. 
Indeed studies confirmed varying levels of basal and induced CYP enzymes in cell lines 
evaluated here. MCL-5 and HepG2 showed highest basal and induced CYP1A1 and CYP1A2 
while AHH-1 showing lower activity. TK6 cells had least CYP1A1 and no CYP1A2 activity.
3.4.1 B[a]P cytotoxicity and genotoxicity in different cell lines
While determining genotoxicity of a compound, it is also important to determine cytotoxicity 
of the compound to understand its effects on cell growth and cell replication. It was observed 
in present study that cell cycle of the cell lines tested ranged from 22-24h, therefore 
differences observed in micronucleus formation were due to the effect of B[a]P rather than the 
difference in cell growth patterns and/or its cell cycle. Furthermore, we used B[a]P doses that 
showed less than 50% cytotoxicity and this dose selection was in accordance with OECD 
guidelines (2007) that recommend that studies aimed at determining genotoxicity of a 
compound should include a dose range that produces a low level of cytotoxicity and a 
maximum of 50+5% cytotoxicity.
Human thymidine kinase heterozygote TK6 cells were used in this study because they express 
wild-type p53, grow rapidly in suspension (population doubling time of 18h), and are 
routinely used in genetic toxicology studies. Results of our study showed non-significant 
effects of B[a]P on either cytotoxicity or genotoxicity of TK6 cell lines (Figure 3.1). The TK6 
cell line had low expression of CYP1A1, and therefore, is unable to metabolize B[a]P. There 
was no significant difference in MN frequency between untreated and B[a]P treated TK6 cells
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therefore, the cell line was excluded from studies aimed at determining the effect of B[a]P 
exposure for 4h.
Results o f  this study with metbolically competent cells confirm that the differences in the 
expression o f  CYP1A1 and the presence o f  microsomal epoxide hydrolase (mEH) play an 
important role in the metabolic activation o f  B[a]P, leading to the formation of  te carcinogenic 
metabolite BPDE. Indeed unlike TK6 cells, B[a]P exposure gave significant increases in 
%Mn/Bn frequencies in AHH-1, MCL-5 and HepG2 cell lines at concentrations giving less 
than 50+5% cyotoxicity (as measured by RPD). The results o f  this comparative study have 
shown that B[a]P has a potential to induce cytotoxic and genotoxic effects in AHH-1, MCL-5 
and HepG2 at both 24h and 4h exposure times (Figure 3.15 and 3.16). In particular, MCL5 
and HepG2 cells showed strong genotoxic responses to B[a]P, which was less apparent in 
AHH-1 cells. These difference appeares to be due to the difference in CYP1A1 induction in 
these cell lines. The study on CYP1A1 expression showed that induction of  CYP1A1 in 
response to B[a]P is higher for MCL-5 and HepG2 as compared to AHH-1 (Figure 3.14).
Figure 3.15 Comparision o f  average percentage of  binucleated cells containing micronuclei 
(%Mn/Bn) in TK.6, AHH-1, MCL-5 and HepG2 cells after treatment with benzo[a]pyrene for 
24h. Points: mean o f  3 replicates, Bars: standard error*, **, Indicates a statistically significant 
difference compared to control (p<0.05 and p<0.01 respectively).
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3.4.2 Effect of differential metabolic competency on micronucleus frequencies after 
24h exposure
The AHH-1 cells express high levels o f  native CYP1A1 (Crespi et a l, 1990). MCL-5 cells 
were developed from a subpopulation o f  AHH-1 cells by transfection of  cDNAs of  the human
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CYP 450s, such as CYP1A2, CYP2A6, CYP2E1, CYP3A4, CYP1A1 and microsomal 
epoxide hydrolase (mEH) (Crespi et a\, 1991). CYP450 cloned in MCL-5 are native in 
HepG2 cells and it also has several other CYP enzymes (Knasmuller et al, 1998) and mEH. It 
should be noted that a dose dependant response was represented after a B[a]P exposure for 
24h for all cell lines, however, the dose range for AHH-1 and MCL-5 is 0 to 70pM whereas 
for HepG2 dose ranges from 0 to 1 OpM. Differences in metabolic competencies may explain 
why MCL-5 and HepG2 display a greater genotoxic response after B[a]P exposure as 
compared to AHH-1 cells. For example, at 24h B[a]P exposure, in AHH-1 cells the first 
significant increase in micronuclei induction using Dunnett’s posthoc test, was observed at 
4pM (p<0.01), whereas it was a lower concentration of 3pM (p<0.05) in both MCL-5 and 
HepG2 cells (Figure 3.4). Further analysis of the data using fold change in micronucleus 
frequency was also comparatively higher in MCL-5 and HepG2 cells than that of AHH-1. For 
example at a B[a]P dose of lOpM, MCL-5 and HepG2 showed 1.5 and 2.3-fold increase in 
micronucleus frequency respectively as compared to the untreated control, however fold 
increase in micronucleus frequency at IOjjM was only 1.27 in AHH-1. A similar trend was 
observed at higher doses (70pM) where MCL-5 showed far more increase in micronucleus 
frequency (2.23 fold) than in AHH-1 (1.65 fold) (Figure 3.17). Due to higher cytotoxicity of 
B[a]P in HepG2, studies were restricted to lOfiM of B[a]P. It should be noted that even at this 
dose the fold increase in micronucleus formation was significantly higher than the 
micronucleus formation observed in AHH-1 at 70pM dose (Figure 3.15).
Further analysis of AHH-1, MCL-5 and HepG2 micronucleus data using hockey stick 
statistical modeling confirmed a linear (non-thresholded) dose-response at 24h exposure to 
B[a]P for all the metabolically competent cell lines (Figures 3.3, 3.5 and 3.7). These findings 
may be explained by the potent formation of stable DNA adducts at N2-guanosine residues 
(Lin et al, 2001) which if left unrepaired, might block replication and transcription. Even a 
single BPDE-DNA adduct can effectively block expression of a reporter gene (Koch et al, 
1993) and has been linked to mutations in multiple genes includes TP53 and Kras, thus 
causing severe damage to cell integrity, function and replication (Denissenko et al, 1996; 
Yoon et al, 2003).
3.4.3 Effect of differential metabolic competency on micronucleus frequencies after 4h 
exposure
The studies at a shorter exposure time allow to compare all cell lines including HepG2 to 
doses ranging from 0 to 70pM. Micronuclei induction in the cell lines following 4h exposure
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to B[a]P showed a similar trend to that observed following B[a]P exposure for 24h (Figure 
3.16). Following 4h exposure, no significant difference in cytotoxicity or micronucleus 
frequency was observed in AHH-1 (Figure 3.8). These findings are in line with our studies at 
B[a]P exposure of 24 hours as well as earlier reports that B[a]P required a longer exposure 
time for efficient metabolic activation to cause genotoxic effects (Yamakage et al, 1998). The 
results of this study indicate that metabolic activity in AHH-1 cells was unable to activate 
B[a]P even at the highest dose of 70pM in 4h (Table 3.3), however, at a longer exposure of 
24h it is capable of activating B[a]P at doses 4pM and above (Table 3.2). These findings also 
indicate that lower levels of CYP1A1 and absence of mEH in AHH-1 cells were unable to 
convert enough B[a]P into mutagenic intermediates. Differences in the dose dependent 
response at 4h and 24h exposure provides further evidence of the role of CYP1A1 and mEH 
in converting B[a]P to its mutagenic metabolites. These findings indicate that B[a]P 
conversion to its mutagenic intermediates in cells devoid of mEH and with lower CYP1A1 
levels is slow and thus requires more time to convert similar quantities of B[a]P into its 
intermediate products at a level or concentration that is required to cause a genotoxic effect.
In the case of MCL-5 at 4h B[a]P exposure, the first significant increase in micronuclei 
induction was observed at 40pM (p<0.05, Dunnett’s posthoc test) (Figure 3.9). In HepG2 
cells micronuclei induction was significantly different from the untreated control and 20pM 
(p<0.05) was the lowest concentration observed to cause a statistically significant effect in 
micronuclei induction (Figure 3.11) and the increase in the frequency of micronuclei was dose 
dependent.
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Figure 3.16- Average percentage o f  binucleated cells containing micronuclei (%Mn/Bn) of 
AHH-1, MCL-5 and HepG2 cells after treatment with benzo[a]pyrene for 4h. Points: mean of 
3 replicates, Bars: standard error, * Indicates a statistically significant difference compared to 
control (p<0.05).
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The statistically significant difference in micronucleated cell frequency between 0 and 70pM 
at 4h B[a]P doses was 1.16 fold in AHH-1, 1.6 fold in MCL-5 and 2.26 fold in HepG2 cells. 
(Figure 3.17).
Figure 3.17 Comparision of fold increase in micronuclei induction in AHH-1, MCL-5 and 
HepG2 cells at lOpM and 70pM benzo[a]pyrene doses following 24h and 4h exposure time. 
HepG2 was not tested at 70pM dose due to very high cytotoxicity.
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According to the CBMN data for both time exposures, the cell lines were ranked in the 
following order according to their metabolic competancy: HepG2 > MCL-5 > AHH-1 > TK6. 
These results clearly indicate that micronucleus induction appeared to link with the levels of 
CYP450 and the exposure to B[a]P. It is worth mentioning that the dose dependent genotoxic 
response is also linked with exposure time indicating a slow conversion rate in these cells 
(Fig. 3.17).
3.4.4 Presence of genotoxic threshold in MCL-5 cell line
The presence of a genotoxic threshold in MCL-5 cells treated for 4h with 20pM of B[a]P 
suggested the role of metabolic activation of B[a]P in its ability to cause genotoxic effects. 
Following a B[a]P exposure for 4h, the MCL-5 cell line appeared to be incapable of activating 
B[a]P to induce genotixicity. With shorter exposure time of 4 h, B[a]P could not induce 
genotoxicity untill a 40pM dose, however, at 24h exposure even a lower dose of 3pM was 
capable of inducing genotoxicity. These findings suggest that longer exposure times allows 
the cells to metabolize B[a]P which could results in accumulation of higher dose of its 
intermediate products that are capable of inducing genotoxicity.
Metabolism of pro-mutagenic compounds may influence dose responses for DNA mutation 
and as such, lack of metabolism may contribute to thresholded dose responses (Jenkins et al, 
2005). At lower doses of the toxin, DNA repair mechanisms are also able to repair DNA 
damage and remove DNA adducts from cells at a relatively faster rate as compared to the 
number of DNA adducts formed, and a NOEL will be observed (Doak et al, 2007). Earlier 
studies by Lutz (1998) have shown that the level of toxicity depends on the availibility of 
DNA repair mechanisms, therefore, we can assume that B[a]P toxicity is a reflection of both 
cellular capacity for B[a]P metabolism as well as the absence or failure of cell mechanisms to 
remove metabolites of B[a]P from cells. We did not measure DNA repair enzyme levels or 
activity here and so cannot comment on the relative role of metabolism and repair.
3.4.5 Effect of microsomal epoxide inhibitor (NCND) on micronucleus induction in 
MCL-5 cells.
The previous and present study strongly suggested a role for CYP1A1 in the metabolism of 
B[a]P to induce chromosomal damage appearing as micronuclei in binucleated cells. A further 
study with MCL-5 cell line was done to confirm the importance of microsomal epoxide 
hydrolase (mEH) which is responsible for inducing increased genotoxic potential in MCL- 
5and HepG2 as compared to AHH-1 cells. N-Cyclohexyl-N’-dodecylurea (NCND), is an
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effective inhibitor for microsomal epoxide hydrolase (Davis et al, 2002) and was used in this 
study. The results (Figure 3.13) showed that the frequency of binucleated cells having 
micronuclei decreased when MCL-5 cells were pre-treated for 2h with NCND (dose 170nM) 
and then exposed to 70pM B[a]P for 24h as compared to cells without this pre-treatment. For 
example, 1.6-fold decrease in %Mn/Bn frequency was observed between MCL-5 cells pre­
treated with NCND and without NCND pre-treatment. Increased micronuclei in MCL-5 
without NCND pre-treatment suggests that mEH along with CYP1A1 play an important role 
in the conversion of B[a]P to compounds that induce chromosomal damage (Figure 3.3). Our 
results correspond with studies performed by Pelkonen and Nebert (1982) and Johnson et al, 
(2010) which also observed higher micronucleus frequencies in MCL-5 cells as compared to 
AHH-1 cell lines. AHH-1 cells did not contain detectable activity of epoxide hydroxylase 
(Penman et al, 1994) therefore, the number of micronucleated cells were relatively low.
In conclusion this study shows that TK6 cells have minimal ability to metabolise B[a]P and 
thus did not show any cyotoxicity nor genotoxicity, suggesting that B[a]P is non-toxic without 
metabolic conversion. Higher levels of genotoxicity and cytotoxicity observed in AHH-1, 
MCL-5 and HepG2 cell lines with higher metabolic activity further confirms that bi-products 
of B[a]P metabolism are involved in its toxicity.
CYP1A1 enzyme and mEH play an important role in the metabolic activation of B[a]P and 
the subsequent observed cytotoxicity and genotoxicity. The combined presence of CYP1A1 
and mEH caused MCL-5 and HepG2 cells to yield more binucleated cells with micronuclei as 
compared to AHH-1 cell as AHH-1 are devoid of mEH. At 24h exposure, there is a dose 
dependent linear increase in the %Mn/Bn frequency observed in AHH-1, MCL-5 and HepG2 
cells. The linear dose-response confirms that there is no safe exposure level for B[a]P in 
metabolically competent cell lines exposed for extended periods to B[a]P. At 4h exposure 
AHH-1 cells did not show a significant induction of cytotoxicity or genotoxicity, whereas 
HepG2 cells showed a linear increase in the frequency of %Mn/Bn cells. Only MCL-5 cells 
are able to produce a thresholded response at 25.46pM following a shorter exposure time of 
4h.. At lower doses with shorter exposure, MCL-5 may not appear to metabolically activate 
sufficient quantities of B[a]P to its genotoxic form, therefore, no stable adduct formation was 
observed. At longer exposure time of 24 h, MCL-5 was able to transform even lower dose of 
3pM to its genotoxic forms.
These findings showed that metabolic activation of B[a]P plays an important role in activating 
B[a]P to compounds that have the potential to induce genotoxicity. Considering the human 
exposure to B[a]P through cigarete smoking, results of this study support previous reports of a
108
Chapter 3
link between cigarette smoking and risk of developing cancer. B[a]P concentration is reported 
to be about 9ng (0.035pM) per cigarette in a full flavoured cigarettes (Chepiga et al, 2000). 
Fowles (2000) reported B[a]P concentrations of 0.0099 and 0.0141 pg in main and sidestream 
respectively (Fowles 2000), therefore, a single cigarette could potentially pose a carcinogenic 
risk among individuals with high metabolic activity. Similarly, regular smoking i.e higher and 
continous exposure to B[a]P may therefore be considered as a relatively higher risk factor, 
however, further in vivo studies are needed to confirm this corelation of cigarette smoking and
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Investigation of Point Mutations Induced by 
Benzo[a]pyrene in Human Cell Lines
4.1 Introduction
B[a]P is one of the most well-known combustion products in vehicle exhausts, cigarette 
smoke and ambient air. B[a]P acts as a substrate for the oxidative reactions carried out by 
CYP450 (Conney, 1992). The metabolic intermediates, hydroxyl and epoxide are highly 
electrophilic and bind covalently to macromolecules to form bulky hydrophobic adducts (Guo 
et al, 2002). BPDE is the major genotoxic product formed from B[a]P metabolism. B[a]P is 
metabolized into four different stereoisomers of BPDE. The (+)-anti-BPDE [(+)-anti-7R,8S- 
diol-9S,10R-epoxide of B[a]P] is formed in great excess, both in vivo and in vitro, as 
compared to the others. This bay region diol epoxide (BPDE) has greatest tumorigenicity in 
vivo (Buening et al, 1978) and it covalently reacts at the N2 position of 2-deoxyguanosine 
(dG) in DNA to form two different adducts: (+)-trans-anti-BPDE-N2-dG and (+)-cis-anti- 
BPDE-N2-dG (Figure 4.1). The (+)-trans-anti-BPDE-N2-dG is the most abundant and major 
adduct formed, and if not repaired can induce mutations such as G->T base pair transversions 
during DNA replication (Luch, 2005).
The mutation profile induced in the HPRT gene of mammalian cells by B[a]P has been 
reported to be dose dependent. For example, the proportion of G->T transversions increased 
from 42% to 69% from 10-480nM dose range of B[a]P (Wei et al, 1991; Wei et al, 1993). 
B[a]P mutagenesis has also been reported in other genes. Among them, the TP53 gene is the 
most studied gene, mainly because of its vast number of mutation sites (nearly 300 sites) 
(Daya-Grosjean et al, 1995) and mutations have already been observed in many of its codons 
(5 to 8) (Fares et al, 2007). B[a]P causes mutations in the p53 gene in lung cancer 
(Denissenko et al, 1996). In lung cancer ~ 40-51% of the mutations are G->T transversions 
(Greenblatt et al, 1994: Yoon et al, 2001: Pfeifer et al, 2002).
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Figure 4.1 Four different stereoisomers o f  benzo[a]pyrene diol epoxide after metabolic 
activation. (+)-trans-anti-BPDE-N2-dG is the most potent product. Modified from Luch 
(2005).
The supF  gene in Escherichia coli has also been used for the detection o f  DNA damage 
induced by B[a]P, where Rodriguez and Loechler (1993b) showed that the metabolised form 
of  B[a]P, (+)-anti-BPDE induced 45% base substitutions, 24% frame shifts, 23% insertions 
and 8% deletions. Where base substitutions occurred significantly they were observed at G:C 
base pairs; with GC->TA (57%), G C ^ A T  (23%) and GC-^CG (20%) reported. Similarly, 
Yoon et al, ( 2001) found a 42% induction o f  G->T transversions in supF  gene by BPDE and 
further analysis o f  embryonic mouse fibroblasts from BigBlue mouse embryos, has shown the 
c/7 and lacl genes to have 56% and 68% BPDE-induced G->T transversion mutations, 
respectively.
4.1.1 Aim of the study
The aim o f  this chapter was to determine the mutagenicity caused by low doses o f  B[a]P 
following a 24h and 4h exposure times in AHH-1 and MCL-5 cell lines. The second part of 
the study focused on the construction of B[a]P-induced mutation spectra for both cell lines to 
determine how differences in metabolic capabilities affect the spectrum of B[a]P-induced 
mutation at 10pM and spontaneous mutation in solvent control after 24h exposure. There are 
conflicting reports regarding mutations in the p53  gene o f  AHH-1 and MCL-5, therefore, we
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conducted further studies to analyse basal mutations in the p53 gene of AHH-1, MCL-5, TK6 
and HepG2 cell lines.
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4.2 Materials and Methods
4.2.1 Cell lines used and their maintenance
AHH-1 and MCL-5 cell lines were selected to study the in vitro effect of B[a]P exposure 
(following 24h and 4h time period) at the genetic level.
Cell culture was performed as described in Chapter 2 Section 2.1.2.
4.2.2 Test chemical B[a]P
Further details in Chapter 3 Section 3.2.3.
4.2.3 HPRT assay
The HPRT assay has three important stages as detailed in Chapter 2 Section 2.5
I HPRT mutant cleansing stage: to reduce the (HPRT-) mutant cells from the AHH-1 
and MCL-5, cell populations of 5x1 O'5 cells / ml were grown for 3 days in 2x1 O'4 mol/L HAT 
(hypoxanthine aminopterin thymidine) media followed by 24h HT (hypoxanthine thymidine) 
media. Cells were then grown for 3 days in normal media to achieve sufficient cell numbers 
for treatment.
II Treatment with chemical and sub-culturing stage: Cells were seeded at 4xl05 ml 
(10 ml) in 25cm flasks. Untreated control and solvent control flasks were also prepared. The 
experiment was repeated three times and treated with freshly prepared stock solution of B[a]P 
from the purchased product following the dose regime mentioned in Chapter 3 Table 3.1. The 
cells were washed with RPMI media (without supplements) twice and then incubated for 13 
days. The cells were diluted in fresh media on days 1, 3, 5, 7, 9, and 11, to replenish the 
nutrients to repopulate the culture. Half of the doses were cryogenically frozen down on day 
7. The other halves of the doses were incubated for a further 13 days before proceeding on to 
the third stage.
III Mutant selection stage: At this stage the cells were diluted at concentration 4 xlO4 
cells/well in a 96 well plate (NUNC) and the HPRT cells isolated by using 6-TG (0.6pg/ml) 
which is toxic for HPRT+ cells, from AHH-1 and MCL-5 cell populations. In addition, plates 
without selection containing 20 cells/well were also prepared to measure the plating 
efficiency (PE). All plates were incubated for another 14 days at 37°C in a humidified 
incubator with 5% CO2, for colony formation. Five plates were prepared for each dose from 
selective and non-selective media. Sixty wells per plate were scored (avoiding perimeter wells 
due to the partial evaporation of media in these wells).
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4.2.4 Scoring of colonies
Colonies were only scored from wells (from plates with and without 6-TG selection) 
containing 20+ cells in diameter (a criteria established and used in our laboratory) and 
colonies clearly separated from each other. Each well represented one observation. The 
colonies were counted using a light microscope and the number of colonies observed used to 
determine the mutation frequency (MF) of each dose as described in Chapter 2 Section 2.5.3.
4.2.5 Statistical analysis
A one-way ANOVA followed by Dunnett’s post-hoc test (2-tailed) was used to compare all 
treatments with control using IBM SPSS statistic software (version 19). Confidence limits of 
95% (p<0.05), 99.9% (p<0.01) and 99.99% (pO.OOl) were applied. The hockey stick 
modelling software, provided by Lutz and Lutz (2009) and implemented in the R package 
(software 2.9.1), was used to estimate a threshold dose.
The t-test was used to assess whether the means of two groups were statistically different 
from each other in untreated and solvent control. The Confidence limit of 95% (p<0.05) was 
applied.
4.2.6 Clonal expansion of mutants
Untreated control, solvent control and lOpM B[a]P treated HPRT mutant colonies were 
transferred to 24 well plates containing 2ml growth media per well and grown for 5 days at 
37°C, 5% CO2, after which cells were carefully mixed with 1.5 ml RNA protect® (Sigma) and 
stored at -20°C for RNA extraction.
4.2.7 RNA extraction
For a detailed description of RNA extraction methodology see Chapter 2 Section 2.6.
4.2.8 Complementary DNA (cDNA) synthesis from HPRT mRNA
For a detailed description of methodology see Chapter 2 Section 2.6.3.
4.2.9 End-point PCR
A detailed description of methodology and primers used in present study was given in 
Chapter 2 Section 2.6.4.
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4.2.10 6% PAGE gel and Silver nitrate staining
Detailed procedures of gel preparation, gel loading, and silver nitrate staining were given in 
Chapter 2 Section 2.7.1 and 2.7.2.
4.2.11 Preparation of samples for sequencing
For detailed methodology see Chapter 2 Section 2.8. Samples were sent to Genome Enterprise 
Limited (Norwich, UK) for sequencing.
4.2.12 Construction of mutation spectra
Mutation spectra was constructed using iMARS software, kindly provide by Dr Paul Lewis at 
Swansea University (Morgan and Lewis, 2006).
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4.3 Results
4.3.1 B[a]P mutation dose-response using the HPRT assay
The HPRT assay was performed with suspension cell lines, AHH-1 and MCL-5 to study the 
low dose effect of 24h and 4h exposures of B[a]P at the genetic level. TK6 and HepG2 cell 
lines were not included here as TK6 cell line did not show any response to B[a]P in MN data 
and minimal CYP450 expression. HepG2 cells are adherent cells and they did not form 
colonies, that we have to count at the end of HPRT assay to calculate MF. Doses selected for 
this study were low doses including the dose that produced the first significant increase in the 
%Mn/Bn frequency in Chapter 3 i.e. 4pM for AHH-1 (p<0.01) and 3pM for MCL-5 cells 
(p<0.05) after 24h exposure and 20pM for MCL-5 (p<0.05) after 4h exposure of cells 
(Chapter 3 Section 3.3.1 and 3.3.2).
4.3.1.1 Mutation frequency of B[a]P after 24h exposure
In the HPRT assay the plating efficiency (PE) of treated cultures was used to measure the 
toxicity. Plating efficiency was based on colony forming ability of cells when inoculated into 
a 96 well plate without 6-thioguanine (non-selective conditions). The colonies grown in non- 
selective conditions and selective conditions were counted to assess the mutant frequency 
(MF). In selective conditions, MF (MFxlO'5) is the frequency of the HPRT mutants in a 
population of cells. PE plates were grown alongside MF plates to assess mutant frequency. 
DMSO was used to dissolve the B[a]P, therefore, it was used as solvent control for both cell 
lines. It was observed that the MF of the cells in solvent control was not statistically different 
from the cells in untreated control in both cell lines by using t-test statistical analysis (Table 
4.1, .Raw data in Appendix IV, Table A. 9 and 11).
Table 4.1 Comparison of mutation frequency xlO'5 and % cell viability in control and solvent 
control in AHH-1 and MCL-5 cell lines
Cell lines B[a]P QiM) MFxlO'5 St. error t test % Cell viability St. error t test
AHH-1
Untreated
control 0.26 0.03 96.93 1.86
Solvent 
control (0) 0.18 0.03 0.08 100.00 0.00 0.11
MCL-5
Untreated
control 2.39 0.13 99.98 1.16
Solvent 
control (0) 2.2 0.15 0.26 100 0.00 0.98
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These studies showed that DMSO is non-mutagenic for both cell lines and as such can be 
used to represent the spontaneous HPRT MF in AHH-1 and MCL-5 cell lines.
Both cell lines, AHH-1 and MCL-5, were treated with B[a]P for a 24h exposure using a dose 
range of 1-lOpM. The average % cell viability and MF (xlO'5) from the triplicates in response 
to different doses of B[a]P is shown in Table 4.2 and individual results are discussed below 
for each cell line.
Table 4.2 A summary table showing the average results of % cell viability and average 
mutation frequency (MFxlO'5) with 24h benzo[a]pyrene treatment in AHH-1 and MCL-5 
cells.
B[a]P (pM )
AHH-1 M CL-5
% Cell viability M F (xlO -5) % Cell viability M F (xlO '5)
0 100.00 0.18 100.00 2.20
1 99.49 0.63 100.92 13.77
2 103.45 1.03 99.70 22.96**
3 97.86 1.71 94.99 28.23***
4 98.26 3.14* 93.58 40.67***
5 93.73 4.42** 84.89 52.27***
10 91.93 5.52*** 74.65 137.00***
*, **, *** Indicates a statistically significant difference compared to control (p<0.05, p<0.01 
and p<0.001, respectively)
4.3.1.1.1 AHH-1 cells
The AHH-1 cell viability decreased with increasing dose of B[a]P but overall the responses 
did not vary significantly with that of the solvent control (Table 4.1 and Figure 4.2, Raw data 
in Appendix IV, Table A. 10). The cell viability was 99.49% at lpM and was reduced to 
91.93% at 10pM. Despite low toxicity levels, AHH-1 cells showed increased MF with 
increasing B[a]P dose, for example, MF was significantly increased from 3.14 xlO'5 at 4jiM 
(p<0.05) to 5.52 xlO"5 at the top dose of lOpM (p<0.001). When MF from treated samples 
was compared to the spontaneous frequency of the solvent control 17.4 and 30.6 fold 
increases in MF were observed at 4jiM and 10pM doses respectively (Figure 4.2).
The increase in MF was observed as a linear dose-response, as confirmed by the result of the 
Hockey stick model for estimation of the dose-response relationship for 24h B[a]P exposure 
in AHH-1 cells (Figure 4.3).
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Figure 4.2 Average mutation frequency (MF xlO0 ) and average % cell viability in AHH-1 
cells after 24h benzo[a]pyrene treatment. Points: mean of 3 replicates, Bars: standard error, *, 
**, *** Indicates a statistically significant difference compared to control (p<0.05, p<0.01 
and p<0.001, respectively)
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Figure 4.3 Graph generated by the Hockey stick tnresnold model using the Lutz approach for 
the analysis o f  dose-response relationship in AHH-1 cells to benzo[a]pyrene.
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4.3.1.1.2 MCL-5 ceils
When dosed with B[a]P for 24h, the % cell viability was not affected in MCL-5 cells until the 
3pM dose, after which a steady linear decrease in % cell viability was observed. At lOpM the 
cell viability was still 74.65% (approximately 25% toxicity) compared to 100% in the solvent 
control (Table 4.2 and Figure 4.4). A linear increase in MF was observed over the l-5pM 
dose range, which was followed by a sharp increase in MF at the 10pM dose. Statistically 
significant increases in the MF were shown at 2pM (22.96 xlO°; p<0.01) and all o f  the doses 
above (p<0.001). For example, there were 10.43, 12.83, 18.48, 23.75 and 62.27 fold increases
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found over the spontaneous frequency at 2pM. 3pM, 4pM, 5pM and 10pM doses respectively 
(Figure 4.4, Raw data in Appendix IV, Table A. 12). MCL-5 was observed to be more 
sensitive than AHH-1 to comparative doses o f  B[a]P.
The Hockey stick modelling for estimation of the dose-response relationship revealed that 
B[a]P exhibited a linear dose-response in MCL-5 cells after 24h exposure (Figure 4.5) and no 
threshold dose was found.
Figure 4.4 Average mutation frequency (MF xlO°) and average % cell viability in in MCL-5 
treated with benzo[a]pyrene for 24h. Points: mean o f  3 replicates, Bars: standard error, **, 
*** Indicates a statistically significant differencein MF compared to control (p<0.01 and 
p<0.001, respectively).
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Figure 4.5 Graph generated by the Hockey stick threshold model using the Lutz approach for 
the analysis of  dose-response relationship in MCL-5 cells to benzo[a]pyrene.
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4.3.1.2 Mutation frequency of B[a]P after 4h exposure
As extended period of 24h exposures to B[a]P caused significant genetic mutations (expressed 
as increases in MF), a shorter (4h) exposure to B[a]P was performed with both cell lines. Both 
cell lines, AHH-1 and MCL-5, were treated with B[a]P for 4h exposure using a dose range of 
10-50pM and 5 - 5 0 |l iM ,  respectively. These doses were selected on the basis of previous 
experiments (Chapter 3) that showed that at 4h exposure required higher doses of B[a]P to 
cause any significant effect. Mean cell viability and MF (xlO'5) from three replicates in 
response to different doses of B[a]P is shown in Table 4.3 and individual results are discussed 
below for each cell line.
Table 4.3 A summary table showing the average results of % cell viability and average 
mutation frequency (MFxlO-5) after 4h benzo[a]pyrene treatment in AHH-1 and MCL-5 cells.
B[a]P (pM)
AHH-1 MCL-5
% Cell viability MF (xlO -5) % Cell viability MF (xlO '*)
0 100.0 0.38 100.00 3.70
5 - - 100.40 6.70
10 111.25 0.91 91.86 13.09**
15 - - 88.50 12.13**
20 100.58 1.25 84.61 20.03***
25 100.55 1.48 83.36 22.1***
30 94.22 1.56 80.03 28.05***
50 95.64 1.60 77.52 29.2***
*** Indicates a statistically signi: leant difference compared to control (p<0.05, p
and p<0.001 respectively). Dashed line: dose not tested.
4.3.1.2.1 AHH-1 cells
AHH-1 cells showed little change in % cell viability with increasing B[a]P dose. The cell 
viability reduced to 95.64% at the highest dose of 50pM B[a]P (Table 4.3). Similarly, a non­
significant increase in MF was observed from 0.91 xlO’5 to 1.60 xlO'5 as the tested dose range 
increased (Figure 4.6, .Raw data in Appendix IV, Table A. 14).
The Hockey stick model for estimation of the dose-response relationship was not applied as 
no significant increase in the MF was observed.
iiI
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Figure 4.16 Average mutation frequency (MF xlO°) and average % cell viability in AHH-1 
cells treated with benzo[a]pyrene for 4h. Points’, mean of  3 replicates, Bars', standard error.
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4.3.1.2.2 MCL-5 cells
MCL-5 cells showed a gradual decrease in % cell viability with increasing dose o f  B[a]P (5- 
50pM). For example, the cell viability dropped to 77.52% at the highest dose o f  50pM from 
100.40% at the lowest dose o f  5pM (Table 4.3 and Figure 4.7). This represents a 23% toxicity 
level which is significantly lower than the maximum toxicity testing limits of 50+5% (OECD 
2007). A linear increase in MF was observed in MCL-5 cells across the range o f  B[a]P doses. 
For example, MF was 3.70% in untreated control which varied non-significantly with B[a]P 
dose o f  5pM, however at 10pM, MF was significantly (p<0.01) higher than the untreated 
control. MF continue to increase with increasing B[a]P dose reaching to 29.2% at 50pM 
(p<0.001). When compared to the spontaneous MF in the solvent control, fold increases of 
3.53 to 7.89 MF were induced by B[a]P exposure (Figure 4.7, Raw data in Appendix IV, 
Table A. 16).
The result of the Hockey stick model for estimation o f  the dose-response relationship revealed 
that B[a]P exhibited a linear dose response in MCL-5 cells after 4hrs exposure and thus 
proves that there is no safe exposure to B[a]P in these metabolically competent cells. Thus, 
low doses of B[a]P are capable o f  inducing gene mutations in these cells (Figure 4.8).
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Figure 4.7 Average mutation frequency (MF xlO°) and average % cell viability in MCL-5 
cells treated with benzo[a]pyrene for 24h. Points: mean of  3 replicates, Bars: standard error, 
**, *** Indicates a statistically significant difference in MF compared to control (p<0.01 and 
p<0.001, respectively).
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Figure 4.8 Graph generated by the Flockey stick threshold model using the Lutz approach for 
the analysis o f  dose-response relationship in MCL-5 cells to benzo[a]pyrene.
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4.3.2 Sequence analysis of HPRT mutants
Mutation spectra were constructed to investigate the type of mutations induced by B[a]P in 
AHH-l and MCL-5 mutants. Since no significant difference in mutation frequency in AHH-1 
was observed at 4h B[a]P exposure, mutants for further studies were selected from the 24h 
experiment. Mutant cells for further studies were selected that were exposed to 10fiM B[a]P
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for 24h as well as mutants obtained from the solvent control (Sections 4.3.1.1.1 and 4.3.1.1.2) 
to further study B[a]P-induced mutations and spontaneous mutations respectively. These 
mutants were isolated and propagated at the end of the HPRT assay for sequence analysis. In 
the AHH-1 cell line 20 mutants were observed for spontaneous mutations and 20 mutants 
were used for B[a]P-induced mutations. Spontaneous mutations were examined in 20 mutants 
of the solvent control and 28 mutants treated with B[a]P in MCL-5 cells. The percentages of 
all the mutations resulting from B[a]P exposure and solvent control in both cell lines are 
shown in Table 4.4.
Table 4.4 Percentages of spontaneous and benzo[a]pyrene-induced mutations (10pM dose, 
24h) at the HPRT locus in AHH-1 and MCL-5 mutants.
Type of 
Mutations 
Base substitutions 
Transitions 1
G A !
T-^ C I
Transversions 
C -> A 
G~> C
T - >  A I
G ->  T
% Transversion j 
mutations
Tandem Mutations j
Deletion/Insertion j
Deletions
Insertions
AHH-1 Sol. AHH-1 B[a]P 
control treated
0
0%
1 (7%)
13 (93%)
11
2 (11%)
1 (5.5%)
8 (44.4%) 
9/18(50%)
6 (33%) 
1 (5.5%)
MCL-5 Sol. j MCL-5 B[a]P
f
control treated
5 I 20
4 (30%)
1 (8%) 
5/13 (38%) 
1 (8%)
7 (54%)
1 (4%)
1 (4%)
18(72%) 
19/25 (76%)
5 (20%)
In the AHH-1 solvent control, a total of 14 mutations with different mutations were found 
from 20 mutants, whereas mutation spectra of the remaining 6 mutants showed mixed colony 
traces, therefore, were excluded them for further analysis. The most dominant spontaneous 
mutations were deletions, constituting 93% of the spontaneous mutation spectra. The other
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7% of mutations represented a single tandem mutation (TG285/6AT) (Table 4.4, Appendix V, 
screen shot A, Figure A.3, A) involving a T->A and G->T mutation at exon 2 of the HPRT 
gene (Table 4.5). Among the 13 deletions, 80bp deletions (Exon 4) and 76bp (Exon 7) 
deletions occurred 7 and 3 times respectively (Table 4.5 Appendix V, screen shot A, Figure 
A. 2, B).
Table 4.5 Spontaneous and benzo[a]pyrene-induced mutational spectrum at the HPRT locus 
in the AHH-1 cell line.
Treatments Mutations Sequence Exon
Solvent control
Tandem
mutations
1 AT ->TA TCATGGA 284
G C -»T A TCATGGA 285
Deletions
1 -106 bp GTG o G A C 195 o  301
1 -1 bp G GAG o C C A 343
7 -80 bp ATG o T T A 490 o  570
3 -76 bp TGT o C A G 700 o  776
1 -16 bp AAT o T G A 777 o  793
B[a]P
Treated
Single bp 
substitutions
1 CG -> AT GCTGAGG 255
1 AT -> CG GACTAAT 289
1 G C -»T A AAGGAGA 333
1 AT CG CCCTCTG 361
6 CG -> AT AAGGGGG 375
1 C G -» GC CAGGGAT 767
Insertions
1 +1 bp G GGG o C T A 379 o  380
Deletions
5 -2 bp TG GTG o  CTC 367 o  368
1 -46 bp A G C o  TTG 653 o  699
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Following treatment with 10pM B[a]P for 24h, from 20 AHH-1 mutants 11 point mutations, 6 
deletions and 1 insertion were observed. The mutation spectra of remaining 2 mutants showed 
mixed colony traces, therefore, were excluded them for further analysis. The predominant 
B[a]P-induced point mutations were G->T transversions which was observed in 9 mutants 
thus representing 50% of the total 18 mutation spectra analysed, (Table 4.4, Appendix V, 
screen shot A, Figure A. 2, A). Out of 11 different point mutations, the G375T substitution 
occurred 6 times while the others appeared only once (Table 4.5). Other mutations such as 
GC->AT transitions (11%), insertion of 1 base pair i.e. G (5.5%) (Appendix IV, screen shot 
A, Figure A. 2, B), and deletions (33%) were also observed (Table 4.4). Of the deletions 
observed base pair (TG) deletions occurred in 5 instances (Table 4.5, Appendix V, screen shot
A, Figure A. 2, C). The ratio of transitions to transversions was 0 for spontaneous and 2:9 for 
B[a]P-induced mutations. The proportion of G-^T transversion mutations was higher as 
compared to other single base pair substitution types.
In the MCL-5 solvent control, 20 mutants were processed and only 13 mutation spectra were 
analysed as mutation spectra of remaining 7 mutants showed mixed colony traces. The 
mutational spectrum constituted of 54% deletions and 38% transversion mutations (Table 
4.4). Among 5 point mutations G648C appeared four times (Appendix V, screen shot B, 
Figure A. 4, A) and a TG285/6AT tandem mutation occurred once (Appendix V, screen shot
B, Figure A. 4, B). Deletions of 1 (n=3), 9 (n=2) and 76 (n=2) base pairs appeared repeatedly 
as spontaneous mutations in MCL-5 mutants (Table 4.6) (Appendix V, screen shot B, Figure 
A. 4, C).
Following treatment with 10pM B[a]P for 24h exposure, 25 different mutations were 
observed from 28 MCL-5 mutants. The predominant B[a]P-induced point mutations were 
GC-^TA transversions, constituting 76% of the mutation spectra (Table 4.4). Out of 20 
different point mutations (Appendix V, screen shot B, Figure A. 5, A), G306T (n=6), G378T 
(n=3) and G 767T (n=2) substitutions occurred frequently (Table 4.6). Other mutations such 
as GC->TA transitions (4%) and deletions (20%) (Appendix V, screen shot B, Figure A. 5, B) 
were also observed (Table 4.4). The ratio of transitions to transversions was 0:5 for 
spontaneous and 1:19 for B[a]P-induced mutations. Among all the point mutations, the 
proportion of G->T transversion mutations was higher as compared to other single base pair 
substitution types.
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Table 4.6 Spontaneous and benzo[a]pyrene-induced mutational spectrum at the HPRT locus 
in the MCL-5 cell line.
Treatments Mutations Sequence Exon
Solvent control Single bp substitutions
1 CG AT AAGGGGG 375
4 GC CG GTCGCAA 648
Tandem
mutation
1 AT TA TCATGGA 284
GC -> TA TCATGGA 285
Deletions
2 -9  bp T G T oG T G 356 o  365
3 -1  bp T CTT o  GCT 604
2 -7 6  bp T G T o  CAG 700 o  776
Bla]P treated Single bp substitutions
1 CG -> AT GATGAAC 207
1 CG -» AT CATGGAC 285
1 GC TA ATGGACA 297
6 C G -» AT ACTGAAC 306
3 CG -> AT GGGGGCT 378
1 GC TA CTGGCAA 586
1 CG -> AT CCACGAA 675
G C -»T A CCAGACT 696
1 GC -> CG TAGGATA 736
1 C G -» AT TCAGGGA 766
GC -> TA CAGGGAT 767
Deletions
1 - 5 bp GTG o T G A 195 o  199
1 -1 bp G CAG o A C T 302
1 - 4 bp GTG o A T A 567 ^  570
1 - 46 bp AGC o T T G 653 o  699
1 - 20 bp CTT o  ACA 700 o  720
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4.3.2.1 Mutation spectra present on the HPRT gene sequence
The spectrum of spontaneous and point mutations along the HPRT mRNA sequence in AHH- 
1 and MCL-5 cell lines are presented in Figures 4.9 and 4.10, respectively. The sequence of 
mRNA used in the present study, is identical to the non-transcribed /anti-sense strand. 
Therefore the mutations identified in the mRNA indicate mutagenesis in the non-transcribed 
strand of the double helix which is the transcription-associated mutagenesis. In the non- 
transcribed strand there was no spontaneously occurring GC-^AT transitions found in both 
cell lines spectrum. In the presence of B[a]P all AT->CG transitions where T-^C change in 
the non-transcribed strand. A clear difference was seen in the distribution of mutations along 
the HPRT target sequence between the solvent control and B[a]P-induced mutants in both cell 
lines. The mutational spectra of AHH-1 mutants from the solvent control (Figure 4.9 A) 
showed deletions of a number of base pairs and most of them occurred at exon 6 and 7 and no 
mutation due to base substitutions was observed. However, B[a]P-induced mutation spectra 
showed mutations due to deletions, insertions and single base pair substitutions (Figure 4.9 
B). The most dominant mutations were observed to be G->T transversions, present at exon 2 
and exon 3 on the HPRT sequence. Other point mutations such as T-^C and G-^C also 
appeared at exon 2 and exon 7, respectively. The insertion of one base (G) and deletions of 
two bases (TG) took place at exon 3 and another 46bp deletion appeared at exon 6.
As seen in AHH-1, the mutational spectra of 20 MCL-5 mutants from the solvent control 
(Figure 4.10 A) also showed deletions of a number of base pairs and other point mutations 
distributed at exons 3, 6 and 7. Among spontaneous mutations (solvent control) more 
deletions were observed as compared to point mutations. The base substitution G->C 
occurred 4 times at exon 6 and 7 as compared to G->T base pair substitution which appeared 
once at exon 3. The B[a]P-induced mutation spectra of 25 mutants showed a mixture of 
mutations such as deletions, insertion and single base pair substitutions (Figure 4.10 B). The 
most dominant mutations were observed to be G->T transvertions, which were present at 
exons 2, 3, 6 and 7 on HPRT sequence. Other point mutations such as C-^T and G-^C were 
also observed at exon 6 and exon 7, respectively. The deletions were distributed all over the 
HPRT sequence, but the majority were located at exon 6 and 7. In the case of both cell lines 
most of the point mutations were GC->TA transversions, with exon 3 of the HPRT sequence 
being the prominent hot spot for mutations to arise.
Tandem mutations at 284-285 base pair were similar in solvent control of both cell lines 
where 1 mutant from each cell line showed this mutation. Solvent control also showed similar
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deletion at 700-776 in both cell lines, however, 3 mutants from AHH-1 and 2 mutants from 
MCL-5 showed these deletions.
There were two similar mutations observed in B[a]P treated AHH-1 and MCL-5 cell lines. 
The G-^T transversion at 767 base pair was common in both cell lines but it appeared only 
once in AHH-1 and twice in MCL-5 cell line. One mutant from each cell line showed deletion 
of 46 bp at 653-699.
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Figure 4.9 Mutation spectra (A) spontaneous and (B) benzo[a]pyrene-induced 
in the HPRT gene in AHH-1 mutants. Each base and its number on the HPRT 
sequence are presented on the x-axis. The number of mutations is portrayed on 
the v- axis. Each base alteration is colour coded where the letter X stands for the 
4 bases; A, C, G or T determined by the position on the sequence. Numbers in 
the rectangular boxes represent the hotspot on exons.
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Figure 4.10 Mutation spectra (A) spontaneous and (B) benzo[a]pyrene-induced 
in the HPRT gene in MCL-5 mutants. Each base and its number on the HPRT 
sequence are presented on the x-axis. The number o f  mutations is portrayed on 
the^ -  axis. Each base alteration is colour coded where the letter X stands for the 
4 bases; A, C, G or T determined by the position on the sequence. Numbers in 
the rectangular boxes represent the hotspots on exons.
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4.3.3 Mutation spectra of TP53 gene
The section of  TP53mRNA spectrum is shown for MCL-5 and AHH-1 cell lines in Figure
4.11 A and B respectively. Sequence analysis o f  the TP53 gene product showed a partial 
CCGG to TTGG transition at codon 281, 282 in exon 8 in both cell lines MCL-5 and AHH-1
A
290 295 30(
3 A G A C C G G C G C A
2,900 2,950 3 ,00(
150 155 - -16(
G A G  A T  T G G C G C A
B
255  260
2,550 2,600
120
Figure 4.11 DNA sequence o f  (A) MCL-5 and (B) AHH-1 cell lines shows a partial CCGG 
to TTGG transition mutation at codon 282 in exon 8 o f  the TP53 gene.
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4.4 Discussion
The methodology of the HPRT assay has been standardised by OECD guidelines (OECD 486, 
1997) for testing and identifying chemicals that may induce DNA mutations. In the present 
study, the HPRT assay was used to elucidate the dose-response relationship of gene mutations 
induced by B[a]P and also to analyse the spontaneous and induced mutational spectra of 
HPRT mutations in 6-TG resistant human cell lines. B[a]P was shown here to be genotoxic 
and have the potential to induce gene mutations in both AHH-1 and MCL-5 cells. B[a]P had 
an increased mutagenic effect in the MCL-5 cell lines compared to AHH-1 cell line (Figures
4.4 and 4.8) at both 24h and 4h time exposures, probably because of the difference in the 
metabolic capabilities of these cell lines. The present studies on TP53 gene analysis showed 
that mutations in exon 8 of TP53 gene are heterozygous in MCL-5 and AHH-1 cell lines. 
Earlier studies by Guest & Parry (1999) have shown that these heterozygous mutations do not 
influence the ability of AHH-1 and MCL-5 to undergo DNA damage induced cell death. 
These findings confirmed that genotoxicity observed in our study is not due to mutations in 
TP53 genes.
4.4.1 Response of 24h exposure of B[a]P on mutation frequency
I observed that long-term, low doses exposure (24h at l-5pM and lOpM doses) of the 
metabolically competent MCL-5 cell line to B[a]P, produces significant increases in mutation 
frequencies (Table 4.2) as compared to short-term, high-doses (4h at 5-25pM) exposure 
(Table 4.3). The reasons for lower mutation frequencies in short-term exposures in both cell 
lines are probably due to the lower metabolic activity to activate lower doses of B[a]P to 
produce mutations. This is consistent with the observations that in MCL-5 cells at 5 and 
IOjjM  the MF were only 6.70x1 O'5 and 13.09x1 O'5 (p<0.01) after 4h exposure (Table 4.3) as 
compared to 24h where the MF were 52.27x1 O'5 and 137x1 O'5 at 5pM and lOpM respectively 
(Table 4.2). In the case of AHH-1 cells, which are less metabolically competent cell line, non­
significant increases in MF were observed at high-doses for a short exposure time (Table 4.3). 
In contrast low doses exposure for a longer time produced significant increases in MF at 
4.42xl0‘5 (p<0.01) and 5.52xl0'5 (p<0.001) at 5 and 10pM observed respectively (Table 4.2). 
Again probably reflecting time needed for efficient metabolism of B[a]P to mutagenic 
metabolites.
There was a linear dose-response observed for B[a]P exposed for 24h in AHH-1 and MCL-5 
cell lines for the induction of gene mutations. The lowest doses that induced a statistically 
significant increase in MF were 4pM with 3.14 xlO'5 (p<0.05) and 2pM with 22.96xl0'5
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values (pO.Ol) in AHH-1 and MCL-5 cell lines respectively. A non-significant increase in 
MF was observed at lower doses when compared to solvent control and these indicate that the 
presence of B[a]P even at lower level has a potential to induce genetic mutations in these cell 
lines after 24h exposure. Indeed the Lutz modelling rejected a non-linear response and 
supported linear increases in mutation frequency.
4.4.2 Response of 4h exposure of B[a]P on mutation frequency
Unlike 24h exposure of B[a]P, which caused significant increase in MF in both AHH-1 and 
MCL-5 cell lines at lower doses, a 4h exposure only showed significant increase in MF with 
MCL-5 cells at low doses (Figure 4.7). The first statistically significant increase in MF was
13.09 xlO'5 at 10pM (p<0.01) observed in MCL-5 cell line and a linear dose-response was 
observed. Non-significant increases in MF were observed from 0.91 xlO'5 to 1.60 xlO'5 as the 
tested dose range increased with AHH-1 cell line (Figure 4.6). This means that dose response 
for B[a]P is highly dependent on metabolic competency and exposure duration. At both 
exposure times and in both cell lines (Table 4.2 and Table 4.3) the first statistically significant 
increases in MFs observed occurred at concentrations where cell viability was not statistically 
decreased, therefore, increases in mutation frequencies observed were not induced via 
cytotoxicity related mechanisms. This lack of observed cell death means that viable mutant 
cells are present, which correlate with increased concern for in vivo tumorgenic potential.
4.4.3 Effect of metabolic competency on occurrence of mutation frequency
At both, 24h and 4h exposure times MCL-5 cells showed dose-dependent increases in 
mutation frequencies. MCL-5 cells were 25 to 14-folds more sensitive than AHH-1 to B[a]P 
induced mutation (10pM) at 24h and 4h respectively. These findings were similar to Crespi et 
al, (1990) where MCL-5 cells were about 833-fold more sensitive than AHH-1 cells in 
comparison to the control. MCL-5 cells are derived from L3 cells, a sub-population of AHH-1 
cells expressing only CYP1A1 and are devoid of mEH activity (Penman et al, 1994). Thus, 
MCL-5 cells have CYP1A1 but have also been transfected with a plasmid which expresses 
other metabolic enzymes such as CYP1A2, CYP2A6, CYP2E1 and CYP3A4 and mEH 
(Crespi et al, 1991). Therefore, MCL-5 cells express all five enzymes and also have higher 
expression of CYP1A1 as compared to AHH-1 cells, and thus produce more B[a]P 
metabolites than AHH-1 following B[a]P exposure. Therefore, this difference in metabolic 
potential is potentially responsible for the difference in the mutation frequencies of AHH-1 
and MCL-5 cell lines. These observations are consistent with CYP1A1 and mEH being
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primarily involved in activating B[a]P in addition to suggesting a role for other transfected 
CYP enzymes.
B[a]P is an extensively studied compound among the group of PAH’s and is present at low 
levels (10-50ng/cigarette) in cigarette smoke (Hecht, 1999). Indeed, the PAH’s (like B[a]P) 
present in smoke are believed to be responsible for the link between smoking and lung cancer. 
B[a]P from cigarette smoke has been linked with lung cancer, and studies by Dennisenko et al 
(1996) have reported distribution of BPDE adducts along exons of the TP 5 3 gene in BPDE- 
treated HeLa cells and bronchial epithelial cells. This study further showed adduct formation 
at guanine positions in codons 157, 248, and 273, which are believed to be major mutational 
hotspot in human lung cancer. B[a]P induces gene mutations by forming bulky nucleotide 
adducts; mainly through BPDE (Singer and Grunberger, 1983; Xue and Warshawsky, 2005). 
The B[a]P adduct that induces point mutations is associated with the level of Benzo[a]pyrene- 
7,8-diol-9,10-epoxide (BPDE) adduct which binds covalently at the N2 position of guanine in 
genomic DNA (BPDE-A -dG) and produces predominantly G:C to T:A transversion 
mutations (Yoon et al, 2001). B[a]P also inefficiently form BPDE- N  6-dA adducts in the 
DNA (Jeffrey et al, 1979) which have different conformation and arrangement of DNA 
complex than the BPDE-dG adducts (Geacintov et al, 1997). BPDE-A2-dG is present in (+)- 
trans and (+)- cis forms (Mocquet et al, 2007). (+)- trans- BPDE- N  2-dG is the most 
abundant and major adduct identified in vivo (Weinstein et al, 1976) and was detected in 45% 
of smokers’ lungs (Boysen and Hecht, 2003).
At low doses, the rate of adduct repair is probably faster than its rate of formation, resulting in 
NOEL (Doak et al, 2007). BPDE-DNA adducts are recognized and repaired mainly by 
nucleotide excision repair (NER) (Hess et al, 1997; Meschini et al, 2008). Hess et al (1997) 
described that the rate of repair of BPDE- N  2-dG depends on their different steriochemical 
configurations. For example, NER lesion recognition complex XPC-HR23B recognized the 
adducts differentially and repaired the c/s-adduct of dG more rapidly than the (+)-trans- 
BPDE- A 2-dG adducts (Macquet et al, 2007). Chen et al, (1992) and Denissenko et al, (1998) 
showed that through transcription-coupled repair, the repair of BPDE-DNA adducts occurs 
much faster in the transcribed strand than in the non-transcribed strand of HPRT or TP53 
genes.
4.4.4 Mutation spectra
Mutation spectra were constructed to find out the difference in mutations induced by B[a]P in 
AHH-1 and MC1-5 cell lines at the HPRT locus. Mutations of the human HPRT gene are
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responsible for a wide spectrum of diseases. The most severe form o f  disease is known as 
Lesch-Nyhan syndrome due to point mutation along the HPRT gene (Jinnah et al, 2000). As 
shown in Figure 4.11 single base substitutions that are responsible for causing this disease are 
spread throughout the 9 exons of  the HPRT  gene.
5 * \ \ \ ? • •• ♦ •••♦ • •  • • • ••  • • * f  'Tt • ♦ •••
I _____
•  •  •
Figure 4.11 Single base substitutions are spread along the protein-coding region (black 
boxes) o f  HPRT  gene and represent the locations o f  point mutations appeared as Lesch-Nyhan 
syndrome. Taken from Jinnah et al (2000)
Spontaneous mutations occur in the normal cells without any exposure to exogenous 
genotoxins in the environment. In the present study, DMSO was used as a solvent control and 
was included in this study as an untreated control, to determine the spontaneous mutations 
and to compare them with B[a]P-induced specific mutations. The MF of  DMSO is therefore 
similar to untreated control. There is no evidence suggesting that DMSO exerts any 
mutagenesis in animal cells, and indeed is known to be a scavenger o f  reactive oxygen species 
(ROS) which are capable of DNA reaction and mutagenesis (Yu and Quinn, 1994). The 
mechanism responsible for spontaneous deletions in H PRT  mRNA is the splicing at intron- 
exon junctions during pre-mRNA maturation prior to translation (O'Neill et al, 1998). The 
sources of  spontaneous mutations are;
• DNA adduction by ROS as a result each nucleotide is susceptible to oxidative damage 
and cause multiple substitutions (Wiseman and Halliwell, 1996)
• Replication over abasic sites from chemically unstable bases, which causes 
transversions and transitions.
• Spontaneous deamination of  5-methylcytosine at CpG sites leading to G C -^A T 
transitions.
• Error in replicating polymerase in DNA synthesis (Tippin et al, 2004).
• Transition associated mutagenesis, causing GC->AT, TA->GC and A T ^ T A  
substitutions (Hudson et al, 2003).
The present study showed that 93% and 54% of the spontaneous mutations were due to 
deletions at different exons o f  the H PRT  locus in AHH-1 and MCL-5 cell lines (Table 4.4). In 
AHH-1 cell line, 93% of the deletion mutations were found on exon 1, 3 and 7, whereas in the 
MCL-5 cell line, 54% of spontaneous events were deletions observed in exon 2 and 3 of  the 
H PRT  gene. It was also observed that there is a variation in spontaneous mutation between
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cell types possibly due to the difference in genotypic variations in cellular mechanisms. 
Earlier studies by Lewis and Parry (2002) confirmed variability among different cell types in 
expressing spontaneous mutations at SupF locus. Variability in culture age, handling 
conditions and differences between laboratories can also contribute towards spontaneous 
mutations; therefore, these factors should be taken into consideration when interpreting results 
of mutation spectra. Similarly it is important to standardize the culture and working 
conditions to minimize inter-laboratory variation.
Analysis of mutation spectra between solvent controls and B[a]P treated cell lines showed 
differences in type of mutations. Mutation spectra of solvent control for both cell lines, AHH- 
1 (Figure 4.9A) and MCL-5 (Figure 4.10A) mainly consist of deletions whereas B[a]P treated 
cell lines mutation spectra shows a range of mutations (Figures 4.9B and 4.1 OB), mostly G to 
T (implicating N2-dG adduct). These findings indicate the influence of B[a]P in inducing 
mutations rather than the induction of mutations resulting from one of the factors responsible 
for spontaneous mutations. Similarly B[a]P treated cell lines showed mutations at different 
exons compared to solvent control thus further indicating that mutations observed in B[a]P 
treated cells are independent of the factors associated with spontaneous mutations. It was 
observed that all the B[a]P induced mutations target guanine on the transcribed strand of the 
HPRT gene in all of the mutants sequenced.
Results of this study suggest the potential of B[a]P in causing cancer through DNA adduct 
formation and mutation. Mutational patterns observed in B[a]P treated cell lines was 
consistent with earlier reports where frequent G to T transversions were observed in the 
smoking associated mutational spectra of human lung cancer (Denissenko et al, 1996; Pfeifer 
et al, 2002). These findings provide further evidence that DNA adducts and mutational pattern 
caused by B[a]P are similar to those observed among smoking associated lung cancers 
(Pfiefer et al, 2002). Furthermore cigarette smoking provides optimum conditions for the 
absorption and metabolism of B[a]P in lungs leading to DNA adduct formation and 
mutations. Pfiefer et al, (2002) also reported a high incidence of G to T transversions in p53 
in lung samples as compared to larynx and the oral cavity of smoking associated cancers. 
These finding indicate a link between absorption and metabolism of B[a]P and incidence of 
mutational patterns. The present study has also shown a similar pattern and assumed that 
higher DNA adduct formation was taken at higher doses. Similarly its prevalence was 
relatively higher in MC1-5 cell line that represents metabolic activity. Furthermore, B[a]P 
treated mutational patterns observed in present study are consistent with those observed in 
cancers associated with smoking.
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Chapter 5
Investigation of the Genotoxic Potential of 
2-Amino-l-methyl-6-phenylimidazo (4, 5-b) pyridine 
in Human Cells With Differing Metabolic 
Activation Capacity
5.1 Introduction
IARC (1997) classified PhIP as a Group 2B carcinogen, “possibly carcinogenic to humans”. 
The U.S. Department of Health and Human Services National Toxicology Program (2011) 
has concluded that PhIP is “reasonably anticipated to be a human carcinogen”. PhIP is formed 
when creatine or creatinine (found in muscle meats), amino acids and sugars are reacting 
together at high temperatures. The formation of PhIP depends upon the type of meat, 
temperature, duration and method of cooking (Cross and Sinha, 2004).
Various in vivo and in vitro studies have concluded that PhIP is a potent mutagen and causes 
multi-organ tumours in laboratory rodents. Low doses of PhIP have been shown to induce 
colon and mammary tumours in F344 rats through diet (Fukushima et al, 2004; Ito et al, 
1991). Also PhIP induces chromosomal abnormalities in Chinese hamster cells in vitro. In 
vivo PhIP formed DNA adducts in both rats and monkeys (Carthew et al, 2010). 
Epidemiological studies also revealed that there is a correlation between high intake of well- 
done meat and high HAAs exposure with cancer of the colorectum, breast, prostate, pancreas, 
lung, stomach and oesophagus in humans (Zheng and Lee, 2009; Shirai et al, 1997).
PhIP is a strong rodent carcinogen and induces tumours at multiple sites during long-term 
feeding studies with mice and rats (Sugimura et al, 2004). Lauber et al (2004) have shown 
recently that PhIP can possess oestroagenic activity but can also invoke a mitogenic response 
at very low doses (10'9 to 10'1]M). Benford and her team in 2009 used a margin of exposure 
(MOE) approach, based on the benchmark lower confidence limit (BMDL), to study the 
prostate and mammary cancer induced by PhIP and concluded that there is no dose of PhIP 
without carcinogenic effect.
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PhIP is a strong mutagen causing DNA adduct formation and mutations. These adducts have 
been found in exposed tissues and organs like colon. For example, Dingley (1999) used 
accelerator mass spectrometry (AMS) and observed DNA and protein adducts in colon tissues 
and blood of humans when a dose of PhIP equivalent to that found in very well-done chicken 
was administered through capsules, but these adducts were unstable and declined over a 24h 
period. Fukushima et al, (2009) investigated dose dependant carcinogenicity of PhIP in 6- 
week old F344 male rats by administering PhIP at different doses in the diet for 16 weeks. 
They noted that only higher doses of 50 to 400ppm were able to induce aberrant crypt foci 
(ACF), a surrogate marker of prenoplastic lesions in colon, however, an increased DNA 
adduct formation was observed at low doses of O.Olppm and higher. These findings suggest 
that even low doses of PhIP are capable of inducing or initiating processes that could lead to 
carcinogenic activity. Adducts are only a marker of exposure of PhIP and they are not 
necessarily linked to mutation that lead to cancer. They can be repaired and not induce 
mutants at all.
PhIP requires metabolic activation to form DNA adducts. CYP enzyme’s activity is central to 
metabolic activation and MCL-5 expresses this activity. Activated PhIP causes adduct 
formation and induced mutations which are mainly at Guanine base pair. Previous studies 
have shown correlation between mutations and DNA adduct formation, however, most of 
these studies were conducted at higher doses of PhIP. This study uses MCL-5 and HepG2 cell 
lines to determine the effect of lower doses on DNA adducts formation and mutations.
5.1.1 Aims of the study
2-Amino-l-methyl-6-phenylimidazo (4, 5-b) pyridine (PhIP), is a heterocyclic aromatic amine 
and its metabolic activation is catalyzed by CYP1A2 enzyme through oxidation. As compared 
to direct acting carcinogens, very little is known of low dose exposures to chemicals that 
require metabolic activation.
This study aims
• to determine the effect of low doses of PhIP on different cell lines
• to investigate the influence of varying metabolic activity particularly the variation in 
the expression of CYP1A1 and CYP1A2 on PhIP dose responses
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5.2 Materials and Methods
5.2.1 Cell lines
Only MCL-5 and HepG2 cells were used for both 4h and 24h exposure studies. AHH-1 cell 
line lacks mEH and did not expressing CYP1A2, while TK6 did not expressed any of the 
CYP enxyme efficiently.
Cell culture was performed as described in Chapter 2 Section 2.1.2.
5.2.2 Treatment with test chemicalPhlP and dosing regime
All the flasks were seeded at lx l0 5cells/ml (lOml/flask, MCL-5) and 1.2xl05 cells/cm2 (10ml 
flask, HepG2) before treatment with the chemical for 24h or 4h at 37°C, 5% CO2. Satellite 
flasks were also prepared for each dose for cytotoxicity analysis.
The lOmM stock of PhIP was prepared by adding 4.46ml of DMSO with a syringe into a 
glass bottle containing lOmg PhIP powder (Santa Cruz, Biothecnology, Inc). The lOOpl 
aliquots were prepared and stored at 4°C for single use. For each replicate a new working 
stock was prepared by further diluting the lOmM stock of PhIP in DMSO+RPMI1640 (1:2) 
The chemical doses were then added to the flasks containing the cells according to Table 5.1 
and incubated for different time points e.g. 4h or 24h. After treatment time the chemical was 
washed off using growth media (without supplements).
Table 5.1 Range of PhIP doses and amount of two working stocks used.
Doses (pM)
ImM working 
stock
lOmM working 
stock
Volume (pi) Volume (pi)
2.5 25 -
5 50 -
7.5 75 -
10 100 -
15 - 15
20 - 20
25 - 25
35 - 35
50 - 50
100 - 100
5.2.3 Cytotoxicity assay
As described in Chapter 2 and Section 2.3. The experiment was repeated three times.
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5.2.4 Micronucleus assay
As described in Chapter 2 Section 2.4. Cells were stained with DAPI + Vectorshield solution 
and then scanned for binucleated cells on the Metafer system.
5.2.5 Scoring
The CBMN assay slides were scored using the criteria described in Chapter 2 Section 2.4.3. 
After getting confidence on the Metafer system and the statistical power of the test this 
experiment was run in triplicate and 6000 binucleated cells were checked for the presence of 
micronuclei per dose.
5.2.6 Statistical Analysis
A one-way ANOVA followed by Dunnetf s post-hoc test (2-tailed) was used to compare all 
treatments including untreated control data using SPSS software (version 19). Confidence 
limits of 95% (p<0.05), 99.9% (p<0.01) and 99.99% (p<0.001) were applied. The Hockey 
stick modelling software provided by Lutz and Lutz (2009) and implemented in the R 
package (software 2.9.1), was used to estimate a threshold dose.
5.2.7 RNA extraction
Total RNA was extracted from the human lymphoblastoid cell line MCL-5 and hepatoma cell 
line HepG2, from control and after 24h PhIP treatments. The doses of PhIP treatment selected 
were based upon the LOEL dose obtained as a result of CBMN assay (Table 5.2 in Section 
5.4.1). Details of methods are described in Chapter 2 Section 2.6.1.
5.2.8 Reverse Transcription with elimination of genomic DNA and cDNA synthesis
The reverse transcription reactions and cDNA synthesis are described in detail in Chapter 2 
Section 2.10.1 and Section 2.10.2. This experiment was repeated three times.
5.2.9 End-point PCR
This procedure was performed to study the expression of CYP1A1 and CYP1A2 in cDNA 
from different treated and untreated cell lines. The GoTaq® Flexi DNA Polymerase kit 
(Promega, Southampton, UK) was used for experiments and the method is described in detail 
in Chapter 2 Section 2.10.3 and Section 2.10.4.
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5.2.10 Real-time PCR
The expression analysis was performed using QuatiFast™ SYBR® Green PCR Kit (Qiagen, 
Sussex, UK). The detailed method was described in Chapter 2 Section 2.11 and 2.11.1.
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5.3 Results
MCL-5 and HepG2 cell lines were used in this study as these express high levels of CYP 450 
enzymes. AHH-1 cell line was not used because it have very low expression of CYP1A2 
which is required for metabolic activation of PhIP and lacks mEH (Wu et al, 2000). TK6 cells 
were not used as they are non-responsive to B[a]P due to the low CYP expressions (See 
Chapter 3). Both MCL-5 and HepG2 cell lines were exposed to different doses of PhIP for 
24h and 4h. The in vitro dose-responses were assessed utilising the CBMN assay. 
Micronucleus frequency was used to assess the levels of chromosomal aberration. The 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) was used to evaluate the 
difference in induced expression of CYP1A1 and 1A2 in MCL-5 and HepG2 cell lines 
(treated with LOEL dose of PhIP for 24h obtained as a result of CBMN assay) and the 
expressions were quantified by Real-time PCR. It is important to note LOEL doses varied for 
each cell line, therefore, in this study each cell line was treated with different PhIP doses i.e. 
its respective LOEL dose. These different doses were selected to compare the effect of PhIP 
on CYP1A1 and CYP1A2 expression at doses where micronucleus induction become 
significant in the respective cell line
5.3.1 Cytotoxicity and genotoxicity of PhIP after 24h exposure
MCL-5 and HepG2 were treated with PhIP for 24h using a dose range of 2.5-100pM. These 
doses were chosen from previously published studies (Hewitt et al, 2007; Majer et al, 2004). 
Relative population doubling (%RPD) and average percentage of binucleated cells that 
contained micronuclei (%Mn/Bn) was used to assess cytotoxicity and genotoxicity 
respectively. For cell lines, average cytotoxicity and genotoxicity (6000 cells were scored 
from three replicates) in response to different doses of PhIP are shown in Table 5.2 and 
individual results are discussed below for both cell lines.
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Table 5.2 A summary table showing the average results of cytotoxicity (%RPD) and average 
percentage of binucleated cells that contain micronuclei (%Mn/Bn) with 24h 2-Amino-l- 
methyl-6-phenylimidazo(4,5-b) pyridine treatment in MCL-5 and HepG2 cell lines.
PhIP dose 
(pM)
MCL-5 HepG2
% RPD % M n/Bn % RPD % M n/Bn
0 1 0 0 1.45 1 0 0 0.9
2.5 99.96 1.33 98.11 0.9
5 98.32 1.3 94.2 0.92
7.5 98.55 1.28 90.15 1 . 0 2
1 0 99.04 1.23 89.72 1 .2 *
15 95.35 1.45 87.69 1.27***
2 0 94.45 1.52 83.05 1.33***
25 85.47 1 .6 82.4 1 42***
35 78.52 1.85* 64.89 1.58***
50 54.13 2.27*** 17.93 1.67***
1 0 0 30.40 2.03*** -16.81 0.90***
*, *** Indicates a statistically significant difference compared to control (p<0.05, and 
pO.OOl respectively).
5.3.1.1 MCL-5 cells
When compared to untreated control, PhIP treated MCL-5 cells showed no difference in 
cytotoxicity with increasing dose until more than 20pM PhIP. The cell viability (RPD) 
observed at the low dose range of 2.5-20pM, was 99.96% to 94.45% respectively when 
compared to 100% RPD of untreated control. The RPD was 85.47% (14.53% cytotoxicity) at 
25pM PhIP, reaching to 30.4% (64.6% cytotoxicity) at the highest dose of PhIP (lOOpM) 
after 24h exposure (Table 5.2, Figure 5.1). At the dose range 2.5-10pM the micronucleus 
frequency ranged from 1.33-1.23% which was non-significantly lower as compared to 1.45% 
observed in the untreated control. A significant increase in micronucleus frequency was 
observed at 35pM (1.85%, p<0.05) and this reached to 2.27% at 50pM (pO.OOl) and then 
dropped to 2.03% at lOOpM (pO.OOl) due to higher cytotoxicity levels (Figure 5.1, Raw data 
in Appendix VI, Table A. 17).
The result of the Hockey stick model for estimation of the dose-response relationship revealed 
that PhIP exhibited a non-linear dose response in MCL-5 cells after 24h exposure and thus a 
threshold dose exists for PhIP induced chromosome breakage in these cells (Figure 5.2). The 
100 pM dose was not included for the estimation of dose-response relationship because of the 
drop in RPD value to 30.40% (70% toxicity) which is below the 50+5% level suggested by 
OECD guidelines (2007). The estimated threshold dose (IP) was 23.69pM. The lower limit of 
90% confidence interval (Cl) was 20.5 pM (indicated by broken line) at pO.OOl.
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Figure 5.1 Relative population doubling (%RPD) and average percentage o f  binucleated cells 
that contain micronuclei (%MnBn) in 2-Amino-l-methyl-6-phenylimidazo(4,5-b)pyridine 
24h treated MCL-5 cells. Points: mean o f  3 replicates, Bars: standard error, *, *** Indicates a 
statistically significant difference compared to control (p<0.05, and pO.OOl respectively).
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Figure 5.2 Graph generated by the Hockey stick threshold model using the Lutz approach for 
the analysis o f  dose-response relationship in MCL-5 cells to 2-Amino-1 -methyl-6- 
phenylimidazo(4,5-b)pyridine.
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5.3.1.2 HepG2 cells
PhIP treated HepG2 cells showed a very small increase in cytotoxicity with increasing dose 
and 50% cytotoxicity was achieved at 50pM (Table 5.2, Figure 5.3). Cell viability (RPD) 
dropped to 17.93% at 50pM and at lOOpM reached -16.81% indicating a strong cytotoxic 
effect. HepG2 cells exhibited increased sensitivity to PhIP over the MCL-5 cell line, for 
example at concentrations of 50pM of PhIP and above where HepG2 cell numbers decrease 
below the original seeded concentration, a phenomenon not observed in MCL-5 cell line. The 
background micronucleus frequency in HepG2 cells was lower (0.9%) as compared to MCL-5 
cells (1.45%). At lower doses 2.5 and 5pM the micronucleus frequency was similar to that o f
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the untreated control. A linear genotoxic dose-response was observed in HepG2 cells treated 
with the 7.5pM to 50pM dose range o f  PhIP. A significant increase in the frequency of 
%Mn/Bn cells was first observed at 10pM which was 1.2% (p<0.05) and this reached 1.67% 
at 50pM (pO.OOl). At the lOOpM dose due to strong cytotoxic effects the %Mn/Bn 
frequency dropped to 0.9% (Figure 5.3, Raw data in Appendix VI, Table A. 18)..
The result o f  the Hockey stick model for estimation of the dose-response relationship revealed 
that PhIP exhibited a linear dose response in HepG2 cells after 24h exposure to PhIP (Figure 
5.4) and no threshold dose was found. The lOOpM and 50pM doses were not included for the 
estimation o f  dose-response relationship because of the drop in RPD values to 17.93% (82% 
toxicity) and -16.81% respectively.
Figure 5.3 Relative population doubling (%RPD) and average percentage o f  binucleated cells 
that contain micronuclei (%MnBn) in 2-Amino-l-methyl-6-phenylimidazo(4,5-b)pyridine 
24h treated HepG2 cells. Points: mean o f  3 replicates. Bars', standard error, *, *** Indicates a 
statistically significant difference compared to control (p<0.05, and pO.OOl respectively)
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Figure 5.4 Graph generated by the Hockey stick threshold model using the Lutz approach for 
the analysis o f  dose-response relationship in HepG2 cells to 2-Amino-l-methyl-6- 
phenylimidazo(4,5-b)pyridine.
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5.3.2 Cytotoxicity and genotoxicity of PhIP after 4h treatm ent
As 24h exposures to PhIP caused significant cytotoxic and genotoxic effects, a shorter 
exposure to PhIP was performed. MCL-5 and HepG2 cell were treated with PhIP for 4h using 
a dose range of 2.5-120pM for cytotoxicity and genotoxicity. The average results of 
cytotoxicity and genotoxicity are shown in Table 5.3. The table shows the dose of PhIP, the 
average percentage of relative population doubling (%RPD) and the average percentage of 
binucleated cells that contained micronuclei (%Mn/Bn) for both cell lines. Individual results 
are discussed below for both cell lines.
Table 5.3 A summary table showing the average results of cytotoxicity (%RPD) and average 
percentage of binucleated cells contain micronuclei (%Mn/Bn) with 4h 2-Amino-l-methyl-6- 
phenylimidazo(4,5-b)pyridine treatment in MCL-5 and HepG2 cell lines.
PhIP dose 
(pM )
M CL-5 HepG2
% RPD % M n/Bn % RPD % M n/Bn
0 1 0 0 1.48 1 0 0 0.97
2.5 101.42 1.45 101.09 0.65
5 109.2 1.40 90.58 0.78
7.5 111.16 1.43 89.39 0.93
1 0 108.15 1.37 79.52 1 . 1 0
25 122.54 1.25 83.39 1.15
50 95.16 1.53 80.30 1.35***
1 0 0 67.68 1.75 50.49 ] 4 3 ***
1 2 0 43.56 2.72*** 34.17 1 g7***
*** Indicates a statistically significant difference compared to control (p<0.001)
5.3.2.1 MCL-5 cells
MCL-5 cells showed no significant change in cytotoxicity until the dose of 50pM was 
reached when cytotoxicity values dropped from 101.42% to 95.16%. A nonlinear increase in 
micronucleus induction was observed in MCL-5 cells across the dose range of PhIP. The 
frequency of micronuclei non-significantly reduced from OpM to 25 pM (as seen in the 24hr 
data, Table 5.2), but then increased at higher doses (50-120pM) to a statistically significant 
2.72% at 120pM (pO.OOl) (Figure 5.5, Raw data in Appendix VI, Table A. 19). The dose 
range 140-180pM was toxic for MCL-5 cells therefore, not included in genotoxicity testing. 
The result of the Hockey stick model for estimation of the dose-response relationship revealed 
that PhIP exhibited a non-linear dose response in MCL-5 cells after 4hrs exposure and thus a 
threshold dose exists for PhIP induced chromosome breakage in these cells (Figure 5.6). The 
estimated threshold dose (IP) was 97.71 pM. The lower limit of 90% confidence interval (Cl)
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is 92.55pM (indicated by broken line) at pO.OOl. It should be noted that estimated threshold 
was 23.69pM at 24h exposure time.
Figure 5.5 Relative population doubling (%RPD) and average percentage of  binucleated cells 
that contain micronuclei (%MnBn) in 2-Amino-1 -methyl-6-phenylimidazo(4,5-b)pyridine 4h 
treated MCL-5 cells. Points: mean o f  3 replicates, Bars: standard error, *** Indicates a 
statistically significant difference compared to control (pO.OOl)
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Figure 5.6 Graph generated by the Hockey stick threshold model using the Lutz approach for 
the analysis o f  dose-response relationship in MCL-5 cells treated with 2-Amino-l -methyl-6- 
phenylimidazo(4,5-b)pyridine for 4h.
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5.3.2.2 HepG2 cells
HepG2 cells showed increases in cytotoxicity across the dose range and 50.49% cytotoxicity 
was reached at the lOOpM dose. At the higher dose 34.17% RPD was observed for 120pM 
(Table 5.3). A non-linear increase in genotoxic dose-response was observed in HepG2 cells 
across the dose range o f  PhIP. A reduction in %Mn/Bn frequency compared to untreated 
control was observed at lower doses until 7.5 pM which had a Mn frequency o f  0.93%. The
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frequency o f  Mn/Bn cells was significantly increased at 50pM to 1.35%, reaching 1.87% 
(pO.OOl) at 120pM (Figure 5.7, Raw data in Appendix VI, Table A. 20).
The result o f  the Hockey stick model for estimation o f  the dose-response relationship after 
4hrs exposure to PhIP, favoured a linear model and rejected a threshold model despite 
showing a non-linear dose curve in HepG2 cells (Figure 5.8) which is similar to the 24h data. 
The PhIP dose 120pM was not included for the estimation of the dose-response relationship 
as %PRD value was dropped to 34.17% (66% toxicity).
Figure 5.7 Relative population doubling (%RPD) and average percentage o f  binucleated cells 
that contain micronuclei (%MnBn) in 2-Amino-1 -methyl-6-phenylimidazo(4,5-b)pyridine 4h 
treated HepG2 cells. Points: mean of 3 replicates, Bars: standard error, *** Indicates a 
statistically significant difference compared to control (pO.OOl).
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Figure 5.8 Graph generated by the Hockey stick threshold model using the Lutz approach 
for the analysis of  dose-response relationship in HepG2 cells treated with 2-Amino- 1-methyl- 
6-phenylimidazo(4,5-b)pyridine for 4h.
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5.3.3 Basal and Induced expression of CYP1A1 and 1A2 enzymes
Expressions o f  CYP1A1 and 1A2 enzymes in MCL-5 and HepG2 cells were determined by 
RT-PCR. The intensity o f  each band was measured by intensitometry method using Chemidot 
software (Appendix V I1, Figure A. 8) and further confirmed by Real-time PCR. There was a 
difference in basal and induced expressions o f  CYP1A1 and 1A2 for both cell lines at 
different doses. The CYP1A1 induction expression was significantly (pO.OOl) higher in 
HepG2 cell line as compared to MCL-5 (Figure 5.9 A). Similarly CYP1A2 induction 
expression was 2.8-fold and 8.3-fold (pO .O l)  in MCL-5 and HepG2 cell lines respectively 
(Figure 5.9 B).
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Figure 5.9 Fold change in (A) CYP 1 Al and (B) CYP1A2 expressions vs. p-actin after 
24h PhIP exposure in (0) Untreated control, MCL-5, (1) 35pM, (2) 50pM and HepG2, (1) 
lOpM, (2) 15pM
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5.4 Discussion
2-amino-l-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) is a mutagenic substance formed 
during the high temperature cooking of meat, fish, poultry and cigarette smoke (Wakabayashi 
et al, 1992; Sugimura et al, 2004; Hecht, 2002). Recently it has been found to be the most 
abundant carcinogen consumed by human populations (Snyderwine et al, 2003; Layton et al,
1995). Initially it was described as a rodent carcinogen (Ito et al, 1991). However, its presence 
in well-done cooked meat and cigarette smoke make it an environmental risk factor for 
development of diet associated cancer in humans such as breast, prostate and colon (Manabe 
et al, 1991; Sinha et al, 2000). In this context, Zhu and co-workers studied the genotoxic 
effect of PhIP in humans and they found PhlP-specific DNA adducts in the mammary gland 
samples of women aged from 25-50 years (Zhu et al, 2003).
After human exposure, PhIP undergoes metabolic transformation to become carcinogenic. 
This process requires CYP 450 enzymes, which effectively cause A-oxidation of PhIP; an 
essential step in the bioactivation of PhIP. The 7V2-hydroxy metabolite is further metabolised 
by conjugation through acetylation or sulfonation to form electrophilic intermediates which 
are capable of covalently binding to DNA and exerting genotoxic effects (Minchin et al, 
1992; Zhao et al, 1994; Chou et al, 1995; Turesky, 2007). In vitro studies by Croft (1998) 
have shown that CYP1A2 has been most closely associated with PhIP metabolism into the N2- 
hydroxy PhIP intermediate than CYP1A1 and CYP1B1 (Croft et al, 1998). Differences in the 
expression of CYP 450 enzymes may play an important role in the differential metabolic 
activation of PhIP and formation of carcinogenic metabolites and thus overall genotoxicity 
exerted.
In the present study, cytotoxic and genotoxic effects of PhIP were examined in the 
metabolically competent human cell lines MCL-5 and HepG2, in order to compare their 
sensitivity to PhIP at low doses. MCL-5 cells are a human lymphoblastoid line that 
constitutively expresses high level of CYP1A1 and also have been transfected with other 
human CYP enzymes including CYP1A2, 2A6, 3A4, 2E1 and epoxide hydrolase (Crespi et 
al, 1991; Schut and Snyderwine, 2004). HepG2 cells are a useful model human hepatoma cell 
line and express many functional Phase I and Phase II CYP450 metabolizing enzymes 
(Hewitt and Hewitt, 2004; Knasmuller et al, 1999, 2004; Majer et al, 2004). Recently it has 
been shown that HepG2 cells possess glutathione-S-transferase (GST) and N-acetyltransferase 
1(NAT1) activity and NAT 2 is lacking; sulfotransferase isozymes SULT1A1 and SULT1A3 
were found active but CYP1A2 and CYP2E1 were not detectable (Majer et al, 2004), the 
glucuronosyltransferase (UGT 1) activity was detectable and that of UGT 2 was below the
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detection limit (Uhl et al, 2003a). Although CYP1A2 is important for the bioactivation of 
aromatic amines and despite its absence in HepG2 cells, such compounds were able to induce 
genotoxic effects due to the presence of CYP1A1 (Knasmtiller et al, 1999). Westerink and 
Schoonen (2007) showed that HepG2 cells have low levels of cytochromes (CYPs) 1A1 and 
1A2 but normal levels of Phase II enzymes with the exception of UDP-glucuronosyl 
transferases.
5.4.1 Cytotoxic effect of PhIP
The results of this study have shown that PhIP has a potential to induce a dose-dependent 
cytotoxic effect in both cell lines after 24h and 4h exposure (decrease in % RPD value) (Table
5.2 and 5.3). MCL-5 cells showed less sensitivity to PhIP as compared to HepG2 cells in 
terms of cytotoxicity which is in line with the expression of CYP1A1 and CYP1A2 (Figure 
5.9). For example, at 50pM PhIP produced 46% cytotoxicity in MCL-5 while HepG2 cells 
showed more cytotoxicity, i.e. 82.07%. Again in HepG2 cells cytotoxicity was higher (- 
116.81%) in comparison with MCL-5 cells 70% cytotoxicity after 24h exposure at lOOpM 
(Table 5.2, Figure 5.1 and Figure 5.3). Similarly after 4h exposure to PhIP at the 120jiM dose 
MCL-5 and HepG2 cells showed 56% and 66% cytotoxicity respectively (Table 5.3, Figure
5.5 and Figure 5.7). In the HepG2 cell line the dose-dependent increase in cytotoxicity was 
observed earlier (5pM) as compared to MCL-5 cells (50pM). Therefore, HepG2 cells showed 
more cytotoxicity and genotoxicity to PhIP due to the presence and expression of a greater 
number of Phase I and Phase II CYP enzymes that bioactivate PhIP. In the case of CYP1A1, 
MCL-5 expressed less CYP1A1 as compared to HepG2 cells. Similarly, HepG2 cells induced 
more CY1A2 after PhIP exposure. There was no difference in CYP1A1 and CY1A2 basal 
expressions in both cell lines (Figure 5.9).
5.4.2 Genotoxic effect of PhIP
The comparative study results have shown that at both 24h and 4h exposure times, PhIP has 
the potential to induce genotoxic effects in both cell lines with HepG2 exhibiting higher 
micronucleus frequency than MCL-5. The increased sensitivity to PhIP in HepG2 cells reflect 
the differences in bioactivation capacities within the cell lines or function of PhIP used. In 
MCL-5 cells it was observed that the micronucleus induction was not statistically significant 
from the control at lower doses (2.5pM to 25pM). The HepG2 cell line showed more 
micronuclei induction as compared to the MCL-5 cell line after PhIP exposure (Table 5.2 and 
5.3). For instance, micronucleus frequency in MCL-5 cells was seen to increase by 1.56-fold
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as compared to the control after 24h exposure to 50pM of PhIP, while it increased by 1.9-fold 
in HepG2 cells at the same dose, therefore, HepG2 cells produced 0.34-fold more binucleated 
cells containing micronuclei (Mn/Bn) as compared to MCL-5 cells (Table 5.2, Figure 5.1 and 
Figure 5.3). The highest dose of PhIP used in the CBMN assay, (lOOpM) was too toxic for the 
analysis of binucleated cells in the HepG2 cell line population due to the high number of 
necrotic cells (Table 5.2, Figure 5.3). Similarly, after 4h exposure of PhIP a higher level of 
genotoxicity was observed in HepG2 cells in comparison to MCL-5 cells. For example, at 
120pM PhIP the micronucleus frequencies were 1.83-fold and 1.92-fold observed in MCL-5 
and HepG2 cells, respectively when compared to control micronuclei frequency (Table 5.3 
Figure 5.5 and Figure 5.7). Indeed, micronucleus induction was 0.09-fold more in the HepG2 
cell line than MCL-5 cells. Even at non-toxic doses such as 25pM, the micronucleus 
frequency was 0.34-fold more in HepG2 cell line as compared to MCL-5 cell line.
The experiments are in agreement with other studies examining the effects of PhIP. In vitro 
studies have shown that a 2-fold increase in micronulei induction was observed at 35.7pM in 
the HepG2 cell line (Majer et al, 2004) and a 25-50pM concentration range was the lowest 
effective micronuclei inducing dose reported by Knasmuller et al, (1999). Pfau (1999) used a 
lOOpM dose to produce micronuclei in the MCL-5 cell line. A positive dose response was 
observed in Chinese hamster lung male V79 cells in a dose range from 50 to 900pM (Perez et 
al, 2002). In in vivo experiment with Male Balb/c mice, there was a significant dose-response 
relationship observed in the induction of MN in erythrocytes up to 36 mg/kg body weight 
(Durling and Abramsson-Zetterberg, 2005).
5.4.3 Difference in CYP 1A1 and 1A2 expressions
The differences observed in micronucleus induction are due to the differential metabolic 
capabilities of both cell lines. The expression of Phase II enzyme such as N-acetyltransferases 
(NATs) is known to be involved in the metabolism of PhIP (Turesky and Marchand, 2011) 
and converts it to its ester intermediate that is capable of binding with DNA and causing a 
genotoxic effect. The expression of CYP1A1 in MCL-5 was lower in comparison to HepG2 
cell line and there was no change in expression observed after 24h PhIP treatment. Similarly 
no difference in basal and induced CYP1A2 expression was noticed in MCL-5; however, in 
HepG2 cell line the induced expression was more as compared to basal (Figure 5.9). It 
showed that in MCL-5 other enzyme system unrelated to CYP1A2 may be responsible for 
PhIP metabolism. The high induction of micronuclei in HepG2 cells is likely to be due to the 
Phase II enzyme A-acetyltransferase (NATs). This assumption is in agreement with a previous
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study by Otsuka (1996) with human and Chinese Hamster cells in which the micronuclei 
induction was increased when Chinese Hamster lung (CHL) cells were transfected with N- 
acetyl-transferase gene (Otsuka, et al, 1996).
5.4.4 Dose- response to PhIP
It is important to obtain the knowledge of a chemical’s dose-response relationship, because if 
a threshold dose exists then there is a non-linear dose response and safe levels of exposure can 
be calculated. If the dose-response is linear then there is perhaps no safe exposure level. From 
the data described here, in MCL-5 cells the dose-response relationship of PhIP was non-linear 
and a threshold dose was calculated after both 24h and 4h exposure times (Figure 5.2 and 
Figure 5.6). The estimated threshold doses of PhIP for MCL-5 cells were 23.69pM and 
97.7uM at 24h and 4h, respectively. This represents a 4 fold increase in estimated threshold 
doses at 4h exposure when compared to 24h PhIP exposure. (Figure 5.2 and Figure 5.6), using 
Hockey stick statistical modelling. In MCL-5 PhIP doses below 15pM at 24h and 50pM at 4h 
exposures also showed a significant reduction in the micronucleus frequencies compared to 
control levels and the dose-response resembles to some extent a J-shaped curve. This type of 
dose-response curve is indicative of a phenomenon termed hormesis, where the lower doses 
have the opposite effect to higher doses (Davis and Svendsgaard, 1990). At such lower doses, 
when DNA damage was induced the DNA defence processes were stimulated either for 
repairing the DNA damage or for removal of the damaged cells through apoptosis (Kinoshita 
et al, 2006). Indeed before threshold doses (23.69pM and 97.7pM) there was no statistically 
significant micronucleus induction observed in comparison to control and PhIP failed to 
induce any toxicity (Figure 5.2 and Figure 5.5) in the MCL-5 cells after 24h and 4h exposure. 
At low doses PhIP may have initiated different cellular responses in human lymphoblastoid 
MCL-5 cells and at high doses it induced DNA damage and influence cell signalling 
processes involved in the cell proliferation. (Gooderham et al, 2007).
The results with HepG2 cells with regards to their genotoxic dose-response relationship 
showed that PhIP exhibited a linear dose-response after 24h and 4h exposure and no threshold 
dose was determined (Figure 5.4 and Figure 5.6) using hockey stick statistical modelling. 
Therefore, no safe exposure level for HepG2 at both time exposures was observed. 
Statistically significant increases in micronucleus frequencies were observed at lOpM 
(p>0.05) and 50pM (p>0.001) doses of PhIP at both 24h and 4h, respectively (Figure 5.3 and 
Figure 5.7). As the HepG2 cells are primary liver cells they are considered to be very
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sensitive towards PhIP and considered a valuable in vitro model to identify compounds that 
are potentially toxic to humans.
Turteltaub (1999) observed that oxidative metabolism of PhIP is different in humans and 
rodents. Both activate and detoxify PhIP whereas humans predominantly convert PhIP to its 
reactive genotoxic metabolites. PhIP metabolism in rodents involves predominantly oxidation 
in the ring system followed by conjugation, however, in humans 7V2-hydroxylation to the 
proximate mutagen 7V2-hydroxy- PhIP is the major metabolic pathway for PhIP followed by 
glucuronidation (Turteltaub et al, 1999). Due to these differences between rodents and 
humans, it is difficult to extrapolate results from animal to determine health risks to humans. 
This study shows that PhIP dose response are highly dependent on exposure time and 
metabolic competency, therefore, it represents relatively higher risks for individuals with 
higher metabolic activity and greater exposure to PhIP. Furthermore, a prolonged exposure to 
low doses of PhIP has the potential to cause DNA damage and act as a tumour initiator.
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Chapter 6
Investigation of Point Mutations Induced by 
2-Amino-l-methyl-6-phenylimidazo(4, 5-b)pyridine
in Human Cell Lines
6.1 Introduction
Induction of DNA adducts and mutations following PhIP exposure have been widely reported 
in a wide range of exposed tissues and organs such as colon, liver, lung, pancreas, stomach, 
prostate, and breast (Dingley, 1999; Zheng and Lee, 2009; Shirai et a\, 1997). PhIP induced 
DNA adducts have also been reported in organs and sites where tumour formation usually 
does not occur, such as kidney. The most frequent cause of PhIP exposure in humans is 
through the consumption of cooked meat. For example, a “well-done” cooked chicken 
contains a very small dose of PhIP which is capable of inducing DNA adducts in colon and 
blood cells. However, these adducts are unstable and decline over a 24 hour period (Dingly 
1999). A gas chromatography / mass spectrometry (GC/MS) assay was used to analyse lOOpg 
of DNA of colorectal mucosae from a number of individuals and long-lived lymphocytes of
o
colorectal cancer, this study detected several dG-C8-PhIP adducts per 10 DNA bases 
(Friesen et al, 1994; Magagnotti et al, 2003). Turesky (2007) reported dG-C8-PhIP DNA 
adduct formation in about 30% of the human population with levels of adduct varying up to 
10 fold between lowest to highest levels. These findings suggest that either quantity of PhIP 
consumption or differences among individuals in their ability to activate PhIP is involved in 
adduct formation. However, dG-C8-PhIP adduct levels were not observed at significantly 
higher levels in smokers or heavy consumers of meat than in individuals who ate meat less 
frequently (<5 servings per week); yet, the individual extent of exposure to PhIP was not 
known.
Gorlewska-Roberts (2002) used the P-postlabeling method and detected a mean value of 4.7 
dG-C8-PhIP adducts/107 nucleotides in the exfoliated epithelial cells from 30 milk samples of 
lactating mothers. Similarly dG-C8-PhIP adduct was identified by an immunohistochemical 
method from the section of human breast tissues at levels of >1 adduct per 107 bases (Zhu et 
al, 2003).
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Glaab (2000) reported mutations in cell lines defective of mismatch repair (MMR) following 
an exposure to 10 pM PhIP using the HPRT assay. Most mutations induced contained G:C to 
T:A transversion mutations, which is consistent with the pro-mutagenic adduct of PhIP at the 
C8 position of guanine miscoding with adenine. This study also showed a hotspot for 
mutation in a run of six guanines in HPRT exon 3, where a total of 23 (27%) of all PhlP- 
induced mutations occurred. These mutations consisted of transversions, transitions, and 
frameshift mutations. Similarly, Yadollahi-Farsani and his team (2002) identified PhlP- 
induced mutations involving G:C base pairs in a Chinese hamster cell line (XE MhlA2-MZ) 
at the HPRT locus (Figure 6.1). The mutations were predominantly GC-^TA transversions 
but a -1G frameshift in a 5'-GGGA sequence was also observed. Exon 3 was reported as the 
hot spot for mutations.
H P R T
exon
l
205 A A G G G G G G C  TAT 216
Figure 6.1 Locations of PhIP induced mutations in the coding region of Chinese hamster 
HPRT gene. Arrowheads show mutations. Modified from Yadollahi-Farsani et al, (2002).
PhIP was also found to be mutagenic in a mammalian assay using repair-deficient CHO cells 
versus Salmonella, and in in vivo Dlb-1 locus mutation assay in the mouse small intestine 
(Thompsom et al, 1987; Brooks et al, 1994). Carothers and co-workers (1994) found PhIP 
induced mutations in the dihydrofolate reductase (DHFR) gene of Chinese hamster ovary cell 
line (UA21) and found 75% G C ^TA  transversions along with deletion of entire locus and -1 
frameshift mutations. These induced mutations targeted the guanine on the non-transcribed 
stand of the gene in all of the mutants sequenced and confirm the presence of the dG-C8-PhIP 
adduct in DNA (Carothers et a\, 1994). The e ll gene in the colon of male rats and mice was 
reported to have highest mutation frequencies induced by PhIP consisting of G:C to A:T 
transitions, G:C to T:A transversions and -G  frameshifts in runs of guanine bases around the 
nucleotide 179 -(G:C) (Stuart et al, 2000). Transversion mutations occurred more frequently 
at the human HPRT gene, where PhIP forms adducts with dG (dG-C8-PhIP) which can mis-
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base pair with adenine. Similarly A-G frameshift mutation in the 5/-GGGA-3/ sequence is a 
frequent signature mutation of PhIP in the HPRT gene as well as the APC tumour suppressor 
gene (Yadollahi-Farsani et al, 1996). One of the hotspots of PhIP induced GC base pair 
deletion in 5'-GTGGGA-3' around codon 653 in the rat is conserved in the human Ape gene 
and represent a signature mutation of PhIP in human colon cancer (Nagao et al, 1997) PhIP 
showed a dose-dependent increase in the mutations at the hprt locus in modified Chinese 
hamster (V79) cells (XEMhlA2) (Wolfel et a\, 1992), with a high percentage of G to T 
transversions along with significant number of -1G:C base pair deletions. Most of these 
guanine-based mutations occurred on the non-transcribed strand (Yadollahi-Farsani et a\,
1996). Similar mutations were identified in vivo in the lacZ transgene of the Mutamouse® 
when 20mg/kg per day PhIP was administered orally for 4 days (Lynch et al, 1998) and in the 
lacl transgene isolated from the colon of Big Blue® mice (Okonogi et a\, 1997; Stuart et al, 
2000).
PhIP requires metabolic activation to form DNA adducts. CYP enzyme’s activity is central to 
metabolic activation and MCL-5 expresses this activity. Activated PhIP causes adduct 
formation and induced mutations which are mainly at Guanine base pair. Previous studies 
have shown correlation between mutations and DNA adduct formation, however, most of 
these studies were conducted at higher doses of PhIP. This study uses MCL-5 cell line to 
determine the effect of lower doses on DNA adducts formation and mutations.
6.1.1 Aims of the study
The aim of this study was to determine the mutagenicity of low doses of PhIP at 24h exposure 
time in MCL-5 cell lines. A gene mutation study was carried out using the in vitro HPRT 
assay. The second part of the study focused on the construction of PhlP-induced mutation 
spectra for the MCL-5 cell line to determine the type and position of mutations caused by 
lower dose of PhIP.
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6.2 Materials and Methods
6.2.1 Cell line used and their maintenance
Only MCL-5 cell line was selected to study the in vitro effect of 24h PhIP exposure at the 
genetic level after metabolic activation. The HepG2 cells are adherent cells and they did not 
grow in the form of colonies. In HPRT assay the live colonies are counted to calculate the 
MF.
Cell culture was performed as described in Chapter 2 Section 2.1.2.
6.2.2 Test chemical
2-Amino-l-methyl-6-phenylimidazo (4, 5-b) pyridine (PhIP) (Santa Cruz Biotechnology, Inc) 
See Chapter 5 Section 5.2.3 for further details.
6.2.3 HPRT assay
Further details in Chapter 4 Section 4.2.3
6.2.4 Scoring of colonies
Further details in Chapter 4 Section 4.2.4
6.2.5 Statistical analysis
A one-way ANOVA followed by Dunnett’s post-hoc test (2-tailed) was used to compare all 
treatments with control using IBM SPSS statistic software (version 19). Confidence limits of 
95% (p<0.05), 99.9% (p<0.01) and 99.99% (pO.OOl) were applied. The hockey stick 
modelling software, provided by Lutz and Lutz (2009) and implemented in the R package 
(software 2.9.1), was used to estimate a threshold dose.
The t-test was used to assess whether the means of two groups were statistically different 
from each other in untreated and solvent control. The Confidence limit of 95% (pO.05) was 
applied.
6.2.6 Clonal expansions of mutants
Untreated control, solvent control and 25pM PhIP treated HPRT mutant colonies were 
transferred to 24well plates containing 2ml growth media per well and grown for 5 days at 
37°C, 5% CO2, after which cells were carefully mixed with 1.5 ml RNA protect (Sigma) and 
stored at -20°C for RNA extraction.
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6.2.7 RNA extraction
For a detailed description of RNA extraction methodology see Chapter 2 Section 2.6.
6.2.8 Complementary DNA (cDNA) synthesis from HPRT mRNA
For a detailed description of methodology see Chapter 2 Section 2.6.3.
6.2.9 End-point PCR
A detailed description of methodology and primers used in present study was given in 
Chapter 2 Section 2.6.4.
6.2.10 % PAGE gel and Silver nitrate staining
Detailed procedures of gel preparation, gel loading, and silver nitrate staining were given in 
Chapter 2 Section 2.7.1 and 2.7.2.
6.2.11 Preparation of samples for sequencing
For detailed methodology see Chapter 2 Section 2.8. Samples were sent to Genome Enterprise 
Limited (Norwich, UK) for sequencing.
6.2.12 Construction of mutation spectra
Mutation spectra was constructed using iMARS software, kindly provide by Dr Paul Lewis at 
Swansea University (Morgan and Lewis, 2006).
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6.3 Results
6.3.1 PhIP mutation dose-response using the HPRT assay
The HPRT assay was performed with MCL-5 cells to study the low dose effect of PhIP at the 
base-pair level after 24h exposure to PhIP. Earlier studies showed similar metabolic activity 
and response to PhIP for HepG2 and MCL-5. Secondly, HepG2 are adherent cells thus 
making it difficult to conduct the HPRT assay. In contrast, the MCL-5 cell line is easy to 
handle and provides a reproducible human system and therefore, only MCL-5 cells were used 
to study PhlP-induced damage at DNA level.
The 24h exposure dose range of PhIP used for this study in MCL-5 cells (0-50pM) was the 
same used to calculate the %Mn/Bn frequency in a previous chapter (Chapter 5 Section 5.4.1). 
The dose range chosen here was 0-50pM selected as the first significant genotoxic effect was 
observed at 35pM.
6.3.1.1 Mutation frequency of PhIP after 24h exposure in MCL-5 cells
In the HPRT assay the plating efficiency (PE) of treated cultures was used to measure the 
toxicity. Toxicity studies were based on colony forming ability of cells when inoculated into a 
96 well plate without 6-thioguanine (non-selective conditions). The PhIP exposed and 
untreated control colonies grown in non-selective conditions and selective conditions were 
counted to access the mutant frequency (MF). In selective conditions, MF (MFxlO-5) is the 
frequency of the HPRT mutants in a population of cells. PE plates were grown alongside MF 
plates to assess mutant frequency.
DMSO was used to dissolve the PhIP, therefore, it was used as an solvent control. It was 
observed that the MF of the solvent control was not statistically different from the untreated 
control by using t-test statistical analysis (Table 6.1, Raw data in Appendix VIII, Table A. 
21). It showed that DMSO is non-mutagenic and as such can be used to represent the 
spontaneous HPRT MF in MCL-5 cell line.
Table 6.1 Mutation frequency xlO'5 and % cell viability in control and solvent control in the 
MCL-5 cell line.
Cell line PhIP(PM) M FxlO5 St. error t test
% Cell 
viability St. error t test
MCL-5
Untreated
control 2.08 0.65 1 0 0 0 .0 0
Solvent 
control (0 ) 1.99 0.43 0.89 101.09 1.47 0.499
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The MCL-5 cell line was treated with PhIP for 24h exposure using a dose range of 2.5- 50pM. 
OECD guidelines (1997) recommend using a maximum of 10,000pM for HPRT experiment 
thus our doses were within the recommended range. The average % cell viability and MF 
(xlO'5) from the triplicates in response to different doses of PhIP is shown in Table 6.2 and 
Fig 6.2 and the data are discussed below.
Table 6.2 A summary table showing the average results of % cell viability and average 
mutation frequency (MFxlO’5) with 24h 2-Amino-1-methyl-6-phenylimidazo (4, 5-b)pyridine 
treatment in MCL-5 cells.
PhIP (pM )
M CL-5
% Cell viability M F (x lO _5)
0 101.09 1.99
2.5 105.34 1 .8 8
5 107.90 1.82
7.5 102.26 2 .1 1
1 0 92.40 3.89***
2 0 95.88 4.83***
25 91.18 5.23***
35 85.51 6.95***
50 77.38 9.98***
*** Indicates a statistically significant difference compared to control (pO.OOl).
When dosed with PhIP for 24h, the % cell viability of MCL-5 cells did not vary significantly 
with that of the solvent control (0) except the highest dose (50pM) (Table 6.2 and Figure 6.2). 
MCL-5 cells showed non-significant decreases in MF at lower doses as compared to the 
control, for example in the control the MF was 1.99x1 O’5 and this decreased to 1.88x1 O'5 and 
1.82xl0"5 at 2.5pM and 5pM PhIP, respectively. A statistically significant increase in MF was 
observed from lOpM which was 3.89x1 O’5 (pO.OOl) and all the doses above (pO.OOl) using 
Dunnett test (2-tailed). There were 1.95, 2.42, 2.62, 3.49 and 5.0 fold increases found over the 
spontaneous frequency at lOpM, 20pM, 25pM, 35pM and 50pM PhIP, respectively (Table
6.2 and Figure 6.2, Raw data in Appendix VIII, Table A. 22).
The result of the Hockey stick model for estimation of the dose-response relationship revealed 
that PhIP exhibited a non-linear dose response in MCL-5 cells after 24h exposure and thus a 
threshold dose exists for PhIP induced DNA damage in these cells (Figure 6.3). The estimated 
threshold dose (IP) was 4.02pM. The lower limit of 90% confidence interval (Cl) was 0.5 pM 
(indicated by broken line) at p<0.05.
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Figure 6.2 Average mutation frequency (MF xlO°) and average % cell viability in MCL-5 
cells after exposure to different doses o f  2-Amino- l-methyl-6-phenylimidazo (4, 5-b) pyridine 
for 24h. Points: mean o f  3 replicates, Error Bars: standard error, *** Indicates a statistically 
significant difference o f  MF compared to control (p<0.001).
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Figure 6.3 Graph generated by the Hockey stick threshold model using the Lutz approach for 
the analysis o f  dose-response relationship in MCL-5 cells after 24h exposure to 2-Amino-1- 
methyl-6-phenylimidazo (4, 5-b)pyridine.
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6.3.2 Sequence analysis of HPRT mutants
A mutation spectrum was constructed to investigate the type and location o f  mutations 
induced by PhIP in MCL-5 mutants. The mutants exposed to 25pM PhIP for 24h and mutants 
obtained from the solvent control were selected to further investigate PhlP-induced mutations 
and spontaneous mutations, respectively. These mutants were isolated and propagated at the 
end o f  the HPRT assay for sequence analysis. Mutations in the coding region were identified 
from the sequencing o f  cDNA o f  the HPRT  gene products obtained by RT-PCR.
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In the MCL-5 cell line 15 mutants were analysed for spontaneous mutations and 20 mutants 
were used for PhlP-induced mutations. The percentages of all the mutations resulting from 
PhIP exposure and solvent control in both cell lines are shown in Table 6.3.
Table 6.3 Mutation types and percentages of spontaneous and 2-Amino-l-methyl-6- 
phenylimidazo (4, 5-b)pyridine-induced mutations (25pM dose, 24h) at the HPRT locus in 15 
solvent control and 20 treated MCL-5 mutants.
Type of MCL-5 Solvent MCL-5 
Mutations control | PhIP treated |;
Base substitutions 7 8 1;
Transitions
G “»  A 2(25%) jj
T ->  C 3(43%) i  j j
Transversions |j
C ->  A I ||
I I I j
C ->  G | 2 (29%) i |
G " » C  1(14%) i  j
G “> T  1(14%) 6(75%) ||
Tandem mutation 2(17%)
Deletion/Insertion
Deletions 3(25%) 11(58%)
Insertions
In the MCL-5 solvent control, 15 mutant colonies were processed and 12 mutations were 
observed from 12 colonies. In the remaining 3 mutant colonies a translocation of 25 bp 
(TCTTGATTGTGGAAGATATAATTGA) was observed at position 489 on the transcribed 
strand (See Appendix IX, Figure A. 9, A). At the HPRT locus 25% deletions, 58% point and 
17% tandem mutations appeared spontaneously. Among the point mutations (See Appendix 
X, Figure A. 9, B) due to base substitutions, 43% transition and 57% transversion mutations 
were observed (Table 6.3). G375T (14%) and C653G (29%) transversion mutations and 
TG285/6AT (17%) tandem mutations each appeared twice; whereas G648C (14%) 
transversion and T370C (43%) transition appeared once and three times respectively. 
Deletions of 1 (n=l), and 13 (n=2) base pairs appeared as spontaneous mutations in MCL-5 
mutants also (Table 6.3 and Table 6.4. See Appendix IX, Figure A.9, C).
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Following treatment with 25pM PhIP for a 24h period, 19 different mutations were observed 
from 20 MCL-5 individual mutant colonies. The PhlP-induced mutations on the HPRT locus 
of MCL-5 were deletions (58%) and point mutations (42%). Point mutations (See Appendix 
IX, Figure A. 10, A) observed due to base substitutions, were represented by 25% transition 
and 75% transversions (Table 6.3). Transition mutations G376A (25%) appeared twice 
whereas G264T (75%) transversion was found six times in different mutant colonies. 
Deletions of 36 (n=3), 45 (n=2), 17 (n=3) and 29 (n=2) base pairs appeared at the HPRT locus 
as PhIP induced mutations in MCL-5 mutants (Table 6.3 and Table 6.4. See Appendix IX, 
Figure A. 10, B). One mutant colony showed a deletion of 58bp
(G AA AG A AT AGA AGT GATT G A AT ATT GTTA ATT AT ACC ACCGT GT GTT AG AAA AG 
TAAGA) from position 1182-1239 and translocated at position 776 on the mutant HPRT 
locus (See Appendix IX, Figure A. 10, C). The ratio of transitions to transversions was 3:4 for 
spontaneous- and 2:6 for PhlP-induced mutations. Among all the point mutations recorded, 
the proportion of G->T transversion mutations was higher in treated MCL-5 mutant colonies 
as compared to solvent control mutant colonies.
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Table 6.4 Spontaneous and 2-Amino-l-methyl-6-phenylimidazo (4, 5-b)pyridine (PhIP) - 
induced mutational spectrum at the HPRT  locus in MCL-5 cell line.
Treatments Mutations Sequence Positions
Solvent control
Single bp 
substitutions
1 G -> T AAGGGGG 375
3 T-» C GCTCAA 370
1 G -> C GTCGCAA 648
2 C-» G AAGCTTG 653
Tandem
mutation
2 T A TCATGGA 284
Deletions
2
G -> T 
- 13 bp
TCATGGA
A A T o T C C
285 
432 o  445
1 - 1 b pT CTT o  GCT 604
PhIP treated
Single bp 
substitutions
6 G -> T TTGGAAA 264
2 G -> A AGGGGGG 376
Deletions
3 - 36 bp T G G o G G C 5 4 8 0 5 8 4
2 - 45 bp T G G o A T G 5 4 8 0 5 9 3
3 - 17 bp A A G o G A T 5 5 2 0 5 6 9
2 -2 9  bp T G G o T G A 5 4 8 0 5 7 7
1 -438 bp A A T o C C A 7 7 6 0 1 2 3 9
6.3.2.1 Location of mutation spectra present on the HPRT  gene sequence
The spectrum o f  spontaneous and point mutations along the H PRT  mRNA sequence in MCL- 
5 cell line are presented in Figure 6.4. The sequence o f  mRNA used in the present study, is 
identical to the non-transcribed /anti-sense strand. Therefore the mutations identified in the 
mRNA indicate mutagenesis in the non-transcribed strand o f  the double helix which is the
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transcription-associated mutagenesis. There was spontaneously occurring GC-^AT transitions 
where T->C change in the non-transcribed strand found in spectrum. In the presence of PhIP 
all GC->AT transitions where G ^ T  change in the non-transcribed strand. This is the 
indicative of the mode of action of the PhIP (Zhang et al, 2001) and is not the effect of 
transription-coupled repair as this strand biased was independent of transcriptional status 
(Palombo et al, 1991) A clear difference was seen in the distribution of mutations along the 
HPRT target sequence between the solvent control and PhlP-induced mutants in MCL-5. 
Spectra for spontaneous mutations showed mutations due to deletions and single base pair 
substitutions. The mutational spectra of 12 MCL-5 mutants from the solvent control showed 
deletions of a number of base pairs and other point mutations distributed at exon 2, 3, 4 and 6 
(Figure 6.4 A). Base substitutions were observed more frequently than deletions for solvent 
control. Tandem mutations were found twice at exon 2. G->T base pair substitution appeared 
once and T->C appeared three times at exon 3. The base substitutions C-^G and G->C 
occurred 2 times and one time respectively at exon 6. Among deletions, 13 base pair deletions 
were observed in two mutant colonies at exon 4 and one base (T) was deleted from one 
colony at exon 6 (Figure 6.4 A).
PhlP-induced mutation spectra in MCL-5 also showed mutations due to deletions and single 
base pair substitutions (Figure 6.4 B). The most dominant mutations were observed to be 
G->T transversions, present at exon 2 on the HPRT sequence. Other point mutations such as 
G->A transition appeared at exon 3. The deletions were distributed all over exon 5 of the 
HPRT sequence, but in one mutant, exon 7 and 12 were partially deleted and exons 8, 9, 10 
and 11 were completely deleted due to the PhIP exposure (Figure 6.4 B). All mutation 
observed whether for solvent control or PhIP treated cells were observed on transcribed 
strand.
166
±688
< . O  O  *—
A A A A "gt g) V838
x .  >e x  » e  -o  .£ 0ZO8
■  ■ ■  *  ■ V8bZ
19ZZ
V09Z
O W L
±83 Z
V81Z
VZ69
OL89
V999
06*9
v*£9
V8L9
±309
0989
0OZ9
0999
±689
0839
VZ09
036*
09zr
V09*
V'***
V88*
08 t*
VZ68
±188
±998
V6*£
v*88
08t8
0308
--------------------------------- 0983
0OZ3
0998
V683
±883
0ZO8
0161
09ZI
0091
0** I
±881
0811
0Z6
0 t8
±99
06*
< ± * £  •
081 
«Tl 7    - y.
«  <M » -  O  -  ^
■< O KJ 
A A A  
>C D<
00
Z £ 3 1 V  
£331 £ 
80311 
£61 I ‘ 
8ZI I 
£ 9 1 1 1  
QV 111 
££ I L £ 
8 1 1 1 1  
€01 L 
6 8 0 IV  
f  Z 0 1 £ 
6 9 0 1 £ i 
frfXHV 
6 .30  I f .  i 
V 10 1 € ' 
6 6 6 1  
f r8 6 0  
6 9 6 0  
F 9 6 3  
1 6 £ 6  
3 * 3 6  
V 6 0 6  
3 9 6 8  
V 0 8 8  
V 9 9 8  
V 0 9 8  
3 9 £ 8  
3 0 3 8  
V 9 0 8  
1 0 6 Z  
V 9ZZ 
3  1-9Z 
1 9 f  Z 
± l£ Z  
± 9 3 9  
3 H  9 
0 9 6 9  
3 1 8 9  
0 Z 9 9  
V 3 9 9  
V Z £ 9  
0 3 3 9  
V Z 0 9  
3 8 1 F  
±£0? 
±88£ 
V £ Z £  
389£ 
I P  8 3  
0 6 9 3  
± P 9 3  
V 6 £ 3  
0 9 3 3  
3 0 1 3  
V 9 6 1  
3 9 0 1  
3 1 6  
3 9 Z  
0  L 9  
± 9 P  
0 3 £  
3 Z t  
. 0 3
Figure 6.4 Mutation spectra (A) spontaneous and (B) 2-Amino-l-methyl-6- 
phenylimidazo (4, 5-b)pyridine (PhlP)-induced in the HPRT  gene in MCL-5 mutants. 
Each base and its number on the HPRT sequence are presented on the x-axis. The 
number of mutations is portrayed on the y- axis. Each base alteration is colour coded 
where the letter X stands for the 4 bases; A, C, G or T determined by the position on 
the sequence. . Numbers in the rectangular boxes represent the hotspots on exons.
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6.4 Discussion
Cooking food at high temperatures is responsible for the production of genotoxins that have 
adverse effect of human health. The consumption of red meat and human cancer are positively 
correlated (Sinha et al, 2005). Among many HAA, PhIP is extensively bioavailabile to 
humans in the form of cooked meat and 0.1-15pg PhIP per day has been consumed. PhIP is 
readily activated by CYP1A1 and 1A2 to produce DNA damage (Zhao et al, 1994). It is 
rodent carcinogens and in rats induces cancer of prostate, colon and mammary glands 
(Sugimura, 1997; Ito et al, 1991). This study was aimed at determining the ability of low 
doses of PhIP to induce gene mutations in the MCL-5 cell line using the HPRT assay. Our 
earlier studies showed that PhIP is capable of causing genotoxicity (significant increase in 
micronucleus frequency was observed at doses 35pM and above). This study focussed on 
understanding the effect of PhIP in inducing gene mutations at low doses as well as to 
compare the level and type of mutation induced by PhIP to those mutations that are observed 
spontaneously without PhIP. The MCL-5 cell line has a high expression of the CYP1A2 
enzyme (Figure 5.10), and is capable of metabolizing PhIP in to its active form following 24h 
exposure, and therefore, serves as a good cell line to determine mutagenic activity of PhIP.
6.4.1 Genetic mutations induced by PhIP
Cell viability assays revealed that PhIP affected cell viability non-significantly at lower doses. 
Only highest test dose of 50pM caused significant reduction in cell viability after 24h. 
exposure. (Table 6.2, Figure 6.2). These results and studies reported in Chapter 5 indicate that 
lower doses of PhIP do not inhibit cell multiplication.
Results of mutation assays, however, showed higher sensitivity to PhIP as significant 
differences in mutation frequency were observed at a dose of 1 OpM. The results showed that 
at PhIP doses of 2.5pM, 5pM, and 7.5pM (1.88xl0'5, 1.82xl0'5, and 2.11xl0'5, respectively) 
mutation frequencies did not differ significantly from the solvent control (1.99x1 O'5). The first 
significant increase in the mutation frequency was noted at the lOpM PhIP dose which was 
3.89x1 O'5 (p<0.001) and all doses above that (p<0.001) using Dunnett's test (2-tailed) in 
MCL-5 cell line. A non-linear dose-response and threshold dose was recorded by using Lutz 
R analysis. The MF thresholded dose was 4.02pM for PhIP induced DNA damage in MCL-5 
cell line (Figure 6.3). Threshold dose for micronucleus assay was 23.69pM therefore it 
indicates that HPRT assay is more sensitive than MN assays.
Similar toxicity and mutagenicity of PhIP in TK6 cells was noted by Margenthaler and 
Holzhauser in 1995 who found that exposure to 2.5pg/ml (llpM ) PhIP for 4h was not
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significantly toxic for TK6 cells growing in the presence of exogenous activating enzyme 
(10% rat liver S9). At highest dose of 5pg/ml (22pM) PhIP, 70% survival and a significant 
increase in mutant fraction (xlO'6) was observed. Similarly, Lauber and his team (2004) 
reported an increase in mutation frequency (24+9 and 173+46 mutant colonies per 
106surviving cells (p< 0.01)) at higher concentrations of PhIP (10'5 M to 10’4 M)) after 24h 
incubation period in the hamster fibroblast cell line V79hl A2 (has very stable karyotype and 
possesses a functional X-linked hprt locus). While lower concentrations of PhIP (10'7M) had 
a non-significant effect on cell survival and mutation frequencies when compared to control 
(Lauber et a\, 2004).
6.4.2 PhIP induced mutations
Our studies also showed that the frequency and type of mutations induced by PhIP were 
different to those occurring in the untreated control (referred to here as spontaneous 
mutations). For example, more G->T transversions were observed in mutants induced by 
PhIP whereas a higher number of T->C transitions and C->G transversions were observed in 
untreated controls (Table 6.3). Although, it might be argued that control cells had been treated 
with DMSO thus these does not reflect spontaneous mutations that are observed in cells 
without any treatment, however, we used DMSO at a final concentration of 0.01% which is 
not believed to be mutagenic in animal cells, therefore. DMSO mutation frequency is similar 
to that of untreated control.
Mutations at the HPRT locus occur due to the PhlP-induced DNA adduct at C8 position of 
deoxyguanosine (dG-C8-PhIP). This adduct can be repaired by DNA-repair processes e.g. 
removed by nucleotide excision repair (NER) (Schut and Snyderwine, 1999). The presence of 
PhIP-DNA adducts causes structural changes in the DNA and mis-pairing leading to 
mutations. PhIP adducts have been reported to induce mutations in genes controlling cell 
proliferation which can potentially lead to tumour formation (Nagaoka et al, 1992).
In the present study, PhIP induced a significant increase in the frequency of mutant MCL-5 
colonies. The percentage of identified mutations from these colonies and their distribution are 
shown in Tables 6.3 and 6.4. Table 6.3 showed 12 spontaneous mutations were identified 
from 15 DMSO control MCL-5 mutant colonies. Among them 58% were point mutations, 
25% were deletions and the remaining 17% were tandem mutations. Among the point 
mutations, 57% were GC-^TA transversion and 43% were transitions. Nineteen mutations 
were identified from 20 PhIP treated MCL-5 mutant colonies. The PhlP-induced mutations on 
HPRT locus of MCL-5 were deletions (58%) and point mutations (42%). Three colonies from
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DMSO and 1 from PhIP treated colony did not show any mutation probably missed as outside 
the sequenced area -  or in introns which were not sequenced as cDNA was used in this study. 
The specificity of mutations induced by PhIP at the HPRT locus is characterized by a high 
percentage of GC->TA transversions (Margenthaler and Holzhauser, 1995; Yodollahi-Farsani 
et al, 1996). Results presented in this chapter (Table 6.3) also showed predominantly 
GC-^TA (75%) transversions (transitions were only 25%). A study on the dihydrofolate 
reductase gene in Chinese hamster ovary cells also showed similar mutation spectra after 
treatment with PhIP (Carothers et al, 1994). These GC->TA transversions are thought to be 
formed by DNA polymerases through preferential incorporation of an adenine residue across 
from a non-instructional base (Brown et al, 1989). The DNA adduct C8-dG-PhIP could also 
induce a conformational change leading to a purine-purine (G with A) mispair that is not 
recognized (Norman et al, 1989).
Our study (Table 6.3) shows that all the point mutations induced by PhIP in the HPRT locus 
were located at GC base pairs (G264T transversion and G376A transition) making them 
targeted mutations. The modified bases form the pre-mutagenic lesions preferably at the 5' 
GG sites (underline base is mutated) (Cariello et al, 1992) by the formation of major DNA 
adduct at the C-8 position of guanine, N -(2 -deoxyguanosin-8-yl)PhIP, in in vivo and in vitro 
treatments (Margenthaler and Holzhauser, 1995; Lin et al, 1992; Fukutome et al, 1994). Our 
study is in line with it and found that G->T mutation induced by PhIP in the HPRT locus in 6 
MCL-5 mutants, in the GG site at 264 base pair while 2 mutants showed G-^A mutations in 
the run of GGGGGG at 376 base pair (Table 6.4). This is a signature of PhIP as other 
chemicals such as BPDE, MNNG and ENU have strong preference for 5' GA sites (Cariello 
and Skopek, 1993).
The mutations spectrum observed in the HPRT gene after PhIP exposure includes only single 
base substitutions at exons 2 and 3, while most of the deletions observed were loss of exon 5 
and partially deletion of exon 6. One mutant colony showed a deletion of 438bp (base pair 
position 776 to 1239) on exon 9, resulting in the partial loss of exon 9 on the HPRT locus. 
Fifty-eight percent of mutants were found to be missing some or all of an exon, probably due 
to a smaller mutation that led to aberrant splicing of mRNA. Mutant mRNA differs not only 
in their amino acid sequence but also in their biological functions. These results are in 
agreement with Margenthaler and Holzhauser (1995) who also observed 40% mutations at the 
HPRT locus due to deletion of exon 3, exon 4, exon 8 and partial loss of exon 9.
The effect of higher doses of PhIP on genotoxicity is well mentioned, whereas, very limited 
information is available on the concentrations that could potentially be present in humans
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following consumption of a cooked meat meal (Sugimura, 1997). Similarly, very little is 
known on the accurate quantity of plasma PhIP after consuming a cooked meat meal as well 
as the chronic effects of consuming low quantities of PhIP through cooked meat (Lauber et a\, 
2004). Our study indicates the potential of PhIP in inducing mutagenicity at a threshold of 
4.2pM, and according to threshold for toxicology concern (TTC) the acceptable daily intake 
values are 1.5ug/day (6.68pM)or 120ug/day (535pM) for <1 month, considered to be the safe 
doses (Muller et al, 2006). However, actual risk is dependent on several factors such as level 
of PhIP in tissue, exposure time, metabolism and finally DNA repair mechanisms. Cooked 
meat contains up to 50ng PhlP/g of meat, therefore, a potential daily intake of PhIP through 
meals could be as high as 50mg. PhIP is extensively absorbed, however, depending upon 
biological activity it could be metabolized leading to varying levels of various intermediates 
in blood and/or other organs and tissues. Sinha (2000) reported higher prevalence of breast 
cancer in women with increased PhIP consumption through dietary intake (Sinha et al, 2000). 
These reports together with results presented in this study clearly indicate the potential of 
PhIP in inducing mutagenic activity.
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General Discussion
The purpose of this project was to investigate in vitro low dose response relationships for the 
pro-carcinogens B[a]P and PhIP. B[a]P and PhIP were used to find out whether they follow 
linear or non-linear (thresholded) dose responses, which is important to investigate the 
biological significance of low dose exposure to improve health risk assessments. B[a]P and 
PhIP both are nontoxic themselves but known to cause genotoxicity through their highly 
reactive metabolites which form adducts such as dG-N -BPDE and dG-C -PhIP respectively, 
however, this is dependent on their metabolism (Cosman et al, 1992). Earlier studies have 
shown the role of CYP450 enzymes in the metabolic activation of B[a]P and PhIP 
(Guengerich, 2000; Miller, 1978). B[a]P is an environmental pollutant mainly produced by 
cigarette smoke and a bi-product of industrial incineration and known to cause different organ 
cancers (Miller et al, 2001; Shimada and Fujii-Kuriyama, 2004; Botteri et al, 2008), 
autoimmune (Neal et al, 2008) and inflammatory diseases (Klareskog et al, 2007). Similarly 
PhIP is a diet associated carcinogen, formed during the cooking of protein rich food like meat 
at high temperatures (Sinha et al, 2005; Felton et al, 2007). PhIP and its metabolites are 
considered as a dietary risk factor for cancer of the colon, breast, stomach and prostate (Tang 
et al, 2007; Choudhary et al, 2012). This study reports the effect of B[a]P and PhIP on 
human cell lines with varying metabolic abilities in response to different doses and exposure 
times. The semi-automated MN detection system was used to investigate the DNA damage 
induction at the chromosomal level. Furthermore, the mechanism of action was investigated at 
the genetic level by using HPRT assay and mutational spectra was used to find out the 
difference in spontaneous and induced mutations and their locations on the HPRT gene. 
Finally to correlate the difference in genotoxic effect of different cell lines, quantitative Real 
Time PCR studies were conducted to show difference in gene expression of CYP450 
enzymes. Findings of these studies are discussed below.
Dose response thresholds for genotoxins can be used to set a safe exposure level. A threshold 
of genotoxic activity indicates that a compound will not produce any mutation below a critical 
exposure level and therefore, this reduces the risk for the induction of cancer or congenital 
abnormalities. The endpoints previously used for the analysis of threshold dose responses 
were DNA adduct formation, gene mutation and chromosomal aberration (Jenkins et al,
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2010). In this study low dose response relationships of pro-carcinogens, B[a]P and PhIP were 
investigated.
7.1 Genotoxic thresholds for B[a]P on cell lines with varying metabolic activity
This study showed that B[a]P influenced cell viability (as measured by RPD) for all cell lines 
at dose range 0-70pM; however, the sensitivity to B[a]P reflected metabolic activation of the 
cell lines (Chapter 3). In the case of TK6, which has minimal ability to metabolize B[a]P, it 
had least cell toxicity while MCL-5 and HepG2 have highest metabolic activity thus showed 
over 50% of cell toxicity at lOpM following 24hr exposure. Similar response was observed 
for AHH-1 with relatively lower cell toxicity when compared with MCL-5 and HepG2 cell 
lines. These findings indicate that reactive metabolites of B[a]P interfere with cell functioning 
and replication, therefore, rate of metabolism is linked with cell toxicity.
Micronucleus induction was also dependant on B[a]P doses and cell metabolic activity as no 
significant MN induction was observed in cells with less capability to metabolize B[a]P. For 
example, the TK6 cell line showed little or no chromosomal damage at B[a]P dose range (0- 
70pM) followed by 18h with cytochalasin B. AHH-1, MCL-5 and HepG2 cells when treated 
with B[a]P (0-70pM) followed by 24h with cytochalasin B showed an increase in MN 
frequency. MCL-5 and HepG2 cell lines are relatively more metabolically competent than 
AHH-1 cell line therefore showed significant increase in MN frequency at lower doses (3pM) 
using Dunnett’s test (p<0.05). In HepG2 cell line, MN induction was 0.23-fold more as 
compared to MCL-5 cell line at 3pM. The Lutz R analysis (Hockey stick model) was used for 
the estimation of dose-response relationship which revealed clear linear dose responses in 
AHH-1, MCL-5 and HepG2 cell lines, indicating that there is no safe exposure level for these 
cell lines when exposed to B[a]P for 24h at lower doses.
However, we extended our studies to check the response of cell lines at the same doses (0- 
70pM) for short exposure time (4h) followed by 24h with cytochalasin B, but we excluded 
TK6 from our later studies due to no metabolic activity. Similarly, our study with shorter 
B[a]P exposure time (i.e. 4h experiment) showed that AHH-1 cell line can tolerate higher 
doses as compared to doses exposed for the longer time of 24h. It was observed that AHH-1 
cell line showed least cytotoxicity but over 50% cytotoxicity was observed at 30pM and 
lOpM for MCL-5 and HepG2 cell lines respectively. The first significant increase in MN 
induction was noticed at 40pM (p<0.05) in MCL-5 cell line as compared to 20pM (p<0.05) in 
HepG2. AHH-1 showed no increase in MN induction. A non-linear (thresholded) dose 
response was observed by Hockey stick model only in MCL-5 cells with an increase in MN
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induction only seen at the higher dose range. The estimated threshold dose (IP) was 25 .46 |llM  
and the lower limit of 90% confidence interval (Cl) is 14.60pM (indicated by broken line) at 
p<0.002 (Chapter 3).
All of these results are in line with the metabolic competency of cell lines used. The metabolic 
activation pathway of B[a]P involves CYP1A1 and mEH. AHH-1 cell line has stable 
expression of only CYP1A1. Long exposure time at low dose of B[a]P could allow B[a]P 
metabolism into its intermediate that could result in chromosome damage and a significant 
increase in MN induction. MC1-5 cell line produced more MN per dose than AHH-1 due to 
higher expression for CYP1A1. MCL-5 also have mEH therefore it is a more competent cell 
line as compared to AHH-1 cell line which is devoid of mEH activity. The expression of 
CYP1A1 increased with higher B[a]P concentration and it was reflected by the induction of 
MN at higher doses of B[a]P in MCL-5 cell line. In the HepG2 cell line the dose-dependent 
increase in the MN frequencies was found to be higher than MCL-5 and AHH-1 after 
treatments making this cell line more sensitive as they express a wide range of Phase I and 
Phase II enzymes. The expression of CYP1A1 was also increased as the B[a]P dose increased 
but this increase in expression was less than MCL-5 indicating that higher MN induction may 
be the result of involvement of other CYP450 such as CYP1A2 or other pathway. The 
expression of CYP1A2 increased as B[a]P dose increased in HepG2 but in MCL-5 no 
difference in the expression of CYP1A2 was observed from control to high dose range. The 
reason for having high MN frequencies in HepG2 cell line after B[a]P exposure is perhaps 
due to the promising activation system of this cell line. HepG2 cells are from primary 
hepatoblastome and their morphology and function resembles liver therefore, when B[a]P 
inhaled through cigarette smoke it can cause cancer of the liver. In fact, the liver plays a 
central role in the mechanism of chemical bio activation and carcinogenesis and the lung 
represents a target organ of PAH carcinogenicity (Goldman et al, 2001).
Our studies showed that dose concentration, exposure time and metabolic activity are central 
to B[a]P genotoxicity, therefore, exposure to B[a]P through cigarette smoking poses a risk to 
cancer. Various studies have reported presence of B[a]P in ‘full-flavoured’ cigarette to about 
9 -lOng per cigarette (Hoffmann and Hoffmann, 1997; Chepiga et al, 2000) leading to an 
intake of about 200ng/day for a pack-a-day cigarette smoker (Scherer et al, 2000). In another 
study Hecht (2006) reported greater uptake of PAH compounds (including B[a]P) in smokers 
as compared to non-smokers.
Pfeifer et al, (2002) reported a link between B[a]P exposure and cancer risk to oral cavity, 
larynx and lungs. Since exposure to cigarette smoke and B[a]P is lower in oral cavity,
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intermediate in larynx and highest in lungs, it is not surprising that lung cancer risk is 
relatively higher than the larynx and oral cavity respectively. Our results confirm this pattern 
as higher genotoxicity was observed with higher dose, exposure and/or metabolic potential of 
the cell lines evaluated. Higher potential of carcinogenicity in lungs could also be attributed to 
higher absorption and metabolic activation of P450’s in lung cells than B[a]P absorption and 
metabolism in larynx and oral cavity.
Further studies on the effect of B[a]P on induced mutation frequency also revealed similar 
pattern whereby mutation frequency increased with increase in B[a]P exposure time from 4h 
to 24h (Chapter 4). Similarly higher mutation frequency was observed in the cell line with 
greater metabolic activity (MCL-5) than in the AHH-1 cell line which is known to have lower 
metabolic activity. These studies suggest an increased risk of cancer in individuals who 
smoke more frequently as amount of B[a]P intake and its subsequent absorption in the body 
would be comparatively higher than those who smoke occasionally. Although, occasional 
smoking does not eliminate the chances of carcinogenic activity however, our studies indicate 
that an occasional smoker (lower exposure to B[a]P) would represent a comparatively lower 
risk than a frequent smoker. Similarly an individuals’ variability in metabolic activity appears 
to be a vital factor in determining an individual risk to cancer following B[a]P exposure 
through smoking.
Studies on the effect of B[a]P on frequency and type of mutation revealed higher frequency of 
G to T transversion in B[a]P treated MCL-5 cells. Earlier studies have also shown that 
metabolic activation of B[a]P in human lung tissues take place via Ah receptor and form PAH 
diol epoxides-DNA adducts and cause G->T transversions that is commonly observed in the 
p53 and K-ras tumor suppressor genes in smoking induced lung tumours (Hecht, 2000; 
Phillips, 2002; Tretyakova et al, 2002; Pfeifer et al, 2003; Hecht, 2006). Results of our study 
indicated that B[a]P is capable of inducing G->T mutations which are specific mutations that 
are associated with carcinogenic activity.
We also observed difference in mutation frequency in response to B[a]P exposure time and 
metabolic activity of the cell with higher frequency of mutation being observed in cells 
exposed for 24h to those exposed for 4h. Similarly, cells with higher metabolic activity 
(MCL-5) showed higher mutation frequency than cells with lower metabolic activity (AHH- 
1). It is important to mention here that metabolism of B[a]P has a dual pathway involving 
process that either lead to its excretion from cells or in the formation of by-products that are 
capable of inducing mutagenic activity. Similarly, the onset of mutagenic activity can either 
result in activation of DNA repair mechanisms or formation of DNA adducts. Since our
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studies focussed on determining the effect of B[a]P on its mutagenic activity, evaluation of 
the DNA repair mechanisms were outside the scope of this study however, presence of such 
processes should not ignored.
7.2 Genotoxic thresholds for PhIP on cell lines with varying metabolic activity
The carcinogenicity of PhIP is associated with the metabolic activity of cells and requires 
CYP1A2 and other P450 enzymes for its conversion into a carcinogenic form (Lin et al, 1992; 
Gooderham et al, 2007) TK6 and AHH-1 cell lines were not used in this part of the study 
because TK6 cells showed little or no chromosomal damage due to having little metabolic 
activity and AHH-1 showed little expression of CYP1A2 after B[a]P treatment (Chapter 3). 
Our results showed that carcinogenicity of PhIP is linked with the metabolic potential of the 
cell line used (Chapter 5). HepG2 cell line has been shown to have multiple metabolic 
pathways to metabolise PhIP as compared to MCL5. We observed higher cytotoxicity and 
genotoxicity in HepG2 cells following PhIP exposure which reflects its metabolic potential. 
The results also reflected that at the dose range (0-3 5 pM), the cytotoxicity increased at doses 
more than 20pM and 50pM in both cell lines with PhIP after 24h and 4h exposures 
respectively.
Micronucleus induction was also dependent on PhIP doses and on cell metabolic competency. 
Both cell lines showed an increase in MN frequency with an increase in PhIP dose. Studies on 
PhIP exposure time showed a similar pattern of increased MN frequency with increasing 
doses, however, significantly higher MN frequency was observed at lower doses following 
24h exposure as compared to 4h exposure. For example, HepG2 cell line showed significant 
increase in MN frequencies at lOpM (p<0.05) after 24h and 50pM (p<0.001) after 4h which 
is 5 times higher than the 24h exposure time. In MCL-5 cell line the significant increase was 
observed at 35pM (p<0.05) and 120pM (p<0.001) at 24h and 4h respectively and again about
3.5 times higher dose than the 24h treatment. At the highest dose (lOOpM) HepG2 cell line 
induced 0.34-fold more MN as compared to MCL-5 cell line. Similarly, at 120pM 4h PhIP 
exposure in HepG2 cell line MN frequency was 0.09-fold more than MCL-5 cell line. A non­
linear (thresholded) dose-response relationship was estimated by the Lutz R analysis (Hockey 
stick model) and the estimated threshold dose (IP) was 23.69pM and 97.71 pM for MCL-5 
cell line at 24h and 4h respectively. A linear dose-response was observed in HepG2 cell line 
making PhIP carcinogenic for all dose ranges at both exposure times.
All of these results indicated that HepG2 cell line is metabolically more competent than 
MCL-5 in converting PhIP to its carcinogenic form. CYP1A2 is considered to be a “liver
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specific” P450; therefore, N-oxidation of PhIP is catalyzed primarily in hepatocytes (Turesky 
et al, 2002). In study we observed that basal expression of CYP1A2 was higher in MCL-5 
cells as compared to HepG2 cells, however, there was a slight increase in the inducible 
expression of CYP1A2 observed in HepG2 cell line at dose range as compared to basal 
expression. Where as, MCL-5 cell line showed no difference in the expression of CYP1A2 
between treated and untreated cell lines. Only a small amount of CYP1A2 in a target cell is 
sufficient to start the process of bio-activation of PhIP that leads to the formation of PhIP 
DNA adduct and ultimately tumorigenesis (Kimura et al, 2003). An increase in CYIA12 
expression and MN frequency in PhIP treated HePG2 cell line thus highlight the importance 
of metabolic potential in PhIP related carcinogenicity. We also have noticed that increased 
levels of CYP1A1 mRNA are B[a]P driven while PhIP is a weak inducer of CYP1A1. 
Thomas (2006) also observed the similar reduction in CYP1A1 expression in MCF10A breast 
epithelial cells treated with PhIP (Thomas et al, 2006).
Our studies also showed an increase in mutation frequency in MCL-5 in response of PhIP 
exposure compared to untreated control (Chapter 6). Similarly the type of mutation caused by 
PhIP was different to those observed in control (spontaneous mutations). The majority of 
PhIP induced mutations observed in this study were G-^T transversions. These transversions 
could be induced by the DNA adduct C8-dG-PhIP that causes a conformational change 
leading to a purine-purine base pair (G with A) (Norman et al, 1989). Since we observed a 
higher MN frequency in PhIP treated cells, these results support a link between PhIP induced 
genotoxicity and PhIP specific mutations. Other mutations observed in the form of deletion in 
PhIP induced MCL-5 cell line were also in confirmation with previous reports of deletion of 
HPRT exon 3, 4, 8 and partial loss of exon 9 (Margenthaler and Holzhauser, 1995).
Our results indicate that metabolic activity, dose and exposure time play an important role in 
PhIP induced carcinogenicity. Non existence of threshold dose for PhIP in highly metabolic 
cell line (HepG2) suggests that individuals with higher metabolic activity are at higher risk to 
PhIP induced carcinogenicity. These risks appear to the relatively lower for individuals with 
lower metabolic activity (as observed in MCL 5), however, an increase in PhIP dose and/or 
exposure time does poses a significant risk to individuals with lower metabolic potentials. 
Thomas et al (2006) reported approximately 6-20ng/kg/day of PhIP consumption through diet 
in western countries. Other report (Sinha et al, 2000) indicates an increasing trend in higher 
intake products containing PhIP which represents a higher risk of PhIP related cancers.
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7.3 Limitations of my study
Like any other thesis there are points that strengthen this study along with some weaknesses. 
The following are some of the points that make my thesis strong, for example, I have used 
several cell lines to get the better picture of differences in their metabolic competency. I have 
used multiple end points like chromosomal damage using CBMN assay and DNA damage 
using HPRT assay to get the better understanding of the effect of pro-carcinogens in causing 
genotoxicity. I have used a wide dose range of B[A]P and PhIP that include some non-toxic 
doses and then performed my study along with 2 time points (24h and 4h). By using the 
mutation spectra I managed to identify the types and locations of mutations on DNA. 
Furthermore, I measured the CYP450 enzymes expressions in all cell lines that are actively 
involved in the metabolism of B[a]P and PhIP.
One of the weaknesses of my study is that the whole study was based on in vitro system. I did 
not use any in vivo system to confirm my results as we are lacking this facility in Swansea 
University. I found DNA damage as a result genotoxins exposure in cell lines but did not do 
study any mechanism that involve in DNA repair. I was not able perform any experiment 
where I can compare the B[a]P doses that are toxic for cell lines are in real life toxic to 
smoker or PhIP doses are harmful to meat eater in humans.
7.4 Concluding remarks
Overall our studies have shown a better understanding of the effect of B[a]P and PhIP on cell 
lines with different metabolic potential. We have shown how cells with differential metabolic 
potential respond to different doses, particularly a dose related response at low doses only in 
highly metabolically competent cells. Similarly we compared the effect of different doses 
with two different exposure times of 4h and 24h and the results of this comparison have 
shown that either an increase in dose or exposure increases the risk of genotoxicity. Our 
studies have shown an increase in CYP1A1 and CYP1A12 expression in B[a]P and PhIP 
treated cell lines thus confirming a link between metabolic potential and B[a]P or PhIP 
induced genotoxicity. Similarly, we have shown that both B[a]P and PhIP increase mutation 
frequency and cause specific mutations.
7.5 Future work
To further understand the carcinogenicity of B[a]P and PhIP „ future studies are required to 
• determine the effect of very low doses such as 0.1-lpM  on genotxicity of cell with 
different metabolic activity.
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• determine the DNA repair mechanisms in response to DNA damage caused by pro­
carcinogens and to understand their role in reducing risks of cancer caused by pro­
carcinogens.
• determine the effect of low doses of B[a]P and PhIP on the cell cycle mechanism and 
expression of cell cycle regulatory genes.
• compare the effect of different dose of B[a]P and PhIP on CYP1A1 and CYP1A2 
expression.
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Appendix I (Chapter 2)
A. Preparation of Hygromvcin B (Invitrogen)
All the preparation was done under aseptic conditions in sterile Biological safety Cabinets 
(Scanlaf Mars Pro class2, VWR International Ltd, Leicestershire, UK) UV sterilized and pre­
cleaned with 70% ethanol.
1. A mixture of 25ml PBS (Gibco) + 50pl Acetic acid (Fisher scientific) was prepared
2. 3.85ml Hygromycin B (50mg/ml) was added to 6.12ml of PBS mixture
3. The diluted Hygromycin B was filter sterilized
4. 200pl aliquots (at a concentration of 200pg/ml) were prepared and stored at -20°C
B. Preparation of 0.1M NaOH
lg of Sodium hydroxide (NaOH; Sigma, Gillingham, UK) was dissolved in 250ml distilled 
water and autoclaved.
C. Preparation of 0.5M EDTA
EDTA (Ethyldiamine tetraacetic acid) was prepared by dissolving 93.05g of EDTA (Sigma) 
in 400ml distilled water. The pH was adjusted with 2M sodium hydroxide (pH 8) and the final 
volume increased to 500ml with distilled water.
D. Preparation of lx  TBE (Tris-Borate-EDTA)
lx TBE buffer was prepared by adding 100ml of lOx TBE into 900ml distilled water.
Chem icals Supplier Am ount Final Volum e
10X TBE
Tris
Boric acid 
0.5M EDTA 
Distilled H20
Sigma, Gillingham, UK 
Sigma, Gillingham, UK 
Sigma, Gillingham, UK
108g
55g
40ml
1L (Autoclaved 
for 20 min)
10% APS
Ammonium per sulphate (APS) 
Distilled H20
Sigma, Gillingham, UK lg
10ml
Silver stain
0.1% Silver nitrate (AgN03) 
Distilled H20
Sigma, Gillingham, UK lg
1L
Developer
Sodium hydroxide (NaOH) 
37% formaldehyde (CH20) 
Distilled H20
Sigma, Gillingham, UK 
Sigma, Gillingham, UK
13.5g 
3.6pl
1L
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Appendix II (Chapter 3)
Micronucleus assay raw data tables for BfalP
Terminology used in data tables
PD Population doubling
%RPD Percentage relative population doubling
Bn Number of binucleated cells
Mn Number of mononucleated cells
%Mn/Bn Frequency of micronucleate in binucleated cells
Av. Average
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Appendices
Appendix III (Chapter 3)
Fold change in CYPs expressions (BlalP)
Figure A. 1. Comparisons o f  Basal and Induced expression o f  CYP 1A1 and 1A2 enzymes in 
MCL-5, AHH-1, TK6 and HepG2 cell lines treated with selected B[a]P doses for 24h. Lanel: 
Untreated control, Lane2: Treated with LOEL dose, Lane3: Dose above LOEL.
CYP1A1 CYP1A2
Lanel Lane2 Lane3 Lanel Lane2 LaneJ
MCL-5
3n.\l 3jiM 4^iM
AHH-1
4nM 5|j.M 4jiM SfiM
TK6
lO^ iM 5>iM lOfiM
HepG2
3filVl 4^iM 3 fiM  4 n \ l
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Appendices
Appendix IV (Chapter 4)
HPRT assay raw data tables for B[alP
Terminology used in data tables
Xo Number of wells with out colonies
>Jo Total number of wells scored
.Xs Number of wells without colonies
TJs Total number of wells scored
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Appendices
A p p e n d ix  V  (C h a p ter  4)
Screen shots of HPRT mutations (BlalP)
A. Screen shots of spontaneous and induced mutation spectra of AHH-1 
mutant colonies
Figure A. 2 Spontaneous mutation spectra o f  AHH-1 solvent mutants.
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Figure A. 3 BaP-induced mutation spectra o f  AHH-1 mutants colonies.
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Figure A. 4 Spontaneous mutation spectra o f  MCL-5 solvent mutants.
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Figure A. 5 BaP-induced mutation spectra of MCL-5 mutants colonies.
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Appendix VI (Chapter 5)
Micronucleus assay raw data tables for PhIP
Terminology used in data tables
PD Population doubling
%RPD Percentage relative population doubling
Bn Number of binucleated cells
Mn Number of mononucleated cells
%Mn/Bn Frequency of micronucleate in binucleated cells
Av. Average
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Appendix VII (Chapter 5)
Fold change in CYPs expressions (PhIP)
Figure A, 8 Comparisons o f  basal and induced expression o f  CYP 1A1 and 1A2 enzymes in 
MCL-5 and HepG2 cell lines treated with selected PhIP doses for 24h. Lanel: Untreated control, 
Lane2: Treated with LOEL dose, Lane3: Dose above LOEL.
MCL-5
HepG2
CYP1A1 
Lanel Lane2 Lane3
C 35|uM 50jj.IM
CYP1A2 
Lanel Lane2 Lane3
35nM 50|aM
lOfiM 15jiM IOjiM 15jiM
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Appendix VIII (Chapter 6)
HPRT assay raw data tables for PhIP
Terminology used in data tables
Xo Number of wells with out colonies
No Total number of wells scored
Xs Number of wells without colonies
Ns Total number of wells scored
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Appendices
Appendix IX (Chapter 6)
Screen shots of HPRT mutations (PhIP)
Screen shots of spontaneous and induced mutations in MCL-5 cell line treated 
with PhIP (25pM for 24h)
Figure A. 9 Spontaneous mutations in MCL-5 solvent controls.
Translocation (A)
490 495 500 505 510 515 520 525 530 535 540 545 550
A T G A C C A G T C A A C A G G G G A C A T  A A A AGT  AAT TGG.T G G A G A T G A T  CT C T C AACT  T T AACT  GGAAAGA AT  
AT GAC C A O T C  AAC AGGGGAC A T A A A AGT  AAT T GGT GGA GAT  GAT CT CT C AAC T T T AAC T G G A A A G A A T 
. AT GT 0 T T G AT T GT GG AAGAT AT AAT T GA AC T G GC AAA AC AAC
555 560 565 570 5
GT CTT GAT T G T G G A A G A T A T  A 
©T CT T GAT  T G T G G A A G A T  AT A
4,900 4,950 5,000 5,050 5,100 5,150 5,200 5,250 5,300 5,350 5,400 5,450 5,500 5,550 5,600 5,650 5,700 5,7
110
N D Q S T G D
115
I K V I
120
G G D D L S T
125
L T G K N
130
V
135
L I  V E D I
N D Q S T 0 D I K V I G G D D L S T I T G K N V L I  V E D I
ereree sequence mutation:;urveyo»_F_Synthesis_312.5cf~> Quakty(0-100):91
J J j
490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 5'
A GAC C A G T C A AC A OGGOAC A I AAA A GI AA T TOGTGGAGA T GAT C 1 C T C.AAC 7 T ! AAC T GOAAa GAAT GT CT GAT T Gi  GO*AGAT AT A
uVy^ Wna — LA
Point and Tandem mutations (B)
375 G -» T 370T -»C 653C ->G
55 290 295
C A A G T  G G G G C  T
A/w\ft
T T G
i70 3,680 3,690 3,700 3,710 3,720
- 100):22
70 2 ,280  2 ,290  2 ,300  2 ,310  2 ,320  2 ,330  2 ,3
T andem  m uta tion648G ->C
220 225
3 G T C G C A A . G - C
2,180 2,200 2,220 2,240 2,2
265
O 2,820 2,840 2,860 2,880 2,9(
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Deletions (C)
13bp l bp
425 430  435 440 445 450 4^
a t  a  G A  A A  T A G  T G A T  A G  A T C C A T  T C  C T A T  G  A C  T
4,250 4 ,300  4 ,350 4,400 4 ,450 4,500 4,5 1,740 1 ,760 1 ,780 1,800
45 350
, A T a  g  a  a  a :t
Figure A. 10 PhlP-lnduced (25pM for 24h) mutations in MCL-5 cell line.
Point mutations (A)
264G—+T 376G—>A
260 265“
T G G A A A <
2,600 2,650
i-100):25
1 80 185
T. 2 - T - - - J  G  - . -T. - . A - A - -A <
3 - 325   330---------
C A A G G A G G G C T  t-
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Deletions (B) 
17bp
1 6 5  1 70  1 7 5  1 80  1 85  1 9 0
G  G  A  A  A  G  A  A  T G T  C T  T G A T T  G T  G G A A G A T  A  T  A  A  T
1 ,650 1 ,700 1 ,750 1 ,800 1 ,850  1 ,900
3 0
A  A  A  G
3 5
G  A  T A T A A T
___ /Y X Y X
58bp deleted from position 1181-1239 position and translocated at 776 position on mRNA
(C)
70 775 730 785 790 795 800 805 810 815 820 825 830 835 840 845 850
T i O A A T  C A T  G T T T G T Q T C A T T AG T G A A A C T G G A A A A Q C  A A A A T  A C A A A GC C T A A g  a  t g g a g I t c a  a  g ! I g a g t 1 t g g a  a  a  c a  1 
T T GA AT C AT GT TT G T O f  C A T T A O  T G A A A C T  G O A A A a O C A A A A T  AC A A A  GC C T A A G A T  G A GA G T T C A A G I  T G A G T T T GG A A A C  AT
T T GA A T G AA A G A AT A G A A G T GAT T GA AT AT T GT T AAT T A T A C C A C C O T G T G T T A G A A A a GT AA GA NT A T T
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215
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ence mutation surveyof_F_Synthe5i5_705.scf—> Quabty(0- 100):87
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